Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2018	Feb. 21, 2019	Jun. 29, 2018
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Trading Symbol	ENDP
Entity Registrant Name	Endo International plc
Entity Central Index Key	0001593034
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Ordinary Shares Outstanding		224,404,247
Entity Public Float			$ 1,788,232,570
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
CURRENT ASSETS:
Cash and cash equivalents	$ 1,149,113	$ 986,605
Restricted cash and cash equivalents	305,368	320,453
Accounts receivable, net	470,570	517,436
Inventories, net	322,179	391,437
Prepaid expenses and other current assets	56,139	43,098
Income taxes receivable	39,781	12,048
Total current assets	2,343,150	2,271,077
MARKETABLE SECURITIES	738	1,456
PROPERTY, PLANT AND EQUIPMENT, NET	498,892	523,971
GOODWILL	3,764,636	4,450,082
OTHER INTANGIBLES, NET	3,457,306	4,317,684
DEFERRED INCOME TAXES	678	11,582
OTHER ASSETS	66,993	59,728
TOTAL ASSETS	10,132,393	11,635,580
CURRENT LIABILITIES:
Accounts payable and accrued expenses	1,009,200	1,096,825
Current portion of legal settlement accrual	905,085	1,087,793
Current portion of long-term debt	34,150	34,205
Income taxes payable	1,661	2,086
Total current liabilities	1,950,096	2,220,909
DEFERRED INCOME TAXES	34,487	43,131
LONG-TERM DEBT, LESS CURRENT PORTION, NET	8,224,269	8,242,032
LONG-TERM LEGAL SETTLEMENT ACCRUAL, LESS CURRENT PORTION	0	210,450
OTHER LIABILITIES	421,824	434,178
COMMITMENTS AND CONTINGENCIES (NOTE 15)
SHAREHOLDERS' (DEFICIT) EQUITY:
Euro deferred shares, $0.01 par value; 4,000,000 shares authorized and issued at both December 31, 2018 and December 31, 2017	46	48
Ordinary shares, $0.0001 par value; 1,000,000,000 shares authorized; 224,382,791 and 223,331,706 shares issued and outstanding at December 31, 2018 and December 31, 2017, respectively	22	22
Additional paid-in capital	8,855,810	8,791,170
Accumulated deficit	(9,124,932)	(8,096,539)
Accumulated other comprehensive loss	(229,229)	(209,821)
Total shareholders' (deficit) equity	(498,283)	484,880
TOTAL LIABILITIES AND SHAREHOLDERS' (DEFICIT) EQUITY	$ 10,132,393	$ 11,635,580

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Euro deferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Euro deferred shares, shares authorized (in shares)	4,000,000	4,000,000
Euro deferred shares, shares issued (in shares)	4,000,000	4,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, shares issued (in shares)	224,382,791	223,331,706
Common stock, shares outstanding (in shares)	224,382,791	223,331,706

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
TOTAL REVENUES	$ 2,947,078	$ 3,468,858	$ 4,010,274
COSTS AND EXPENSES:
Cost of revenues	1,631,682	2,228,530	2,634,973
Selling, general and administrative	646,037	629,874	770,728
Research and development	185,826	172,067	183,372
Litigation-related and other contingencies, net	13,809	185,990	23,950
Asset impairment charges	916,939	1,154,376	3,781,165
Acquisition-related and integration items	21,914	58,086	87,601
OPERATING LOSS FROM CONTINUING OPERATIONS	(469,129)	(960,065)	(3,471,515)
INTEREST EXPENSE, NET	521,656	488,228	452,679
LOSS ON EXTINGUISHMENT OF DEBT	0	51,734	0
OTHER INCOME, NET	(51,953)	(17,023)	(338)
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAX	(938,832)	(1,483,004)	(3,923,856)
INCOME TAX EXPENSE (BENEFIT)	22,935	(250,293)	(700,084)
LOSS FROM CONTINUING OPERATIONS	(961,767)	(1,232,711)	(3,223,772)
DISCONTINUED OPERATIONS, NET OF TAX (NOTE 3)	(69,702)	(802,722)	(123,278)
CONSOLIDATED NET LOSS	(1,031,469)	(2,035,433)	(3,347,050)
Less: Net income attributable to noncontrolling interests	0	0	16
NET LOSS ATTRIBUTABLE TO ENDO INTERNATIONAL PLC	$ (1,031,469)	$ (2,035,433)	$ (3,347,066)
NET LOSS PER SHARE ATTRIBUTABLE TO ENDO INTERNATIONAL PLC ORDINARY SHAREHOLDERS—BASIC:
Continuing operations (in dollars per share)	$ (4.29)	$ (5.52)	$ (14.48)
Discontinued operations (in dollars per share)	(0.32)	(3.60)	(0.55)
Basic (in dollars per share)	(4.61)	(9.12)	(15.03)
NET LOSS PER SHARE ATTRIBUTABLE TO ENDO INTERNATIONAL PLC ORDINARY SHAREHOLDERS—DILUTED:
Continuing operations (in dollars per share)	(4.29)	(5.52)	(14.48)
Discontinued operations (in dollars per share)	(0.32)	(3.60)	(0.55)
Diluted (in dollars per share)	$ (4.61)	$ (9.12)	$ (15.03)
WEIGHTED AVERAGE SHARES:
Basic (shares)	223,960	223,198	222,651
Diluted (shares)	223,960	223,198	222,651

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Statement of Comprehensive Income [Abstract]
CONSOLIDATED NET LOSS	$ (1,031,469)	$ (2,035,433)	$ (3,347,050)
Net unrealized gain (loss) on securities, net of tax:
Unrealized gain (loss) arising during the period		(515)	(914)
Less: reclassification adjustments for (gain) loss realized in net loss	0	0	(6)
Net unrealized gain (loss) on securities	0	(515)	(920)
Net unrealized (loss) gain on foreign currency, net of tax:
Foreign currency translation (loss) gain arising during the period	(19,408)	31,202	31,729
Less: reclassification adjustments for loss realized in net loss	0	112,926	0
Foreign currency translation gain (loss)	(19,408)	144,128	31,729
OTHER COMPREHENSIVE (LOSS) INCOME	(19,408)	143,613	30,809
CONSOLIDATED COMPREHENSIVE LOSS	(1,050,877)	(1,891,820)	(3,316,241)
Less: Net income attributable to noncontrolling interests	0	0	(16)
Less: Other comprehensive income attributable to noncontrolling interests	0	0	38
COMPREHENSIVE LOSS ATTRIBUTABLE TO ENDO INTERNATIONAL PLC	$ (1,050,877)	$ (1,891,820)	$ (3,316,295)

Consolidated Statement of Shareholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Total Endo International plc Shareholders' Equity (Deficit)	Ordinary Shares	Euro Deferred Shares	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Noncontrolling Interests
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' equity, beginning balance	$ 5,967,976	$ 5,968,030	$ 22	$ 43	$ 8,693,385	$ (2,341,215)	$ (384,205)	$ (54)
Shareholders' equity, beginning balance (in shares) at Dec. 31, 2015			222,124,282	4,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' equity, beginning balance	2,701,589	2,701,589	$ 22	$ 42	8,743,240	(5,688,281)	(353,434)	0
Net (loss) income	(3,347,050)	(3,347,066)				(3,347,066)		16
Other comprehensive income (loss)	30,809	30,771					30,771	38
Compensation related to share-based awards	59,769	59,769			59,769
Exercise of options (in shares)			62,589
Exercise of options	1,952	1,952			1,952
Tax benefits of share awards, net	(5,449)	(5,449)			(5,449)
Issuance of ordinary shares related to the employee stock purchase plan (in shares)			306,918
Issuance of ordinary shares related to the employee stock purchase plan	5,119	5,119			5,119
Ordinary shares issued (in shares)			460,386
Ordinary shares issued	0
Tax withholding for restricted shares	(11,500)	(11,500)			(11,500)
Other	(37)	(37)		$ (1)	(36)		0
Shareholders' equity, ending balance (in shares) at Dec. 31, 2016			222,954,175	4,000,000
Shareholders' equity, ending balance at Dec. 31, 2016	2,701,589	2,701,589	$ 22	$ 42	8,743,240	(5,688,281)	(353,434)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' equity, beginning balance	2,701,589	2,701,589	22	42	8,743,240	(5,688,281)	(353,434)	0
Effect of adopting accounting principle	(372,825)
Effect of adopting accounting principle \| Accounting Standards Update 2016-16		(372,825)				(372,825)
Shareholders' equity, adjusted beginning balance	2,328,764	2,328,764	22	42	8,743,240	(6,061,106)	(353,434)	0
Shareholders' equity, beginning balance	484,880	484,880	$ 22	48	8,791,170	(8,096,539)	(209,821)	0
Net (loss) income	(2,035,433)	(2,035,433)				(2,035,433)		0
Other comprehensive income (loss)	143,613	143,613					143,613	0
Compensation related to share-based awards	50,149	50,149			50,149
Ordinary shares issued (in shares)			377,531
Ordinary shares issued	0
Tax withholding for restricted shares	(2,078)	(2,078)			(2,078)
Other	(135)	(135)		$ 6	(141)		0
Shareholders' equity, ending balance (in shares) at Dec. 31, 2017			223,331,706	4,000,000
Shareholders' equity, ending balance at Dec. 31, 2017	484,880	484,880	$ 22	$ 48	8,791,170	(8,096,539)	(209,821)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' equity, beginning balance	484,880	484,880	22	48	8,791,170	(8,096,539)	(209,821)	0
Effect of adopting accounting principle	3,076
Effect of adopting accounting principle \| ASC 606		3,076				3,076
Shareholders' equity, adjusted beginning balance	487,956	487,956	22	48	8,791,170	(8,093,463)	(209,821)	0
Shareholders' equity, beginning balance	(498,283)	(498,283)	$ 22	46	8,855,810	(9,124,932)	(229,229)	0
Net (loss) income	(1,031,469)	(1,031,469)				(1,031,469)		0
Other comprehensive income (loss)	(19,408)	(19,408)					(19,408)	0
Compensation related to share-based awards	54,071	54,071			54,071
Exercise of options (in shares)			94,392
Exercise of options	933	933			933
Ordinary shares issued (in shares)			956,693
Ordinary shares issued	0
LTCI modification (NOTE 18)	14,936	14,936			14,936
Tax withholding for restricted shares	(5,375)	(5,375)			(5,375)
Other	73	73		$ (2)	75		0
Shareholders' equity, ending balance (in shares) at Dec. 31, 2018			224,382,791	4,000,000
Shareholders' equity, ending balance at Dec. 31, 2018	(498,283)	(498,283)	$ 22	$ 46	8,855,810	(9,124,932)	(229,229)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' equity, beginning balance	$ (498,283)	$ (498,283)	$ 22	$ 46	$ 8,855,810	$ (9,124,932)	$ (229,229)	$ 0

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
OPERATING ACTIVITIES:
CONSOLIDATED NET LOSS	$ (1,031,469)	$ (2,035,433)	$ (3,347,050)
Adjustments to reconcile Consolidated net loss to Net cash provided by operating activities:
Depreciation and amortization	723,707	983,765	983,309
Inventory step-up	261	390	108,768
Share-based compensation	54,071	50,149	59,769
Amortization of debt issuance costs and discount	20,514	22,694	28,514
Deferred income taxes	5,557	(156,129)	(745,341)
Change in fair value of contingent consideration	19,910	49,949	23,823
Loss on extinguishment of debt	0	51,734	0
Asset impairment charges	916,939	1,154,376	3,802,493
(Gain) loss on sale of business and other assets	(45,155)	(13,809)	3,192
Changes in assets and liabilities which provided (used) cash:
Accounts receivable	17,090	484,710	(502)
Inventories	67,269	147,189	66,876
Prepaid and other assets	(12,797)	5,345	69,273
Accounts payable, accrued expenses and other liabilities	(425,336)	(87,944)	(1,207,047)
Income taxes payable/receivable	(43,291)	(103,001)	682,066
Net cash provided by operating activities	267,270	553,985	528,143
INVESTING ACTIVITIES:
Purchases of property, plant and equipment, excluding capitalized interest	(83,398)	(125,654)	(138,856)
Capitalized interest payments	(3,549)	0	0
Acquisitions, net of cash and restricted cash acquired	0	0	(30,394)
Decrease in notes receivable	0	7,000	0
Product acquisition costs and license fees	(3,000)	0	(19,206)
Proceeds from sale of business and other assets, net	70,369	223,237	10,870
Other investing activities	1,678	0	34
Net cash (used in) provided by investing activities	(17,900)	104,583	(177,552)
FINANCING ACTIVITIES:
Proceeds from issuance of notes	0	300,000	0
Proceeds from issuance of term loans	0	3,415,000	0
Principal payments on term loans	(34,150)	(3,730,951)	(103,625)
Proceeds from draw of revolving debt	0	0	380,000
Repayments of revolving debt	0	0	(605,000)
Principal payments on other indebtedness	(5,222)	(6,154)	(7,736)
Deferred financing fees	0	(57,773)	(500)
Payments for contingent consideration	(37,758)	(85,037)	(55,896)
Payments of tax withholding for restricted shares	(5,375)	(2,078)	(11,500)
Exercise of options	933	0	1,952
Issuance of ordinary shares related to the employee stock purchase plan	0	0	5,119
Net cash used in financing activities	(81,572)	(166,993)	(397,186)
Effect of foreign exchange rate	(1,975)	2,515	436
Movement in cash held for sale	0	11,744	(11,744)
NET INCREASE IN CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS	165,823	505,834	(57,903)
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, BEGINNING OF PERIOD	1,311,014	805,180	863,083
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, END OF PERIOD	1,476,837	1,311,014	805,180
SUPPLEMENTAL INFORMATION:
Cash paid for interest, excluding capitalized interest	515,042	467,017	429,172
Cash paid for income taxes	17,639	28,675	63,983
Cash received from U.S. Federal tax refunds	0	29,825	759,950
Cash paid into Qualified Settlement Funds for mesh legal settlements	336,648	668,306	831,131
Cash paid out of Qualified Settlement Funds for mesh legal settlements	353,032	632,176	1,134,734
Other cash distributions for mesh legal settlements	$ 25,222	$ 19,243	$ 7,830

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Significant Accounting Policies

Consolidation and Basis of Presentation. The Consolidated Financial Statements include the accounts of wholly owned subsidiaries after the elimination of intercompany accounts and transactions.

Reclassifications. Certain prior period amounts have been reclassified to conform to the current period presentation.

Use of Estimates. The preparation of our Consolidated Financial Statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts and disclosures in our Consolidated Financial Statements, including the notes thereto, and elsewhere in this report. For example, we are required to make significant estimates and assumptions related to revenue recognition, including sales deductions, financial instruments, long-lived assets, goodwill, other intangibles, income taxes, contingencies and share-based compensation, among others. Some of these estimates can be subjective and complex. Although we believe that our estimates and assumptions are reasonable, there may be other reasonable estimates or assumptions that differ significantly from ours. Further, our estimates and assumptions are based upon information available at the time they were made. Actual results may differ significantly from our estimates.

We regularly evaluate our estimates and assumptions using historical experience and other factors, including the economic environment. As future events and their effects cannot be determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Market conditions, such as illiquid credit markets, volatile equity markets, dramatic fluctuations in foreign currency rates and economic downturn, can increase the uncertainty already inherent in our estimates and assumptions. We also are subject to other risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation and regulations. We adjust our estimates and assumptions when facts and circumstances indicate the need for change. Those changes generally will be reflected in our Consolidated Financial Statements on a prospective basis.

Customer, Product and Supplier Concentration. We primarily sell our generic and branded pharmaceuticals to wholesalers, retail drug store chains, supermarket chains, mass merchandisers, distributors, mail order accounts, hospitals and government agencies. Our wholesalers and distributors purchase products from us and, in turn, supply products to retail drug store chains, independent pharmacies and managed health care organizations. Customers in the managed health care market include health maintenance organizations, nursing homes, hospitals, clinics, pharmacy benefit management companies and mail order customers. Total revenues from direct customers that accounted for 10% or more of our total consolidated revenues during the years ended December 31, 2018, 2017 and 2016 are as follows:



	2018		2017		2016
AmerisourceBergen Corporation	32	%	25	%	25	%
McKesson Corporation	27	%	25	%	27	%
Cardinal Health, Inc.	26	%	25	%	26	%

Revenues from these customers are included within each of our segments.

VASOSTRICT^® accounted for 15% and 12% of our 2018 and 2017 total revenues, respectively. No other products accounted for 10% or more of our total revenues during the years ended December 31, 2018, 2017 or 2016.

We have agreements with certain third parties for the manufacture, supply and processing of certain of our existing pharmaceutical products. See Note 15. Commitments and Contingencies for information on material manufacturing, supply and other service agreements.

We are subject to risks and uncertainties associated with these concentrations that could have a material adverse effect on our financial position and results of operations in future periods, including in the near term.

Revenue Recognition and Sales Deductions. The Company adopted Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (ASC 606) on January 1, 2018 using the modified retrospective method for all revenue-generating contracts, including modifications thereto, that were not completed contracts at the date of adoption. ASC 606 applies to contracts with commercial substance that establish the payment terms and each party’s rights regarding the goods or services to be transferred, to the extent collection of substantially all of the related consideration is probable. Under ASC 606, we recognize revenue for contracts meeting these criteria when (or as) we satisfy our performance obligations for such contracts by transferring control of the underlying promised goods or services to our customers. The amount of revenue we recognize reflects our estimate of the consideration we expect to be entitled to receive, subject to certain constraints, in exchange for such goods or services. This amount is referred to as the transaction price.

Our revenue consists almost entirely of sales of our pharmaceutical products to customers, whereby we ship products to a customer pursuant to a purchase order. For contracts such as these, revenue is recognized when our contractual performance obligations have been fulfilled and control has been transferred to the customer pursuant to the contract’s terms, which is generally upon delivery to the customer. The amount of revenue we recognize is equal to the fixed amount of the transaction price, adjusted for our estimates of a number of significant variable components including, but not limited to, estimates for chargebacks, rebates, sales incentives and allowances, DSA and other fees for services, returns and allowances, which we collectively refer to as sales deductions. The Company utilizes the expected value method when estimating the amount of variable consideration to include in the transaction price with respect to each of the foregoing variable components and the most likely amount method when estimating the amount of variable consideration to include in the transaction price with respect to future potential milestone payments that do not qualify for the sales- and usage-based royalty exception. Variable consideration is included in the transaction price only to the extent that it is probable that a significant revenue reversal will not occur when the uncertainty associated with the variable consideration is resolved. Payment terms for these types of contracts generally fall within 30 to 90 days of invoicing.

At December 31, 2018 and 2017, our reserves for sales deductions totaled $772.3 million and $942.8 million, respectively. These amounts relate primarily to our estimates of our unsettled obligations for returns and allowances, rebates and chargebacks. Our estimates are based on factors such as our direct and indirect customers’ buying patterns and the estimated resulting contractual deduction rates, historical experience, specific known market events and estimated future trends, current contractual and statutory requirements, industry data, estimated customer inventory levels, current contract sales terms with our direct and indirect customers and other competitive factors. Significant judgment and estimation is required in developing the foregoing and other relevant assumptions. The most significant sales deductions are further described below.

Returns and Allowances—Consistent with industry practice, we maintain a return policy that allows our customers to return products within a specified period of time both subsequent to and, in certain cases, prior to the products’ expiration dates. Our return policy generally allows customers to receive credit for expired products within six months prior to expiration and within one year after expiration. Our provision for returns and allowances consists of our estimates for future product returns, pricing adjustments and delivery errors.

Rebates—Our provision for rebates, sales incentives and other allowances can generally be categorized into the following four types:


•	direct rebates;


•	indirect rebates;


•	governmental rebates, including those for Medicaid, Medicare and TRICARE, among others; and


•	managed-care rebates.

We establish contracts with wholesalers, chain stores and indirect customers that provide for rebates, sales incentives, DSA fees and other allowances. Some customers receive rebates upon attaining established sales volumes. Direct rebates are generally rebates paid to direct purchasing customers based on a percentage applied to a direct customer’s purchases from us, including fees paid to wholesalers under our DSAs, as described above. Indirect rebates are rebates paid to indirect customers which have purchased our products from a wholesaler under a contract with us.

We are subject to rebates on sales made under governmental and managed-care pricing programs based on relevant statutes with respect to governmental pricing programs and contractual sales terms with respect to managed-care providers and group purchasing organizations. For example, we are required to provide a discount on our brand-name drugs to patients who fall within the Medicare Part D coverage gap, also referred to as the donut hole.

We participate in various federal and state government-managed programs whereby discounts and rebates are provided to participating government entities. For example, Medicaid rebates are amounts owed based upon contractual agreements or legal requirements with public sector (Medicaid) benefit providers after the final dispensing of the product by a pharmacy to a benefit plan participant.

Chargebacks—We market and sell products to both: (i) direct customers including wholesalers, distributors, warehousing pharmacy chains and other direct purchasing groups and (ii) indirect customers including independent pharmacies, non-warehousing chains, managed-care organizations, group purchasing organizations and government entities. We enter into agreements with certain of our indirect customers to establish contract pricing for certain products. These indirect customers then independently select a wholesaler from which to purchase the products at these contracted prices. Alternatively, we may pre-authorize wholesalers to offer specified contract pricing to other indirect customers. Under either arrangement, we provide credit to the wholesaler for any difference between the contracted price with the indirect customer and the wholesaler’s invoice price. Such credit is called a chargeback.

Contract Assets and Contract Liabilities. Contract assets represent the Company’s right to consideration in exchange for goods or services that the Company has transferred to a customer when that right is conditioned on something other than the passage of time including, for example, the entity’s future performance. The Company records revenue and a corresponding contract asset when it fulfills a contractual performance obligation, but must also fulfill one or more additional performance obligations before being entitled to payment. Once the Company’s right to consideration becomes unconditional, the contract asset amount is reclassified as Accounts receivable.

Contract liabilities represent the Company’s obligation to transfer goods or services to a customer. The Company records a contract liability generally upon receipt of consideration in advance of fulfilling one or more of its contractual performance obligations. Upon completing each performance obligation, the corresponding contract liability amount is reversed and revenue is recognized.

Contract assets and liabilities related to rights and obligations arising from a single contract, or a series of contracts combined and accounted for as a single contract, are generally presented on a net basis. Contract assets and liabilities are further described in Note 12. Contract Assets and Liabilities.

Research and Development (R&D). Expenditures for research and development are expensed as incurred. Total R&D expenses include the costs of discovery research, preclinical development, early- and late-clinical development and drug formulation, clinical trials, medical support of marketed products, upfront, milestone and other payments under third-party collaborations and contracts and other costs. R&D spending also includes enterprise-wide costs which support our overall R&D infrastructure. Property, plant and equipment that are acquired or constructed for research and development activities and that have alternate future uses are capitalized and depreciated over their estimated useful lives on a straight-line basis. Contractual upfront and milestone payments made to third parties are generally: (i) expensed as incurred up to the point of regulatory approval and (ii) capitalized and amortized over the related product’s remaining useful life subsequent to regulatory approval. Amounts capitalized for such payments are included in Other intangibles, net in the Consolidated Balance Sheets.

Cash and Cash Equivalents. The Company considers all highly liquid money market instruments with an original maturity of three months or less when purchased to be cash equivalents. At December 31, 2018 and 2017, cash equivalents were deposited in financial institutions and consisted of immediately available fund balances and time deposits. The Company maintains its cash deposits and cash equivalents with financial institutions it believes to be well-known and stable.

Restricted Cash and Cash Equivalents. Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are excluded from Cash and cash equivalents in the Consolidated Balance Sheets. For additional information see Note 7. Fair Value Measurements.

Marketable Securities. The Company has equity securities, which consist of investments in the stock of publicly traded companies. For additional information see Note 7. Fair Value Measurements.

Accounts Receivable. Accounts receivable are stated at their net realizable value and the Company maintains an allowance for doubtful accounts against gross accounts receivable. The allowance is not material to the Company’s Consolidated Financial Statements at December 31, 2018 and 2017. In addition, accounts receivable is reduced by certain sales deduction reserves where we have the right of offset with the customer.

Concentrations of Credit Risk. Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash equivalents, restricted cash equivalents, marketable debt securities and accounts receivable. From time to time, we invest our excess cash in high-quality, liquid money market instruments and time deposits maintained by major banks and financial institutions. We have not experienced any losses on our cash equivalents.

We perform ongoing credit evaluations of our customers and generally do not require collateral. We have no history of significant losses from uncollectible accounts. Approximately 87% and 89% of our gross trade accounts receivable balances represent amounts due from three customers (Cardinal Health, Inc., McKesson Corporation and AmerisourceBergen Corporation) at December 31, 2018 and 2017, respectively.

We do not expect our current or future exposures to credit risk to have a significant impact on our operations. However, there can be no assurance that any of these risks will not have an adverse effect on our business.

Inventories. Inventories consist of raw materials, work-in-process and finished goods. Inventory that is in excess of the amount expected to be sold within one year is classified as long-term inventory and is recorded in Other assets in the Consolidated Balance Sheets. The Company capitalizes inventory costs associated with certain generic products prior to regulatory approval and product launch when it is reasonably certain, based on management’s judgment of future commercial use and net realizable value, that the pre-launch inventories will be saleable. The determination to capitalize is made on a product-by-product basis and generally occurs when: (i) the Company (or its third party development partners) has filed an ANDA that has been acknowledged by the FDA as containing sufficient information to allow the FDA to conduct its review in an efficient and timely manner and (ii) management is reasonably certain that all regulatory and legal requirements will be cleared. The Company could be required to write down previously capitalized costs related to pre-launch inventories upon a change in such judgment, a denial or delay of approval by regulatory bodies, a delay in commercialization or other potential factors. Our inventories are stated at the lower of cost or net realizable value. Cost is determined by the first-in, first-out method and includes materials, direct labor and an allocation of overhead. Net realizable value is determined by the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. When necessary, we write-down inventories to net realizable value based on forecasted demand and market and regulatory conditions, which may differ from actual results.

Property, Plant and Equipment. Property, plant and equipment is generally stated at cost less accumulated depreciation. Major improvements are capitalized, while routine maintenance and repairs are expensed as incurred. Costs incurred during the construction or development of property plant and equipment are capitalized as assets under construction. Once an asset has been put into service, depreciation expense is taken over the estimated useful life of the related assets or, in the case of leasehold improvements and capital lease assets, over the shorter of the estimated useful life or the lease term. Depreciation expense is recorded on a straight-line basis. Depreciation expense is not recorded on Assets held for sale. Gains and losses on disposals are included in Other income, net in the Consolidated Statements of Operations. Depreciation is based on the following estimated useful lives, as of December 31, 2018:



	Range of Useful Lives, from:
Buildings	10 years	to	30 years
Machinery and equipment	2 years	to	15 years
Leasehold improvements	Shorter of useful life or lease term
Computer equipment and software	1 year	to	7 years
Assets under capital lease	Shorter of useful life or lease term
Furniture and fixtures	3 years	to	10 years

Computer Software. The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software, including external direct costs of material and services, and payroll costs for employees directly involved with the software development. Capitalized software costs are included in Property, plant and equipment, net in the Consolidated Balance Sheets and depreciated beginning when the software project is substantially complete and the asset is ready for its intended use. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.

Lease Accounting. The Company accounts for operating lease transactions by recording rent expense on a straight-line basis over the expected life of the lease, commencing on the date it gains possession of leased property. The Company includes tenant improvement allowances and rent holidays received from landlords and the effect of any rent escalation clauses as adjustments to straight-line rent expense over the expected life of the lease.

Capital lease transactions are reflected as a liability at the inception of the lease based on the present value of the minimum lease payments or, if lower, the fair value of the property. Assets under capital leases are recorded in Property, plant and equipment, net in the Consolidated Balance Sheets and depreciated in a manner similar to other Property, plant and equipment.

Certain construction projects may be accounted for as direct financing arrangements, whereby the Company records, over the construction period, the full cost of the asset in Property, plant and equipment, net in the Consolidated Balance Sheets. A corresponding liability is also recorded, net of leasehold improvements paid for by the Company, and is amortized over the expected lease term through monthly rental payments using an effective interest method. Assets recorded under direct financing arrangements are depreciated over the lease term.

Finite-Lived Intangible Assets. Our finite-lived intangible assets, which consist of license rights and developed technology, are initially recorded at fair value upon acquisition. There are several methods that can be used to determine fair value. For intangible assets, we typically use the income method. This method starts with our forecast of all of the expected future net cash flows. Revenues are estimated based on relevant market size and growth factors, expected industry trends, individual project life cycles and, if applicable, the life of any estimated period of marketing exclusivity, such as that granted by a patent. The pricing, margins and expense levels of similar products are considered if available. For certain licensed assets, our estimates of future cash flows consider periods covered by renewal options to the extent we have the intent and ability, at the date of the estimate, to renew the underlying license agreements. These cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams.

To the extent an intangible asset is deemed to have a finite life, it is then amortized over its estimated useful life using either the straight-line method or, in the case of certain developed technology assets, the economic benefit model. The values of these various assets are subject to continuing scientific, medical and marketplace uncertainty. Factors giving rise to our initial estimate of useful lives are subject to change. Significant changes to any of these factors may result in a reduction in the useful life of the asset and an acceleration of related amortization expense, which could cause our operating income, net income and net income per share to decrease. Amortization expense is not recorded on assets held for sale.

Developed Technology. Our developed technology assets subject to amortization have useful lives ranging from 4 years to 20 years, with a weighted average useful life of approximately 11 years. We determine amortization periods and methods of amortization for developed technology assets based on our assessment of various factors impacting estimated useful lives and the timing and extent of estimated cash flows of the acquired assets, including the strength of the intellectual property protection of the product, contractual terms and various other competitive and regulatory issues.

License Rights. Our license rights subject to amortization have useful lives ranging from 10 years to 15 years, with a weighted average useful life of approximately 12 years. We determine amortization periods for licenses based on our assessment of various factors including the expected launch date of the product, the strength of the intellectual property protection of the product, contractual terms and various other competitive, developmental and regulatory issues.

Long-Lived Asset Impairment Testing. Long-lived assets, including property, plant and equipment and finite-lived intangible assets, are assessed for impairment whenever events or changes in circumstances indicate the carrying amounts of the assets may not be recoverable. Recoverability of an asset that will continue to be used in our operations is measured by comparing the carrying amount of the asset to the forecasted undiscounted future cash flows related to the asset. In the event the carrying amount of the asset exceeds its undiscounted future cash flows and the carrying amount is not considered recoverable, impairment may exist. An impairment loss, if any, is measured as the excess of the asset’s carrying amount over its fair value, generally based on a discounted future cash flow method, independent appraisals or offers from prospective buyers. An impairment loss would be recognized in the Consolidated Statements of Operations in the period that the impairment occurs.

In-Process Research and Development Assets (IPR&D). IPR&D assets are considered indefinite-lived intangible assets. Similar to finite-lived intangible assets, IPR&D assets are initially recorded at fair value. While amortization expense is not initially recorded for IPR&D assets, these assets are subject to impairment reviews. Impairment tests for an IPR&D asset occur at least annually on October 1^st of each year, but also whenever events or changes in circumstances indicate that the asset might be impaired. If the fair value of the intangible assets is less than its carrying amount, an impairment loss is recognized for the difference. For those assets that reach commercialization, the assets are reclassified and accounted for as finite-lived intangible assets.

Goodwill. Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. While amortization expense is not recorded on goodwill, goodwill is subject to impairment reviews. Impairment tests for goodwill occur at least annually on October 1^st of each year, but also whenever events or changes in circumstances indicate that the asset might be impaired.

Following our early adoption, effective January 1, 2017, of ASU 2017-04, we perform our goodwill impairment tests by comparing the fair value and carrying amount of each of our reporting units. Any goodwill impairment charge we recognize for a reporting unit is equal to the lesser of (i) the total goodwill allocated to that reporting unit and (ii) the amount by which that reporting unit’s carrying amount exceeds its fair value.

Contingencies. The Company is subject to various patent challenges, product liability claims, government investigations and other legal proceedings in the ordinary course of business. Legal fees and other expenses related to litigation are expensed as incurred and included in Selling, general and administrative expenses or Discontinued operations, net of tax in the Consolidated Statements of Operations. Contingent accruals and legal settlements are recorded in the Consolidated Statements of Operations as Litigation-related and other contingencies, net (or Discontinued operations, net in the case of vaginal mesh matters) when the Company determines that a loss is both probable and reasonably estimable. Due to the fact that legal proceedings and other contingencies are inherently unpredictable, our estimates of the probability and amount of any such liabilities involve significant judgment regarding future events. The Company records a receivable from its product liability insurance carriers only when the resolution of any dispute has been reached and realization of the potential claim for recovery is considered probable.

Contingent Consideration. Certain of the Company’s business acquisitions involve the potential for future payment of consideration that is contingent upon the achievement of operational and commercial milestones and/or royalty payments on future product sales. The fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period, the Company remeasures its contingent consideration liability to its current fair value, with changes recorded in earnings. Changes to any of the inputs used in determining fair value may result in fair value adjustments that differ significantly from the actual remeasurement adjustments recognized.

Share Repurchases. The Company accounts for the repurchase of ordinary shares, if any, at par value. Under applicable Irish law, ordinary shares repurchased are retired and not displayed separately as treasury stock. Upon retirement of the ordinary shares, the Company records the difference between the weighted average cost of such ordinary shares and the par value of the ordinary shares as an adjustment to Accumulated deficit in the Consolidated Balance Sheets.

Advertising Costs. Advertising costs are expensed as incurred and included in Selling, general and administrative expenses in the Consolidated Statements of Operations. Advertising costs amounted to $49.6 million, $42.0 million and $47.9 million for the years ended December 31, 2018, 2017 and 2016, respectively.

Cost of Revenues. Cost of revenues includes all costs directly related to bringing both purchased and manufactured products to their final selling destination. Amounts include purchasing and receiving costs, direct and indirect costs to manufacture products including direct materials, direct labor and direct overhead expenses necessary to acquire and convert purchased materials and supplies into finished goods, royalties paid or owed by Endo on certain in-licensed products, inspection costs, depreciation of certain property, plant and equipment, amortization of intangible assets, warehousing costs, freight charges, costs to operate our equipment and other shipping and handling costs, among others.

Share-Based Compensation. The Company grants share-based compensation awards to certain employees and non-employee directors. Generally, the grant-date fair value of each award is recognized as expense over the requisite service period. However, expense recognition differs in the case of certain performance share units where the ultimate payout is performance-based. For these awards, at each reporting period, the Company estimates the ultimate payout and adjusts the cumulative expense based on its estimate and the percent of the requisite service period that has elapsed. Share-based compensation expense is reduced for estimated future forfeitures. These estimates are revised in future periods if actual forfeitures differ from the estimates. Changes in forfeiture estimates impact compensation expense in the period in which the change in estimate occurs. New ordinary shares are generally issued upon the exercise of stock options or vesting of stock awards by employees and non-employee directors. Refer to Note 18. Share-based Compensation for additional discussion, including the accounting treatment for long-term cash incentive awards that will be settled in ordinary shares.

Foreign Currency. The Company operates in various jurisdictions both inside and outside of the U.S. While the Company’s reporting currency is the U.S. dollar (USD), the Company has concluded that certain of its distinct and separable operations have functional currencies other than the USD. Further, certain of the Company’s operations hold assets and liabilities and recognize income and expenses denominated in various local currencies, which may differ from their functional currencies.

Assets and liabilities are first remeasured from local currency to functional currency, generally using end-of-period exchange rates. Foreign currency income and expenses are generally remeasured using average exchange rates in effect during the year. In the case of nonmonetary assets and liabilities such as inventories, prepaid expenses, property, plant and equipment, goodwill and other intangible assets, and related income statement amounts, such as depreciation expense, historical exchange rates are used for remeasurement. The net effect of remeasurement is included in Other income, net in the Consolidated Statements of Operations.

As part of the Company’s consolidation process, assets and liabilities of entities with functional currencies other than the USD are translated into USD at end-of-period exchange rates. Income and expenses are translated using average exchange rates in effect during the year. The net effect of translation is included as foreign currency translation, a component of Other comprehensive (loss) income. Upon the sale or liquidation of an investment in a foreign operation, the Company records a reclassification adjustment out of Other comprehensive (loss) income for the corresponding amount of accumulated currency translation.

Income Taxes. The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company records net deferred tax assets to the extent it believes these assets will more likely than not be realized. In making such a determination, the Company considers all available positive and negative evidence, including projected future taxable income, tax-planning strategies and results of recent operations. In the event that the Company were to determine that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income tax.

The Company records uncertain tax positions on the basis of a two-step process whereby the Company first determines whether it is more likely than not that the tax positions will be sustained based on the technical merits of the position and then measures those tax positions that meet the more-likely-than-not recognition threshold. The Company recognizes the largest amount of tax benefit that is greater than 50% likely to be realized upon ultimate settlement with the tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within the Income tax expense (benefit) line in the Consolidated Statements of Operations. Accrued interest and penalties are included within the related tax liability line in the Consolidated Balance Sheets.

Comprehensive Income. Comprehensive income or loss includes all changes in equity during a period except those that resulted from investments by or distributions to a company’s shareholders. Other comprehensive income or loss refers to revenues, expenses, gains and losses that are included in comprehensive income, but excluded from net income as these amounts are recorded directly as an adjustment to shareholders’ equity.

Recent Accounting Pronouncements

Recently Issued Accounting Pronouncements Not Yet Adopted at December 31, 2018

In February 2016, the Financial Accounting Standards Board (FASB) issued ASU No. 2016-02, “Leases (Topic 842)” (ASU 2016-02) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Under the new guidance, lessees are required to recognize a lease liability, which represents the discounted obligation to make future minimum lease payments, and a corresponding right-of-use asset on the balance sheet for most leases. In July 2018, the FASB issued ASU No. 2018-10, “Codification Improvements to Topic 842, Leases” (ASU 2018-10), which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU No. 2018-11, “Leases (Topic 842) - Targeted Improvements” (ASU 2018-11), which addresses implementation issues related to the new lease standard. This guidance is effective for the Company as of January 1, 2019 and the Company will adopt this guidance using the modified retrospective approach and will recognize a cumulative-effect adjustment to the opening balance of Accumulated deficit in that period. This guidance includes a number of optional practical expedients that the Company may elect to apply, including an expedient that permits lease agreements that are twelve months or less to be excluded from the balance sheet. The Company is finalizing the impact that this new guidance will have on its consolidated financial statements, including its disclosures. The primary impact upon adoption will be the recognition, on a discounted basis, of the Company’s minimum commitments under noncancelable operating leases as right of use assets and obligations on the consolidated balance sheets. This will result in a significant increase in assets and liabilities on the Company’s consolidated balance sheets. In preparation for the adoption of this guidance, the Company’s process of identifying and validating the Company’s lease information and evaluating the impact that this new guidance will have on its processes and controls is substantially complete.

In August 2018, the FASB issued ASU No. 2018-13, “Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement” (ASU 2018-13). ASU 2018-13 modifies the disclosure requirements on fair value measurements in Accounting Standards Codification Topic 820, Fair Value Measurement. ASU 2018-13 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Certain aspects of ASU 2018-13 require prospective treatment, while others require retrospective treatment. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2018-13 on the Company’s disclosures.

In August 2018, the FASB issued ASU No. 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” (ASU 2018-15). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (including hosting arrangements where a software license is deemed to exist). ASU 2018-15 also requires the customer to expense any such capitalized implementation costs over the term of the hosting arrangement and to apply the existing impairment guidance for long-lived assets to such capitalized costs. Additionally, ASU 2018-15 sets forth required disclosures and guidance on financial statement classification for expenses, cash flows and balances related to implementation costs within the scope of ASU 2018-15. ASU 2018-15 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years; however, early adoption is permitted. The guidance may be applied retrospectively or prospectively to implementation costs incurred after the date of adoption. The Company will adopt this guidance during the first quarter of 2019 on a prospective basis.

In November 2018, the FASB issued ASU No. 2018-18, “Clarifying the Interaction Between Topic 808 and Topic 606” (ASU 2018-18). The main provisions of ASU 2018-18 include: (i) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and (ii) precluding the presentation of transactions with collaborative arrangement participants that are not directly related to sales to third parties together with revenue. ASU 2018-18 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. ASU 2018-18 should be applied retrospectively to the date of initial application of ASC 606 (January 1, 2018 for the Company) and early adoption is permitted. The Company is currently evaluating the impact of ASU 2018-18 on the Company’s consolidated results of operations, financial position and disclosures.

Recent Accounting Pronouncements Adopted or Otherwise Effective as of December 31, 2018

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” (ASU 2014-09), which was subsequently amended and supplemented by several additional ASUs including:


•	ASU No. 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” (issued in August 2015), which deferred the effective date of ASU 2014-09 by one year, such that ASU 2014-09 became effective for Endo for annual and interim reporting periods beginning after December 15, 2017;


•	ASU No. 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Consideration (Reporting Revenue Gross versus Net)” (issued in March 2016), which clarified the guidance on reporting revenue as a principal versus agent;


•	ASU No. 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing” (issued in April 2016), which clarified the guidance on identifying performance obligations and accounting for intellectual property licenses; and


•	ASU No. 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients” and ASU No. 2016-20, “Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers,” (issued in May 2016 and December 2016, respectively), which amended certain narrow aspects of Topic 606.

These ASUs have generally been codified in Accounting Standards Codification Topic 606, “Revenue from Contracts with Customers”, and are collectively referred to herein as ASC 606. ASC 606 supersedes the revenue recognition requirements in Accounting Standards Codification Topic 605, “Revenue Recognition” (ASC 605), and requires entities to recognize revenue when control of promised goods or services is transferred to customers at an amount that reflects the consideration to which entities expect to be entitled in exchange for those goods or services.

The Company adopted ASC 606 on January 1, 2018 using the modified retrospective method for all revenue-generating contracts, including modifications thereto, that were not completed contracts at the date of adoption. Under the modified retrospective method, results beginning on January 1, 2018 are presented under ASC 606, while the comparative prior period results continue to be presented under ASC 605 based on the accounting standards originally in effect for such periods. As a result of adopting ASC 606, the Company recorded a net decrease of $3.1 million to its accumulated deficit at January 1, 2018, representing the cumulative impact of adopting ASC 606.

The current year impact of adoption on our Consolidated Statements of Operations and Consolidated Balance Sheets is as follows (in thousands, except per share amounts):



	Year Ended December 31, 2018
Statement of Operations:	Amounts reported under ASC 606			Amounts assuming continued application of ASC 605			Effect of adoption of ASC 606 (1)
Total revenues	$	2,947,078		$	2,947,930		$	(852	)
Cost of revenues	$	1,631,682		$	1,633,294		$	(1,612	)
Other income, net	$	(51,953	)	$	(50,953	)	$	(1,000	)
Loss from continuing operations	$	(961,767	)	$	(963,527	)	$	1,760
Net loss attributable to Endo International plc	$	(1,031,469	)	$	(1,033,229	)	$	1,760
Net loss per share attributable to Endo International plc ordinary shareholders—Basic:
Continuing operations	$	(4.29	)	$	(4.30	)	$	0.01
Total basic	$	(4.61	)	$	(4.61	)	$	—
Net loss per share attributable to Endo International plc ordinary shareholders—Diluted:
Continuing operations	$	(4.29	)	$	(4.30	)	$	0.01
Total diluted	$	(4.61	)	$	(4.61	)	$	—

__________


(1)	Amounts may not add due to rounding.



	At December 31, 2018
Balance Sheet:	Amounts reported under ASC 606			Amounts assuming continued application of ASC 605			Effect of adoption of ASC 606
Assets:
Inventories, net	$	322,179		$	329,684		$	(7,505	)
Prepaid expenses and other current assets	$	56,139		$	46,832		$	9,307
Other assets	$	66,993		$	64,235		$	2,758
Liabilities:
Accounts payable and accrued expenses	$	1,009,200		$	1,009,476		$	(276	)
Shareholders' (deficit) equity:
Accumulated deficit	$	(9,124,932	)	$	(9,129,768	)	$	4,836

In May 2017, the FASB issued ASU No. 2017-09, “Compensation - Stock Compensation” (ASU 2017-09). ASU 2017-09 provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. It is intended to reduce both (1) diversity in practice and (2) cost and complexity when accounting for changes to the terms or conditions of share-based payment awards. ASU 2017-09 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. The Company adopted the new standard on January 1, 2018, effective for any award modified on or after the adoption date.

Discontinued Operations and Divestitures

12 Months Ended

Dec. 31, 2018

Discontinued Operations and Disposal Groups [Abstract]

DISCONTINUED OPERATIONS AND DIVESTITURES

NOTE 3. DISCONTINUED OPERATIONS AND DIVESTITURES

Astora

The operating results of the Company’s Astora business, which the Board of Directors resolved to wind-down in 2016, are reported as Discontinued operations, net of tax in the Consolidated Statements of Operations for all periods presented.

The following table provides the operating results of Astora Discontinued operations, net of tax, for the years ended December 31, 2018, 2017 and 2016 (in thousands):



	2018			2017			2016
Revenue	$	—		$	338		$	30,101
Litigation-related and other contingencies, net	$	34,000		$	775,474		$	20,115
Asset impairment charges	$	—		$	—		$	21,328
Loss from discontinued operations before income taxes	$	(69,702	)	$	(816,426	)	$	(123,164	)
Income tax benefit	$	—		$	(13,704	)	$	—
Discontinued operations, net of tax	$	(69,702	)	$	(802,722	)	$	(123,164	)

Substantially all of the amounts reported in the table above as Litigation-related and other contingencies, net relate to charges for vaginal-mesh-related matters, which are further described in Note 15. Commitments and Contingencies. Loss from discontinued operations before income taxes also includes mesh-related legal defense costs, restructuring-related costs and certain other items.

The cash flows from discontinued operating activities related to Astora included the impact of net losses of $69.7 million, $802.7 million and $123.2 million for the years ended December 31, 2018, 2017 and 2016, respectively, and the impact of cash activity related to vaginal mesh cases. There were no material net cash flows related to Astora discontinued investing activities during the years ended December 31, 2018, 2017 and 2016. There was no depreciation or amortization during the years ended December 31, 2018, 2017 or 2016 related to Astora.

Astora Restructuring Initiative

The Astora wind-down process included a restructuring initiative implemented in 2016, which included a reduction of the Astora workforce consisting of approximately 250 employees (the Astora Restructuring Initiative).

A summary of expenses related to the Astora Restructuring Initiative is included below for the year ended December 31, 2016 (in thousands):



	2016
Employee separation, retention and other benefit-related costs	$	20,476
Asset impairment charges	21,328
Contract termination-related items	8,074
Other wind-down costs	10,972
Total	$	60,850

These restructuring costs are included in Discontinued operations in the Consolidated Statements of Operations. The Company did not incur any pre-tax charges during the years ended December 31, 2018 or 2017 as a result of the Astora Restructuring Initiative and the Company anticipates there will be no significant additional pre-tax restructuring expenses. The majority of these actions were completed as of September 30, 2016.

Litha

During the fourth quarter of 2016, the Company initiated a process to sell Litha and, on February 27, 2017, the Company entered into a definitive agreement to sell Litha to Acino Pharma AG (Acino). The sale closed on July 3, 2017 and the Company received net cash proceeds of approximately $94.2 million, after giving effect to cash and net working capital purchase price adjustments, as well as a short-term receivable of $4.4 million, which was subsequently collected in October 2017. No additional gain or loss was recognized upon sale. However, in December 2017, Acino became obligated to pay $10.1 million of additional consideration to the Company related to the settlement of certain contingencies set forth in the purchase agreement, which was subsequently paid to the Company in January 2018. In December 2017, the Company recorded a short-term receivable and a gain on the sale of Litha for this amount. The gain was recorded in Other income, net in the Consolidated Statements of Operations. Litha was part of the Company’s International Pharmaceuticals segment. Litha does not meet the requirements for treatment as a discontinued operation.

Somar

On June 30, 2017, the Company entered into a definitive agreement to sell Somar and all of the securities thereof, to AI Global Investments (Netherlands) PCC Limited acting for and on behalf of the Soar Cell (the Purchaser). The sale closed on October 25, 2017 and the Purchaser paid an aggregate purchase price of approximately $124 million in cash, after giving effect to estimated cash, debt and net working capital purchase price adjustments. The Company recognized a $1.3 million loss upon sale. Somar was part of the Company’s International Pharmaceuticals segment. Somar does not meet the requirements for treatment as a discontinued operation.

Restructuring

12 Months Ended

Dec. 31, 2018

Restructuring and Related Activities [Abstract]

RESTRUCTURING

NOTE 4. RESTRUCTURING

Set forth below are disclosures relating to restructuring initiatives that resulted in material expenses or cash expenditures during any of the years ended December 31, 2018, 2017 or 2016 or had material restructuring liabilities at either December 31, 2018 or December 31, 2017. Employee separation, retention and certain other employee benefit-related costs related to our restructurings are expensed ratably over the requisite service period. Other restructuring costs are generally expensed as incurred.

2016 U.S. Generic Pharmaceuticals Restructuring Initiative

As part of the ongoing U.S. Generic Pharmaceuticals integration efforts initiated in connection with the acquisition of Par in September 2015, the Company announced a restructuring initiative in May 2016 to optimize its product portfolio and rationalize its manufacturing sites to expand product margins (the 2016 U.S. Generic Pharmaceuticals Restructuring Initiative). These measures included certain cost savings initiatives, including a reduction in headcount and the disposal of our Charlotte, North Carolina manufacturing facility (the Charlotte facility). On October 31, 2016, we entered into a definitive agreement to sell the Charlotte facility for cash proceeds of $14 million. The transaction closed in January 2017.

As a result of the 2016 U.S. Generic Pharmaceuticals Restructuring Initiative, the Company incurred pre-tax charges of $1.0 million and $173.9 million during the years ended December 31, 2017 and 2016, respectively. The Company did not incur any pre-tax restructuring expenses related to this initiative during the year ended December 31, 2018.

The 2017 charges related primarily to employee separation and other benefit-related costs.

The 2016 charges consisted of certain asset impairment charges of $107.2 million, charges to increase excess inventory reserves of $33.3 million, charges related to employee separation, retention and other benefit-related costs of $17.0 million, accelerated depreciation of $10.2 million and other charges of $6.2 million.

These charges are included in the U.S. Generic Pharmaceuticals segment and are included in Asset impairment charges, Cost of revenues and Selling, general and administrative expenses in the Consolidated Statements of Operations. The Company does not expect to incur additional significant expenses related to this restructuring initiative.

Substantially all related cash payments were made by the end of 2017.

2016 U.S. Branded - Specialty & Established Pharmaceuticals Restructuring Initiative

In December 2016, the Company announced that it was terminating its worldwide license and development agreement with BioDelivery Sciences International, Inc. (BDSI) for BELBUCA™ and returning the product to BDSI. This termination was completed on January 6, 2017. As a result of this announcement and a comprehensive assessment of its product portfolio, the Company restructured its U.S. Branded - Specialty & Established Pharmaceuticals segment sales organization during the fourth quarter of 2016 (the 2016 U.S. Branded - Specialty & Established Pharmaceuticals Restructuring Initiative), which included the elimination of an approximate 375-member U.S. Branded - Specialty & Established Pharmaceuticals pain field sales force and the termination of certain contracts.

The Company incurred total pre-tax charges of approximately $61.5 million during the fourth quarter of 2016. These charges consisted of a non-cash intangible asset impairment charge of approximately $36.8 million, employee separation and other benefit-related costs of $16.5 million, early contract termination fees of $5.2 million and $3.0 million of inventory write-offs. These charges are included in the U.S. Branded - Specialty & Established Pharmaceuticals segment and are included in Asset impairment charges, Cost of revenues, and Selling, general and administrative expenses in the Consolidated Statements of Operations.

The Company did not incur any other material pre-tax charges as a result of the 2016 U.S. Branded - Specialty & Established Pharmaceuticals Restructuring Initiative and does not expect to incur additional material pre-tax restructuring-related expenses related to this initiative. Actions related to this initiative were completed by December 31, 2016 and substantially all of the cash payments were made by the end of 2017.

The liability related to the 2016 U.S. Branded - Specialty & Established Pharmaceuticals Restructuring Initiative is included in Accounts payable and accrued expenses in the Consolidated Balance Sheets. Changes to this liability during the year ended December 31, 2017 were as follows (in thousands):



	Employee Separation and Other Benefit-Related Costs			Contract Termination Charges			Total
Liability balance as of January 1, 2017	$	16,544		$	5,224		$	21,768
Cash distributions	(16,544		)	(5,224		)	(21,768		)
Liability balance as of December 31, 2017	$	—		$	—		$	—

January 2017 Restructuring Initiative

On January 26, 2017, the Company announced a restructuring initiative implemented as part of its ongoing organizational review (the January 2017 Restructuring Initiative). This restructuring was intended to further integrate, streamline and optimize the Company’s operations by aligning certain corporate and research and development (R&D) functions with its recently restructured U.S. generics and U.S. branded business units in order to create efficiencies and cost savings. As part of this restructuring, the Company undertook certain cost reduction initiatives, including a reduction of approximately 90 positions of its workforce, primarily related to corporate and branded R&D functions in Malvern, Pennsylvania and Chestnut Ridge, New York, a streamlining of general and administrative expenses, an optimization of commercial spend and a refocusing of research and development efforts.

During the year ended December 31, 2017, the Company incurred total pre-tax charges of approximately $15.1 million related to employee separation and other benefit-related costs. Of the total charges incurred, $6.9 million was included in the U.S. Branded - Specialty & Established Pharmaceuticals segment, $4.9 million was included in Corporate unallocated costs and $3.3 million was included in the U.S. Generic Pharmaceuticals segment. These charges were included in Selling, general and administrative expenses in the Consolidated Statements of Operations.

The Company did not incur any other material pre-tax charges as a result of the January 2017 Restructuring Initiative and does not expect to incur additional material pre-tax restructuring-related expenses related to this initiative. Substantially all of the actions associated with this restructuring were completed by the end of April 2017.

The liability related to the January 2017 Restructuring Initiative is included in Accounts payable and accrued expenses in the Consolidated Balance Sheets. Changes to this liability during the years ended December 31, 2018 and 2017 were as follows (in thousands):



	Total
Liability balance as of January 1, 2017	$	—
Expenses	15,072
Cash distributions	(12,391		)
Liability balance as of December 31, 2017	$	2,681
Cash distributions	(2,681		)
Liability balance as of December 31, 2018	$	—

2017 U.S. Generic Pharmaceuticals Restructuring Initiative

On July 21, 2017, the Company announced that after completing a comprehensive review of its manufacturing network, it would be ceasing operations and closing its manufacturing and distribution facilities in Huntsville, Alabama (the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative). The closure of the facilities was completed in June 2018 and the facilities were sold in the fourth quarter of 2018 for net cash proceeds of $23.1 million, resulting in a net gain on disposal of $12.5 million, which is included in Other income, net in the Consolidated Statements of Operations.

As a result of the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative, the Company incurred pre-tax charges of $61.6 million and $286.7 million during the years ended December 31, 2018 and 2017, respectively. The 2018 amount does not include the $12.5 million gain on the sale of the Huntsville facilities described above.

During the year ended December 31, 2018, the expenses consisted of charges relating to accelerated depreciation of $35.2 million, employee separation, retention and other benefit-related costs of $9.1 million, asset impairment charges of $2.6 million and certain other charges of $14.7 million, partially offset by the gain on the sale of the Huntsville facilities described above.

During the year ended December 31, 2017, the expenses included accelerated depreciation charges of $123.3 million, employee separation, retention and other benefit-related costs of $29.6 million, certain intangible asset and property, plant and equipment impairment charges of $104.7 million, charges to increase excess inventory reserves of $12.1 million and certain other charges of $17.0 million.

These charges are included in the U.S. Generic Pharmaceuticals segment. Accelerated depreciation, employee separation, retention and other benefit-related costs and charges to increase excess inventory reserves are included in Cost of revenues in the Consolidated Statements of Operations. Impairment charges are included in Asset impairment charges. Certain other charges are included in both Cost of revenues and Selling, general and administrative expenses.

The liability related to the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative is primarily included in Accounts payable and accrued expenses in the Consolidated Balance Sheets. Changes to this liability during the years ended December 31, 2018 and 2017 were as follows (in thousands):



	Employee Separation and Other Benefit-Related Costs			Other Restructuring Costs			Total
Liability balance as of January 1, 2017	$	—		$	—		$	—
Expenses	29,553			13,724			43,277
Cash distributions	(6,578		)	(12,114		)	(18,692		)
Liability balance as of December 31, 2017	$	22,975		$	1,610		$	24,585
Expenses	9,090			11,294			20,384
Cash distributions	(27,826		)	(12,856		)	(40,682		)
Liability balance as of December 31, 2018	$	4,239		$	48		$	4,287

Substantially all cash payments are expected to be made by the end of the third quarter in 2019.

January 2018 Restructuring Initiative

In January 2018, the Company initiated a restructuring initiative that included a reorganization of its U.S. Generic Pharmaceuticals segment’s research and development network, a further simplification of the Company’s manufacturing networks and a company-wide unification of certain corporate functions (the January 2018 Restructuring Initiative).

As a result of the January 2018 Restructuring Initiative, the Company incurred pre-tax charges of $23.5 million and $2.6 million during the years ended December 31, 2018 and 2017, respectively.

The expenses in 2018 consisted primarily of employee separation, retention and other benefit-related costs of $21.7 million and certain other charges of $1.8 million. Of the total charges incurred, $10.6 million are included in the U.S. Generic Pharmaceuticals segment, $5.2 million are included in Corporate unallocated costs, $3.9 million are included in the U.S. Branded - Sterile Injectables segment, $3.1 million are included in the International Pharmaceuticals segment and $0.7 million are included in the U.S. Branded - Specialty & Established Pharmaceuticals segment.

The expenses in 2017 consisted of certain property, plant and equipment impairment charges of $2.0 million and certain other charges of $0.6 million. These charges are primarily included in the U.S. Generic Pharmaceuticals segment.

Employee separation, retention and other benefit-related costs are included in Cost of revenues, Selling, general and administrative and Research and development expenses in the Consolidated Statements of Operations. Certain other charges are primarily included in Selling, general and administrative expenses. Impairment charges are included in Asset impairment charges.

The Company did not incur any other material pre-tax charges as a result of the January 2018 Restructuring Initiative and does not expect to incur additional material pre-tax restructuring-related expenses related to this initiative.

The liability related to the January 2018 Restructuring Initiative is primarily included in Accounts payable and accrued expenses in the Consolidated Balance Sheets. Changes to this liability during the year ended December 31, 2018 were as follows (in thousands):



	Employee Separation and Other Benefit-Related Costs			Other Restructuring Costs			Total
Liability balance as of January 1, 2018	$	—		$	650		$	650
Expenses	21,754			1,764			23,518
Cash distributions	(20,925		)	(2,094		)	(23,019		)
Liability balance as of December 31, 2018	$	829		$	320		$	1,149

Substantially all cash payments are expected to be made by the end of the second quarter in 2019.

Acquisitions	12 Months Ended
Acquisitions	Dec. 31, 2018
Business Combinations [Abstract]
ACQUISITIONS	NOTE 5. ACQUISITIONS VOLTAREN^® Gel The Company had exclusive U.S. marketing rights to VOLTAREN^® Gel through June 30, 2016 pursuant to a License and Supply Agreement entered into in 2008 with and among Novartis AG and Novartis Consumer Health, Inc. (the 2008 VOLTAREN^® Gel Agreement). On December 11, 2015, the Company, Novartis AG and Sandoz Inc. entered into a new License and Supply Agreement (the 2015 VOLTAREN^® Gel Agreement) whereby the Company licensed exclusive U.S. marketing and license rights to commercialize VOLTAREN^® Gel and to launch an authorized generic of VOLTAREN^® Gel effective July 1, 2016. Pursuant to the 2015 VOLTAREN^® Gel Agreement, the former 2008 VOLTAREN^® Gel Agreement expired on June 30, 2016 in accordance with its terms. The Company accounted for this transaction as a business combination as of the effective date in accordance with the relevant accounting literature. The Company acquired the product for consideration of approximately $162.7 million, consisting of an upfront payment of $16.2 million and contingent cash consideration with an acquisition-date fair value of approximately $146 million, including the impact of a measurement period adjustment recorded during the fourth quarter of 2016. See Note 7. Fair Value Measurements for further discussion of this contingent consideration. The preliminary fair values of the net identifiable assets acquired totaled approximately $162.7 million, resulting in no goodwill. The amount of net identifiable assets acquired in connection with the VOLTAREN^® Gel acquisition includes approximately $162.7 million of identifiable developed technology intangible assets to be amortized over an initial average life of approximately 7 years. The operating results of VOLTAREN^® Gel under business combination accounting are included in the accompanying Consolidated Statements of Operations for the years ended December 31, 2018 and 2017 and for the six months ended December 31, 2016. The results included in the accompanying Consolidated Statements of Operations for the six months ended June 30, 2016, were accounted for under the previous license and supply agreement, which was not treated as a business combination. Pro forma results of operations have not been presented because the effect of the 2015 VOLTAREN^® Gel Agreement was not material. The estimates of the fair values of the net assets acquired were finalized and all measurement period adjustments were complete as of December 31, 2016.

Segment Results

12 Months Ended

Dec. 31, 2018

Segment Reporting [Abstract]

SEGMENT RESULTS

NOTE 6. SEGMENT RESULTS

As of January 1, 2018, we made changes to our reportable segments. Following these changes, the four reportable business segments in which we operate are: (1) U.S. Branded - Specialty & Established Pharmaceuticals, (2) U.S. Branded - Sterile Injectables, (3) U.S. Generic Pharmaceuticals and (4) International Pharmaceuticals. Previously, we had three reportable segments: (1) U.S. Generic Pharmaceuticals, (2) U.S. Branded Pharmaceuticals and (3) International Pharmaceuticals. The updates to our reportable segments were made based on first quarter 2018 changes to the way we manage and evaluate our business.

Our new U.S. Branded - Sterile Injectables segment consists of our sterile injectables product portfolio, which was previously part of our former U.S. Generic Pharmaceuticals segment. Our new U.S. Generic Pharmaceuticals segment represents the remainder of our former U.S. Generic Pharmaceuticals segment. Additionally, our former U.S. Branded Pharmaceuticals segment has been renamed “U.S. Branded - Specialty & Established Pharmaceuticals.”

Our segments reflect the level at which the chief operating decision maker regularly reviews financial information to assess performance and to make decisions about resources to be allocated. Each segment derives revenue from the sales or licensing of its respective products and is discussed in more detail below.

We evaluate segment performance based on each segment’s adjusted income from continuing operations before income tax, which we define as Loss from continuing operations before income tax and before certain upfront and milestone payments to partners; acquisition-related and integration items, including transaction costs and changes in the fair value of contingent consideration; cost reduction and integration-related initiatives such as separation benefits, retention payments, other exit costs and certain costs associated with integrating an acquired company’s operations; asset impairment charges; amortization of intangible assets; inventory step-up recorded as part of our acquisitions; litigation-related and other contingent matters; gains or losses from early termination of debt; gains or losses from the sales of businesses and other assets; foreign currency gains or losses on intercompany financing arrangements; and certain other items.

Certain of the corporate expenses incurred by the Company are not attributable to any specific segment. Accordingly, these costs are not allocated to any of the Company’s segments and are included in the results below as “Corporate unallocated costs.” Interest income and expense are also considered corporate items and not allocated to any of the Company’s segments. The Company’s consolidated adjusted income from continuing operations before income tax is equal to the combined results of each of its segments less these unallocated corporate items.

U.S. Branded - Specialty & Established Pharmaceuticals

Our U.S. Branded - Specialty & Established Pharmaceuticals segment includes a variety of branded prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain and orthopedics. The products in this segment include XIAFLEX^®, SUPPRELIN^®LA, NASCOBAL^® Nasal Spray, TESTOPEL^®, AVEED^®, PERCOCET^®, VOLTAREN^®Gel, LIDODERM^®, FORTESTA^®Gel, EDEX^® and TESTIM^®, among others.

U.S. Branded - Sterile Injectables

Our U.S. Branded - Sterile Injectables segment consists primarily of branded sterile injectable products such as VASOSTRICT^®, ADRENALIN^® and APLISOL^®, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others.

U.S. Generic Pharmaceuticals

Our U.S. Generic Pharmaceuticals segment consists of a differentiated product portfolio including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics and sprays and includes products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health and cardiovascular disease markets, among others.

International Pharmaceuticals

Our International Pharmaceuticals segment includes a variety of specialty pharmaceutical products sold outside the U.S., primarily in Canada through our operating company Paladin. This segment’s key products serve growing therapeutic areas, including attention deficit hyperactivity disorder, pain, women’s health and oncology. This segment also included: (i) our South African Litha business, which was sold in July 2017, and (ii) our Latin American Somar business, which was sold in October 2017.

The following represents selected information for the Company’s reportable segments for the years ended December 31, 2018, 2017 and 2016 (in thousands):



	2018		2017		2016
Net revenues from external customers:
U.S. Branded - Specialty & Established Pharmaceuticals	$	862,832	$	957,525	$	1,166,294
U.S. Branded - Sterile Injectables	929,566		750,471		576,399
U.S. Generic Pharmaceuticals	1,012,215		1,530,530		1,988,214
International Pharmaceuticals (1)	142,465		230,332		279,367
Total net revenues from external customers	$	2,947,078	$	3,468,858	$	4,010,274
Adjusted income from continuing operations before income tax:
U.S. Branded - Specialty & Established Pharmaceuticals	$	368,790	$	485,515	$	553,806
U.S. Branded - Sterile Injectables	695,363		563,103		426,170
U.S. Generic Pharmaceuticals	317,892		501,249		653,309
International Pharmaceuticals	59,094		58,308		84,337
Total segment adjusted income from continuing operations before income tax	$	1,441,139	$	1,608,175	$	1,717,622

__________


(1)	Revenues generated by our International Pharmaceuticals segment are primarily attributable to external customers located in Canada and, prior to the sale of Litha in July 2017 and Somar in October 2017, South Africa and Latin America.

There were no material revenues from external customers attributed to an individual country outside of the U.S. during any of the periods presented. There were no material tangible long-lived assets in an individual country other than the U.S. as of December 31, 2018 or December 31, 2017.

The table below provides reconciliations of our Total consolidated loss from continuing operations before income tax, which is determined in accordance with U.S. generally accepted accounting principles (U.S. GAAP), to our total segment adjusted income from continuing operations before income tax for the years ended December 31, 2018, 2017 and 2016 (in thousands):



	2018			2017			2016
Total consolidated loss from continuing operations before income tax	$	(938,832	)	$	(1,483,004	)	$	(3,923,856	)
Interest expense, net	521,656			488,228			452,679
Corporate unallocated costs (1)	200,592			165,298			189,043
Amortization of intangible assets	622,339			773,766			876,451
Inventory step-up and certain manufacturing costs that will be eliminated pursuant to integration plans	261			390			125,699
Upfront and milestone payments to partners	45,108			9,483			8,330
Separation benefits and other cost reduction initiatives (2)	86,295			212,448			107,491
Impact of VOLTAREN® Gel generic competition	—			—			(7,750		)
Certain litigation-related and other contingencies, net (3)	13,809			185,990			23,950
Asset impairment charges (4)	916,939			1,154,376			3,781,165
Acquisition-related and integration items (5)	21,914			58,086			87,601
Loss on extinguishment of debt	—			51,734			—
Foreign currency impact related to the remeasurement of intercompany debt instruments	(5,486		)	(1,403		)	366
Other, net (6)	(43,456		)	(7,217		)	(3,547		)
Total segment adjusted income from continuing operations before income tax	$	1,441,139		$	1,608,175		$	1,717,622

__________


(1)	Amounts include certain corporate overhead costs, such as headcount, facility and corporate litigation expenses and certain other income and expenses.

(2)

Amounts in 2018 primarily relate to employee separation costs of $31.7 million, accelerated depreciation of $35.2 million, charges to increase excess inventory reserves of $2.9 million and other charges of $16.5 million, each of which related primarily to our restructuring initiatives. Amounts in 2017 primarily relate to employee separation costs of $53.0 million, accelerated depreciation of $123.7 million, charges to increase excess inventory reserves of $13.7 million and other charges of $22.0 million. These charges were related primarily to the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative. Amounts in 2016 primarily relate to employee separation costs of $60.2 million, charges to increase excess inventory reserves of $24.5 million and other restructuring costs of $25.1 million, consisting primarily of contract termination fees and building costs. See Note 4. Restructuring for discussion of our material restructuring initiatives.


(3)	Amounts include adjustments for Litigation-related and other contingencies, net as further described in Note 15. Commitments and Contingencies.


(4)	Amounts primarily relate to charges to impair goodwill and intangible assets as further described in Note 10. Goodwill and Other Intangibles as well as charges to write down certain property, plant and equipment as further described in Note 4. Restructuring, Note 7. Fair Value Measurements and Note 9. Property, Plant and Equipment.


(5)	Amounts include charges due to changes in the fair value of contingent consideration of $19.9 million, $49.9 million and $23.8 million, respectively. All other amounts are directly related to costs associated with acquisition and integration efforts.


(6)	Amounts in 2018 primarily relate to gains on sales of businesses and other assets, as further described in Note 19. Other Income, Net.

The Company disaggregates its revenue from contracts with customers into the categories included in the table below (in thousands). The Company believes these categories depict how the nature, timing and uncertainty of revenue and cash flows are affected by economic factors.



	2018		2017		2016
U.S. Branded - Specialty & Established Pharmaceuticals:
Specialty Products:
XIAFLEX®	$	264,638	$	213,378	$	189,689
SUPPRELIN® LA	81,707		86,211		78,648
Other Specialty (1)	156,607		153,384		138,483
Total Specialty Products	$	502,952	$	452,973	$	406,820
Established Products:
PERCOCET®	$	122,901	$	125,231	$	139,211
VOLTAREN® Gel	57,700		68,780		100,642
OPANA® ER	—		83,826		158,938
Other Established (2)	179,279		226,715		360,683
Total Established Products	$	359,880	$	504,552	$	759,474
Total U.S. Branded - Specialty & Established Pharmaceuticals (3)	$	862,832	$	957,525	$	1,166,294
U.S. Branded - Sterile Injectables:
VASOSTRICT®	$	453,767	$	399,909	$	343,468
ADRENALIN®	143,489		76,523		22,172
Ertapenem for injection	57,668		—		—
Other Sterile Injectables (4)	274,642		274,039		210,759
Total U.S. Branded - Sterile Injectables (3)	$	929,566	$	750,471	$	576,399
Total U.S. Generic Pharmaceuticals (5)	$	1,012,215	$	1,530,530	$	1,988,214
Total International Pharmaceuticals (6)	$	142,465	$	230,332	$	279,367
Total Revenues	$	2,947,078	$	3,468,858	$	4,010,274

__________


(1)	Products included within Other Specialty include NASCOBAL^®Nasal Spray, TESTOPEL^® and AVEED^®.


(2)	Products included within Other Established include, but are not limited to, LIDODERM^®, FORTESTA^® Gel, EDEX^® and TESTIM^® including the authorized generics of TESTIM^® and FORTESTA^® Gel.


(3)	Individual products presented above represent the top two performing products in each product category and/or any product having revenues in excess of $100 million during any of the years ended December 31, 2018, 2017 and 2016 or $25 million during any quarterly period in 2018.


(4)	Products included within Other Sterile Injectables include, but are not limited to, APLISOL^® and ephedrine sulfate injection.

(5)

The U.S. Generic Pharmaceuticals segment is comprised of a portfolio of products that are generic versions of branded products, are distributed primarily through the same wholesalers, generally have no intellectual property protection and are sold within the U.S. Combined sales of ezetimibe tablets and quetiapine ER tablets, for which we lost temporary marketing exclusivity during the second quarter of 2017, made up 7% of consolidated total revenue in both 2017 and 2016. No other individual product within this segment has exceeded 5% of consolidated total revenues for the periods presented.


(6)	The International Pharmaceuticals segment, which accounted for 5%, 7% and 7% of consolidated total revenues in 2018, 2017 and 2016, respectively, includes a variety of specialty pharmaceutical products sold outside the U.S., primarily in Canada through our operating company Paladin. This segment also included Litha, which was sold in July 2017, and Somar, which was sold in October 2017.

The following represents depreciation expense for our reportable segments for the years ended December 31, 2018, 2017 and 2016 (in thousands):



	2018		2017		2016
U.S. Branded - Specialty & Established Pharmaceuticals	$	14,542	$	16,957	$	16,294
U.S. Branded - Sterile Injectables	10,500		8,411		9,023
U.S. Generic Pharmaceuticals	66,016		174,652		70,816
International Pharmaceuticals	4,925		3,332		2,557
Corporate unallocated	5,385		6,647		8,168
Total depreciation expense	$	101,368	$	209,999	$	106,858

Asset information is not reviewed or included within our internal management reporting. Therefore, the Company has not disclosed asset information for each reportable segment.

Fair Value Measurements

12 Months Ended

Dec. 31, 2018

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

NOTE 7. FAIR VALUE MEASUREMENTS

Financial Instruments

The financial instruments recorded in our Consolidated Balance Sheets include cash and cash equivalents (including money market funds and time deposits), restricted cash and cash equivalents, accounts receivable, marketable securities, equity and cost method investments, accounts payable and accrued expenses, acquisition-related contingent consideration and debt obligations. Included in cash and cash equivalents and restricted cash and cash equivalents are money market funds representing a type of mutual fund required by law to invest in low-risk securities (for example, U.S. government bonds, U.S. Treasury Bills and commercial paper). Money market funds pay dividends that generally reflect short-term interest rates. Due to their short-term maturity, the carrying amounts of non-restricted and restricted cash and cash equivalents (including money market funds and time deposits), accounts receivable, accounts payable and accrued expenses approximate their fair values.

The following table presents current and non-current restricted cash and cash equivalent balances at December 31, 2018 and 2017 (in thousands):



	2018		2017
Restricted cash and cash equivalents—current portion (1)	$	305,368	$	320,453
Restricted cash and cash equivalents—noncurrent portion (2)	22,356		3,956
Restricted cash and cash equivalents—total (3)	$	327,724	$	324,409

__________


(1)	These amounts are reported in our Consolidated Balance Sheets as Restricted cash and cash equivalents.


(2)	These amounts are reported in our Consolidated Balance Sheets as Other assets.

(3)

Approximately $299.7 million and $313.8 million of our restricted cash and cash equivalents are held in qualified settlement funds (QSFs) for mesh-related matters at December 31, 2018 and December 31, 2017, respectively. The remaining amount of restricted cash and cash equivalents at December 31, 2018 primarily relates to other litigation-related matters. See Note 15. Commitments and Contingencies for further information.

Fair value guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:


•	Level 1—Quoted prices in active markets for identical assets or liabilities.


•	Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.


•	Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Marketable Securities

Equity securities consist of investments in the stock of publicly traded companies, the values of which are based on quoted market prices and thus represent Level 1 measurements within the above-defined fair value hierarchy. These securities are not held to support current operations and are therefore classified as non-current assets. Equity securities are included in Marketable securities in our Consolidated Balance Sheets at December 31, 2018 and December 31, 2017.

Acquisition-Related Contingent Consideration

The fair value of contingent consideration liabilities is determined using unobservable inputs; hence these instruments represent Level 3 measurements within the above-defined fair value hierarchy. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period, the contingent consideration liability is remeasured at current fair value with changes recorded in earnings. Changes in any of these estimated inputs used as of the date of this report could have resulted in significant adjustments to fair value. See Recurring Fair Value Measurements below for additional information on acquisition-related contingent consideration.

Recurring Fair Value Measurements

The Company’s financial assets and liabilities measured at fair value on a recurring basis at December 31, 2018 and 2017 were as follows (in thousands):



	Fair Value Measurements at December 31, 2018 using:
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets:
Money market funds	$	137,215	$	—	$	—	$	137,215
Equity securities	738		—		—		738
Total	$	137,953	$	—	$	—	$	137,953
Liabilities:
Acquisition-related contingent consideration—short-term	$	—	$	—	$	36,514	$	36,514
Acquisition-related contingent consideration—long-term	—		—		80,189		80,189
Total	$	—	$	—	$	116,703	$	116,703



	Fair Value Measurements at December 31, 2017 using:
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets:
Money market funds	$	439,831	$	—	$	—	$	439,831
Time deposits	—		303,410		—		303,410
Equity securities	1,456		—		—		1,456
Total	$	441,287	$	303,410	$	—	$	744,697
Liabilities:
Acquisition-related contingent consideration—short-term	$	—	$	—	$	70,543	$	70,543
Acquisition-related contingent consideration—long-term	—		—		119,899		119,899
Total	$	—	$	—	$	190,442	$	190,442

At December 31, 2018 and December 31, 2017, money market funds include $86.9 million and $35.6 million, respectively, in QSFs to be disbursed to mesh-related or other product liability claimants. Amounts in QSFs are considered restricted cash equivalents. See Note 15. Commitments and Contingencies for further discussion of our product liability cases. At December 31, 2018 and December 31, 2017, the differences between the amortized cost and the fair value of our money market funds and equity securities, as well as the related gross unrealized gains or losses, were not material, individually or in the aggregate.

Fair Value Measurements Using Significant Unobservable Inputs

The following table presents changes to the Company’s liability for acquisition-related contingent consideration, which was measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the years ended December 31, 2018 and 2017 (in thousands):



	2018			2017
Beginning of period	$	190,442		$	262,113
Amounts settled	(92,627		)	(122,559		)
Changes in fair value recorded in earnings	19,910			49,949
Effect of currency translation	(1,022		)	939
End of period	$	116,703		$	190,442

At December 31, 2018, the fair value measurements of the contingent consideration obligations were determined using risk-adjusted discount rates ranging from approximately 9.5% to 17.0% (weighted average rate of approximately 13.2%). Changes in fair value recorded in earnings related to acquisition-related contingent consideration are included in our Consolidated Statements of Operations as Acquisition-related and integration items, and amounts recorded for the short-term and long-term portions of acquisition-related contingent consideration are included in Accounts payable and accrued expenses and Other liabilities, respectively, in our Consolidated Balance Sheets.

The following table presents changes to the Company’s liability for acquisition-related contingent consideration during the year ended December 31, 2018 by acquisition (in thousands):



	Balance as of December 31, 2017		Fair Value Adjustments and Accretion			Payments and Other			Balance as of December 31, 2018
Auxilium acquisition	$	13,061	$	2,941		$	(1,845	)	$	14,157
Lehigh Valley Technologies, Inc. acquisitions	63,001		19,146			(47,447		)	34,700
VOLTAREN® Gel acquisition	98,124		9			(41,893		)	56,240
Other	16,256		(2,186		)	(2,464		)	11,606
Total	$	190,442	$	19,910		$	(93,649	)	$	116,703

The following table presents changes to the Company’s liability for acquisition-related contingent consideration during the year ended December 31, 2017 by acquisition (in thousands):



	Balance as of December 31, 2016		Fair Value Adjustments and Accretion			Payments and Other			Balance as of December 31, 2017
Auxilium acquisition	$	21,097	$	467		$	(8,503	)	$	13,061
Lehigh Valley Technologies, Inc. acquisitions	96,000		40,016			(73,015		)	63,001
VOLTAREN^® Gel acquisition	118,395		18,586			(38,857		)	98,124
Other	26,621		(9,120		)	(1,245		)	16,256
Total	$	262,113	$	49,949		$	(121,620	)	$	190,442

Nonrecurring Fair Value Measurements

The Company’s financial assets and liabilities measured at fair value on a nonrecurring basis during the years ended December 31, 2018 and 2017 were as follows (in thousands):



	Fair Value Measurements during the Year Ended December 31, 2018 (1) using:						Total Expense for the Year Ended December 31, 2018
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Expense for the Year Ended December 31, 2018
Assets:
Intangible assets, excluding goodwill (Note 10)	$	—	$	—	$	239,857	$	(230,418	)
Certain property, plant and equipment (2)	—		—		—		(6,521		)
Total	$	—	$	—	$	239,857	$	(236,939	)



	Fair Value Measurements during the Year Ended December 31, 2017 (1) using:						Total Expense for the Year Ended December 31, 2017
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Expense for the Year Ended December 31, 2017
Assets:
Intangible assets, excluding goodwill (Note 10)	$	—	$	—	$	423,258	$	(799,957	)
Certain property, plant and equipment (2)	—		—		—		(65,676		)
Total	$	—	$	—	$	423,258	$	(865,633	)

__________


(1)	The fair value amounts are presented as of the date of the fair value measurement as these assets are not measured at fair value on a recurring basis. Such measurements generally occur in connection with our quarter-end financial reporting close procedures.

(2)

Amount in 2018 includes $2.6 million related to the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative, which is described further in Note 4. Restructuring. Amount in 2017 relates primarily to an aggregate charge of $47.2 million recorded in connection with the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative, which is described further in Note 4. Restructuring, and $11.9 million recorded following the initiation of held-for-sale accounting resulting from the Company’s June 30, 2017 definitive agreement to sell Somar, which is described in Note 3. Discontinued Operations and Divestitures.

Additionally, the Company recorded aggregate pre-tax non-cash goodwill impairment charges during the years ended December 31, 2018 and 2017 of $680.0 million and $288.7 million, respectively. Refer to Note 10. Goodwill and Other Intangibles for further description, including the valuation methodologies utilized.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Property, Plant And Equipment

12 Months Ended

Dec. 31, 2018

Property, Plant and Equipment [Abstract]

PROPERTY, PLANT AND EQUIPMENT

NOTE 9. PROPERTY, PLANT AND EQUIPMENT

Changes in the amount of Property, plant and equipment for the year ended December 31, 2018 are set forth in the table below (in thousands).



Cost:	Land and Buildings			Machinery and Equipment			Leasehold Improvements			Computer Equipment and Software			Assets under Capital Lease			Furniture and Fixtures			Assets under Construction			Total
At January 1, 2018	$	331,466		$	267,818		$	60,464		$	131,451		$	4,896		$	13,124		$	119,035		$	928,254
Additions	20,317			34,570			12,925			18,660			2,286			490			5,549			94,797
Disposals, transfers, impairments and other	(126,961		)	(90,795		)	(4,030		)	(32,602		)	(1,969		)	(1,101		)	(3,545		)	(261,003		)
Effect of currency translation	—			(102		)	(103		)	(375		)	—			(18		)	(15		)	(613		)
At December 31, 2018	$	224,822		$	211,491		$	69,256		$	117,134		$	5,213		$	12,495		$	121,024		$	761,435
Accumulated Depreciation:
At January 1, 2018	$	(149,402	)	$	(134,741	)	$	(26,867	)	$	(82,792	)	$	(4,161	)	$	(6,320	)	$	—		$	(404,283	)
Additions	(39,253		)	(32,273		)	(6,583		)	(21,105		)	(670		)	(1,484		)	—			(101,368		)
Disposals, transfers and other	121,861			83,037			2,806			32,235			1,969			842			—			242,750
Effect of currency translation	—			71			44			225			—			18			—			358
At December 31, 2018	$	(66,794	)	$	(83,906	)	$	(30,600	)	$	(71,437	)	$	(2,862	)	$	(6,944	)	$	—		$	(262,543	)
Net Book Amount:
At December 31, 2018	$	158,028		$	127,585		$	38,656		$	45,697		$	2,351		$	5,551		$	121,024		$	498,892
At December 31, 2017	$	182,064		$	133,077		$	33,597		$	48,659		$	735		$	6,804		$	119,035		$	523,971

Depreciation expense, including expense related to assets under capital lease, was $101.4 million, $210.0 million and $106.9 million for the years ended December 31, 2018, 2017 and 2016, respectively.

During the years ended December 31, 2018, 2017 and 2016, the Company recorded impairment charges totaling $6.5 million, $65.7 million and $15.9 million, respectively. These charges are included in the Asset impairment charges line item in our Consolidated Statement of Operations.

In 2018 and 2016, impairment charges reflect the write-off of certain property, plant and equipment, including amounts that were abandoned or sold as part of our ongoing efforts to improve our operating efficiency and consolidate certain locations.

In 2017, charges primarily relate to an aggregate charge of $47.2 million recorded in connection with the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative, which is described further in Note 4. Restructuring, and $11.9 million recorded following the initiation of held-for-sale accounting resulting from the Company’s June 30, 2017 definitive agreement to sell Somar, which is described in Note 3. Discontinued Operations and Divestitures.

Goodwill And Other Intangibles

12 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND OTHER INTANGIBLES

NOTE 10. GOODWILL AND OTHER INTANGIBLES

Goodwill

Changes in the carrying amount of our goodwill for the years ended December 31, 2018 and 2017 were as follows (in thousands):



	U.S. Branded - Specialty & Established Pharmaceuticals			U.S. Branded - Sterile Injectables		U.S. Generic Pharmaceuticals			International Pharmaceuticals			Total
Goodwill as of December 31, 2016	$	1,009,248		$	—	$	3,531,301		$	188,846		$	4,729,395
Effect of currency translation	—			—		—			9,431			9,431
Goodwill impairment charges	(180,430		)	—		—			(108,314		)	(288,744		)
Goodwill as of December 31, 2017	$	828,818		$	—	$	3,531,301		$	89,963		$	4,450,082
Allocation to current segments (1)	—			2,731,193		(2,731,193		)	—			—
Effect of currency translation	—			—		—			(5,446		)	(5,446		)
Goodwill impairment charges	—			—		(649,000		)	(31,000		)	(680,000		)
Goodwill as of December 31, 2018	$	828,818		$	2,731,193	$	151,108		$	53,517		$	3,764,636

__________


(1)	This allocation relates to the change in segments described in Note 6. Segment Results. The amount of goodwill initially attributed to the new U.S. Branded - Sterile Injectables and U.S. Generic Pharmaceuticals segments was determined using a relative fair value methodology in accordance with U.S. GAAP.

The carrying amounts of goodwill at December 31, 2018 and December 31, 2017 are net of the following accumulated impairments (in thousands):



	U.S. Branded - Specialty & Established Pharmaceuticals		U.S. Branded - Sterile Injectables		U.S. Generic Pharmaceuticals		International Pharmaceuticals		Total
Accumulated impairment losses as of December 31, 2017	$	855,810	$	—	$	2,342,549	$	463,545	$	3,661,904
Accumulated impairment losses as of December 31, 2018	$	855,810	$	—	$	2,991,549	$	456,408	$	4,303,767

Other Intangible Assets

Changes in the amount of other intangible assets for the year ended December 31, 2018 are set forth in the table below (in thousands).



Cost basis:	Balance as of December 31, 2017			Acquisitions			Impairments			Other (1)			Effect of Currency Translation			Balance as of December 31, 2018
Indefinite-lived intangibles:
In-process research and development	$	347,200		$	—		$	(87,900	)	$	(165,400	)	$	—		$	93,900
Total indefinite-lived intangibles	$	347,200		$	—		$	(87,900	)	$	(165,400	)	$	—		$	93,900
Finite-lived intangibles:
Licenses (weighted average life of 12 years)	$	457,402		$	—		$	—		$	—		$	—		$	457,402
Tradenames	6,409			—			—			—			—			6,409
Developed technology (weighted average life of 11 years)	6,187,764			3,000			(142,518		)	154,753			(20,984		)	6,182,015
Total finite-lived intangibles (weighted average life of 11 years)	$	6,651,575		$	3,000		$	(142,518	)	$	154,753		$	(20,984	)	$	6,645,826
Total other intangibles	$	6,998,775		$	3,000		$	(230,418	)	$	(10,647	)	$	(20,984	)	$	6,739,726

Accumulated amortization:	Balance as of December 31, 2017			Amortization			Impairments			Other (1)			Effect of Currency Translation			Balance as of December 31, 2018
Finite-lived intangibles:
Licenses	$	(370,221	)	$	(27,961	)	$	—		$	—		$	—		$	(398,182	)
Tradenames	(6,409		)	—			—			—			—			(6,409		)
Developed technology	(2,304,461		)	(594,378		)	—			10,647			10,363			(2,877,829		)
Total other intangibles	$	(2,681,091	)	$	(622,339	)	$	—		$	10,647		$	10,363		$	(3,282,420	)
Net other intangibles	$	4,317,684														$	3,457,306

__________


(1)	Other adjustments relate to reclassification adjustments of $165.4 million for certain developed technology intangible assets, previously classified as in-process research and development, that were placed in service during the year ended December 31, 2018 and the removal of certain fully amortized intangible assets.

Amortization expense for the years ended December 31, 2018, 2017 and 2016 totaled $622.3 million, $773.8 million and $876.5 million, respectively. Amortization expense is included in Cost of revenues in the Consolidated Statements of Operations. Estimated amortization of intangibles for the five fiscal years subsequent to December 31, 2018 is as follows (in thousands):



2019	$	550,574
2020	$	479,358
2021	$	445,215
2022	$	418,844
2023	$	384,223

Impairments

Endo tests goodwill and indefinite-lived intangible assets for impairment annually, or more frequently whenever events or changes in circumstances indicate that the asset might be impaired. Our annual assessment is performed as of October 1st.

As part of our goodwill and intangible asset impairment assessments, we estimate the fair values of our reporting units and our intangible assets using an income approach that utilizes a discounted cash flow model or, where appropriate, a market approach. The discounted cash flow models are dependent upon our estimates of future cash flows and other factors. These estimates of future cash flows involve assumptions concerning (i) future operating performance, including future sales, long-term growth rates, operating margins, tax rates, variations in the amount and timing of cash flows and the probability of achieving the estimated cash flows and (ii) future economic conditions. These assumptions are based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy. The discount rates applied to the estimated cash flows for the Company’s October 1, 2018, 2017 and 2016 annual goodwill and indefinite-lived intangible assets impairment test ranged from 9.5% to 11.5%, from 9.5% to 12.5% and from 8.5% to 11.0%, respectively, depending on the overall risk associated with the particular assets and other market factors. We believe the discount rates and other inputs and assumptions are consistent with those that a market participant would use. Any impairment charges resulting from annual or interim goodwill and intangible asset impairment assessments are recorded to Asset impairment charges in our Consolidated Statements of Operations.

During the years ended December 31, 2018, 2017 and 2016, the Company incurred the following goodwill and other intangible asset impairment charges (in thousands):



	2018		2017		2016
Goodwill impairment charges	$	680,000	$	288,745	$	2,676,350
Other intangible asset impairment charges	$	230,418	$	799,955	$	1,088,903

A summary of significant goodwill and other intangible asset impairment tests and related charges is included below. Other pre-tax non-cash intangible asset impairment charges that are not included in the below narrative totaled $230.4 million, $586.9 million and $862.0 million during the years ended December 31, 2018, 2017 and 2016, respectively. These charges relate primarily to certain in-process research and development and/or developed technology intangible assets that were tested for impairment following changes in market conditions and certain other factors impacting recoverability.

Annual Goodwill Impairment Tests

As a result of our annual test performed as of October 1, 2018, the Company determined that the estimated carrying amounts of the U.S. Generic Pharmaceuticals and Paladin reporting units exceeded their respective fair values; therefore, the Company recorded pre-tax non-cash goodwill impairment charges of $258.0 million and $31.0 million, respectively, during the fourth quarter of 2018.

The U.S. Generic Pharmaceuticals impairment can be primarily attributed to an increase in the discount rate used in the determination of fair value and unfavorable underlying business outlook assumption changes. The Paladin impairment was primarily a result of increased competition and slower than expected product launches in our Canadian market. We did not record goodwill impairment charges for the other reporting units as a result of the annual tests.

As a result of our annual test performed as of October 1, 2017, the Company determined that the estimated fair values of its Branded, Generics and Paladin reporting units exceeded their carrying amounts; therefore, no related goodwill impairment charge was required.

Certain of our 2016 impairment charges discussed below related to our 2016 annual goodwill impairment test. After performing this test, we concluded that the carrying amounts of our Generics, Paladin, Somar and Litha reporting units each exceeded their respective estimated fair values and recorded goodwill impairment charges of $2,342.5 million, $272.6 million, $33.0 million and $26.3 million, respectively. The impairments were a result of a combination of factors, including increased buying power from the continued consolidation of our generic business customer base, a significant change in the value derived from the level and frequency of anticipated future pricing opportunities and increased levels of competition, particularly in our Generics reporting unit, due to the entry of new low cost competitors and accelerated FDA ANDA approvals. These factors were exacerbated by an increase in the risk factor included in the discount rate used to calculate the Generics discounted cash flows since the date of the preceding interim test. The increase in the discount rate was due to the implied control premium resulting from recent trading values of our stock. On a combined basis, these factors reduced the estimated fair value of our reporting units.

Other Impairment Tests

Our first quarter 2018 change in segments described in Note 6. Segment Results resulted in changes to our reporting units for goodwill impairment testing purposes, including the creation of a new U.S. Branded - Sterile Injectables reporting unit, which was previously part of our Generics reporting unit. As a result of these changes, under U.S. GAAP, we tested the goodwill of the former Generics reporting unit immediately before the segment realignment and the goodwill of both the new U.S. Branded - Sterile Injectables and U.S. Generic Pharmaceuticals reporting units immediately after the segment realignment. These goodwill tests were performed using an income approach that utilizes a discounted cash flow model. The results of these goodwill impairment tests were as follows:


•	The former Generics reporting unit’s estimated fair value (determined using a discount rate of 9.5%) exceeded its carrying amount, resulting in no related goodwill impairment charge.


•	The new U.S. Branded - Sterile Injectables reporting unit’s estimated fair value (determined using a discount rate of 9.5%) exceeded its carrying amount, resulting in no related goodwill impairment charge.


•	The new U.S. Generic Pharmaceuticals reporting unit’s carrying amount exceeded its estimated fair value (determined using a discount rate of 9.5%), resulting in a pre-tax non-cash goodwill impairment charge of $391.0 million.

In March 2017, we announced that the FDA’s Drug Safety and Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees voted that the benefits of reformulated OPANA^®ER (oxymorphone hydrochloride extended release) no longer outweigh its risks. In June 2017, we became aware of the FDA’s request that we voluntarily withdraw OPANA^®ER from the market and, in July 2017, after careful consideration and consultation with the FDA, we decided to voluntarily remove OPANA^®ER from the market. As a result of our decision, the Company determined that the carrying amount of its OPANA^® ER intangible asset was no longer recoverable, resulting in a pre-tax, non-cash impairment charge of $20.6 million in the second quarter of 2017, representing the remaining carrying amount.

As a result of the withdrawal of OPANA^® ER from the market and the continued erosion of our U.S. Branded - Specialty & Established Pharmaceuticals segment’s Established Products portfolio, we initiated an interim goodwill impairment analysis of our Branded reporting unit during the second quarter of 2017. We recorded a pre-tax, non-cash goodwill impairment charge of $180.4 million during the three months ended June 30, 2017 for the amount by which the reporting unit’s carrying amount exceeded its fair value. We estimated the fair value of the Branded reporting unit using an income approach that utilized a discounted cash flow model. The discount rate applied to the estimated cash flows for our Branded goodwill impairment test was 9.5%.

Following the announcement of the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative, which is further described in Note 4. Restructuring, the Company assessed the recoverability of certain products that were discontinued as part of this initiative, resulting in pre-tax, non-cash intangible asset impairment charges of approximately $57.5 million during the second quarter of 2017.

Pursuant to an existing agreement with a wholly owned subsidiary of Novartis AG (Novartis), Paladin licensed the Canadian rights to commercialize serelaxin, an investigational drug for the treatment of acute heart failure (AHF). In March 2017, Novartis announced that a Phase 3 study of serelaxin in patients with AHF failed to meet its primary endpoints. As a result, we concluded that the full carrying amount of our serelaxin in-process research and development intangible asset was impaired, resulting in a $45.5 million pre-tax non-cash impairment charge during the three months ended March 31, 2017. In addition, and as a result of the serelaxin impairment, we assessed the recoverability of our Paladin goodwill balance and determined that the estimated fair value of the Paladin reporting unit was below its carrying amount. We recorded a pre-tax, non-cash goodwill impairment charge of $82.6 million during the three months ended March 31, 2017 for the amount by which the carrying amount exceeded the reporting unit’s fair value. We estimated the fair value of the Paladin reporting unit using an income approach that utilized a discounted cash flow model. The discount rate applied to the estimated cash flows for our Paladin goodwill impairment test was 10.0%.

As further discussed in Note 3. Discontinued Operations and Divestitures, we entered into a definitive agreement to sell Somar on June 30, 2017, which resulted in Somar’s assets and liabilities being classified as held for sale. The initiation of held-for-sale accounting, together with the agreed upon sale price, triggered an impairment review. Accordingly, we performed an impairment analysis using a market approach and determined that impairment charges were required. We recorded pre-tax, non-cash impairment charges of $25.7 million and $89.5 million related to Somar’s goodwill and other intangible assets, respectively, during the second quarter of 2017, each of which represented the remaining carrying amounts of the corresponding assets.

During the first quarter of 2016, the Company recognized pre-tax, non-cash asset impairment charges of $100.3 million related to the 2016 U.S. Generic Pharmaceuticals Restructuring Initiative, which resulted from the discontinuation of certain commercial products and the abandonment of certain IPR&D projects. See Note 4. Restructuring for discussion of our material restructuring initiatives.

As a result of unfavorable formulary changes and generic competition for sumatriptan, we experienced a downturn in the performance of our SUMAVEL^® DOSEPRO^® product in 2016, which is a needle-free delivery system for sumatriptan acquired from Zogenix, Inc. in 2014. As a result of this underperformance, we concluded during the third quarter of 2016 that an impairment assessment was required to evaluate the recoverability of SUMAVEL^® DOSEPRO^®. After performing this assessment, we recorded a pre-tax, non-cash intangible asset impairment charge of $72.8 million during the third quarter of 2016, representing the remaining carrying amount.

During the third quarter of 2016, we determined that we would not pursue commercialization of a product in certain international markets. Accordingly, we tested the finite-lived intangible asset associated with this product for impairment and determined that the carrying amount was no longer fully recoverable, resulting in a pre-tax, non-cash intangible asset impairment charge of $16.2 million during the third quarter of 2016.

During the fourth quarter of 2016, we recognized a pre-tax, non-cash intangible asset impairment charge of $37.6 million resulting primarily from the termination of our BELBUCA™ product and the return of this product to BDSI. We also recognized a pre-tax, non-cash goodwill impairment charge of $1.9 million at this time, primarily relating to BELBUCA™.

License And Collaboration Agreements	12 Months Ended
License And Collaboration Agreements	Dec. 31, 2018
License And Collaboration Agreements [Abstract]
LICENSE AND COLLABORATION AGREEMENTS	NOTE 11. LICENSE AND COLLABORATION AGREEMENTS Our subsidiaries have entered into certain license, collaboration and discovery agreements with third parties for product development. These agreements require our subsidiaries to share in the development costs of such products and the third parties grant marketing rights to our subsidiaries for such products. Generally, under these agreements: (i) we are required to make upfront payments and other payments upon successful completion of regulatory or sales milestones and (ii) we are required to pay royalties on sales of the products arising from these agreements. BioSpecifics Technologies Corp. The Company, through an affiliate, is party to a development and license agreement, as amended (the BioSpecifics Agreement) with BioSpecifics Technologies Corp. (BioSpecifics). The BioSpecifics Agreement was originally entered into in June 2004 to obtain exclusive worldwide rights to develop, market and sell certain products containing BioSpecifics’ enzyme CCH, which we market for approved indications under the trademark XIAFLEX^®. The Company’s licensed rights concern the development and commercialization of products, other than dermal formulations labeled for topical administration, and currently, the Company’s licensed rights cover the indications of Dupuytren’s contracture (DC), Dupuytren’s nodules, Peyronie’s disease (PD), adhesive capsulitis, cellulite, canine and human lipomas, plantar fibromatosis, lateral hip fat and other potential aesthetic indications. The Company may further expand the BioSpecifics Agreement, at its option, to cover other indications as they are developed by the Company or BioSpecifics. Under the BioSpecifics Agreement, we are responsible, at our own cost and expense, for developing the formulation and finished dosage form of products and arranging for the clinical supply of products. BioSpecifics is currently conducting exploratory clinical trials evaluating CCH as a treatment for a number of conditions, including uterine fibroids. The Company has the option to license development and marketing rights to these indications based on a full analysis of the data from the clinical trials, which would transfer responsibility for the future development costs to the Company and trigger opt-in payments and potential future milestone and royalty payments to BioSpecifics. The BioSpecifics Agreement extends, on a country-by-country and product-by-product basis, for the longer of the patent life, the expiration of any regulatory exclusivity period or twelve years from the effective date. Either party may terminate the BioSpecifics Agreement as a result of the other party’s breach or bankruptcy. We may terminate the BioSpecifics Agreement with 90 days’ written notice. We must pay BioSpecifics on a country-by-country and product-by-product basis a specified percentage within a range of 5% to 15% of net sales for products covered by the BioSpecifics Agreement. This royalty applies to net sales by the Company or its sublicensees, including Asahi Kasei Pharma Corporation and Swedish Orphan Biovitrum AB. We are also obligated to pay a percentage of any future regulatory or commercial milestone payments received from such sublicensees. In addition, the Company and its affiliates pay BioSpecifics an amount equal to a specified mark-up on certain cost of goods related to supply of XIAFLEX^® (which mark-up is capped at a specified percentage within the range of 5% to 15% of the cost of goods of XIAFLEX^®) for products sold by the Company and its affiliates. Other During the second quarter of 2018, we entered into a development, license and commercialization agreement with a third party pharmaceutical company related to five sterile injectable product candidates. Pursuant to this agreement, the third party will generally be responsible, at its expense, to develop and seek regulatory approval for these product candidates, and the Company will generally be responsible, at its expense, to launch and distribute any products that are approved. The Company will have exclusive license rights to all of these products launched in the U.S. and a first right of refusal for the Canadian territory. Upon entering into this agreement, the Company became obligated to make an upfront payment, which was recorded as Research and development expense in the Consolidated Statements of Operations during the three months ended June 30, 2018. The Company could become obligated to make additional payments based on certain potential future milestones being achieved.

Contract Assets and Liabilities

12 Months Ended

Dec. 31, 2018

Contract with Customer, Asset and Liability [Abstract]

Contract Assets and Liabilities

NOTE 12. CONTRACT ASSETS AND LIABILITIES

Our revenue consists almost entirely of sales of our pharmaceutical products to customers, whereby we ship products to a customer pursuant to a purchase order. Revenue contracts such as these do not generally give rise to contract assets or contract liabilities because: (i) the underlying contracts generally have only a single performance obligation and (ii) we do not generally receive consideration until the performance obligation is fully satisfied. At December 31, 2018, the unfulfilled performance obligations for these types of contracts relate to ordered but undelivered products. We generally expect to fulfill the performance obligations and recognize revenue within one week of entering into the underlying contract. Based on the short-term initial contract duration, additional disclosure about the remaining performance obligations is not required.

Certain of our other revenue-generating contracts, including license and collaboration agreements, may result in contract assets and/or contract liabilities. For example, we may recognize contract liabilities upon receipt of certain upfront and milestone payments from customers when there are remaining performance obligations.

The following table shows the opening and closing balances of contract assets and contract liabilities from contracts with customers (dollars in thousands):



	December 31, 2018		January 1, 2018		$ Change			% Change
Contract assets, net (1)	$	12,065	$	11,287	$	778		7	%
Contract liabilities, net (2)	$	19,217	$	20,954	$	(1,737	)	(8	)%

__________

(1)

At December 31, 2018 and January 1, 2018, approximately $9.3 million and $8.2 million, respectively, of these contract asset amounts are classified as current assets and are included in Prepaid expenses and other current assets in the Company’s Consolidated Balance Sheets. The remaining amounts are classified as non-current and are included in Other assets. The net increase in contract assets during the year ended December 31, 2018 was primarily due to certain sales activity during the period, partially offset by reclassifications to accounts receivable following the resolution of certain conditions other than the passage of time affecting the Company’s rights to consideration for the sale of certain goods.

(2)

At December 31, 2018 and January 1, 2018, approximately $1.7 million and $1.9 million, respectively, of these contract liability amounts are classified as current liabilities and are included in Accounts payable and accrued expenses in the Company’s Consolidated Balance Sheets. The remaining amounts are classified as non-current and are included in Other liabilities. During the year ended December 31, 2018, the Company recognized revenue of $1.7 million that was included in the contract liability balance at January 1, 2018, resulting in a corresponding decrease in contract liabilities.

During the year ended December 31, 2018, we recognized revenue of $2.8 million relating to performance obligations satisfied, or partially satisfied, in prior periods. Such revenue generally relates to changes in estimates with respect to our variable consideration.

Debt

12 Months Ended

Dec. 31, 2018

Debt Disclosure [Abstract]

DEBT

NOTE 14. DEBT

The following table presents information about the Company’s total indebtedness at December 31, 2018 and December 31, 2017 (dollars in thousands):



	December 31, 2018						December 31, 2017
	Effective Interest Rate		Principal Amount		Carrying Amount		Effective Interest Rate		Principal Amount		Carrying Amount
7.25% Senior Notes due 2022	7.91	%	$	400,000	$	392,947	7.91	%	$	400,000	$	390,974
5.75% Senior Notes due 2022	6.04	%	700,000		694,464		6.04	%	700,000		692,855
5.375% Senior Notes due 2023	5.62	%	750,000		743,438		5.62	%	750,000		742,048
6.00% Senior Notes due 2023	6.28	%	1,635,000		1,616,817		6.28	%	1,635,000		1,613,446
5.875% Senior Secured Notes due 2024	6.14	%	300,000		296,062		6.14	%	300,000		295,513
6.00% Senior Notes due 2025	6.27	%	1,200,000		1,183,415		6.27	%	1,200,000		1,181,243
Term Loan B Facility Due 2024	7.02	%	3,363,775		3,331,276		6.09	%	3,397,925		3,360,103
Other debt			—		—		1.50	%	55		55
Total long-term debt, net			$	8,348,775	$	8,258,419			$	8,382,980	$	8,276,237
Less current portion, net			34,150		34,150				34,205		34,205
Total long-term debt, less current portion, net			$	8,314,625	$	8,224,269			$	8,348,775	$	8,242,032

The obligations of the borrowers under the credit agreement are guaranteed by the Company and the subsidiaries of the Company (with certain customary exceptions). The unsecured senior notes are issued by certain of the Company’s subsidiaries and are guaranteed on a senior unsecured basis by the subsidiaries of Endo International plc that also guarantee the credit agreement, except for a de minimis amount of the 7.25% Senior Notes due 2022, which are issued by Endo Health Solutions Inc. (EHSI) and guaranteed on a senior unsecured basis by the guarantors named in the Fifth Supplemental Indenture relating to such notes. The senior secured notes are issued by certain of the Company’s subsidiaries and are guaranteed on a senior secured basis by Endo International plc and its subsidiaries that also guarantee the credit agreement. The obligations under (i) the credit agreement and related loan documents and (ii) the senior secured notes are secured on a pari passu basis by a perfected first priority (subject to certain permitted liens) lien on the collateral securing such instruments, which collateral represents substantially all of the assets of the issuers or borrowers and the guarantors party thereto (subject to customary exceptions). Our senior unsecured notes are unsecured and effectively subordinated in right of priority to our credit agreement and our senior secured notes, in each case to the extent of the value of the collateral securing such instruments.

The aggregate estimated fair value of the Company’s long-term debt, which was estimated using inputs based on quoted market prices for the same or similar debt issuances, was $7.2 billion and $7.5 billion at December 31, 2018 and December 31, 2017, respectively. Based on this valuation methodology, we determined these debt instruments represent Level 2 measurements within the fair value hierarchy.

Credit Facilities

The Company and certain of its subsidiaries are party to a credit agreement (the Credit Agreement), which provides for (i) a senior secured revolving credit facility generally allowing for borrowings in a principal amount of up to $1,000.0 million (the Revolving Credit Facility) and (ii) a senior secured term loan facility in an initial principal amount of $3,415.0 million (the Term Loan Facility and, together with the Revolving Credit Facility, the Credit Facilities). We have $997.3 million of remaining credit available through the Revolving Credit Facility at December 31, 2018.

The Credit Agreement contains affirmative and negative covenants that the Company believes to be usual and customary for a senior secured credit facility of this type. The negative covenants include, among other things, limitations on asset sales, mergers and acquisitions, indebtedness, liens, dividends and other restricted payments, investments and transactions with the Company’s affiliates. As of December 31, 2018 and 2017, we were in compliance with all such covenants.

The Revolving Credit Facility generally matures in 2022. Principal payments on the Term Loan Facility equal to 0.25% of the initial principal amount are generally payable quarterly until the Term Loan Facility’s maturity date in 2024. However, on an annual basis commencing with the year ended December 31, 2018, the Company is required to perform a calculation of Excess Cash Flow (as defined in the Credit Agreement), which could result in certain pre-payments of the principal relating to the Term Loan Facility in accordance with the terms of the Credit Agreement. No such payment is required at December 31, 2018. In addition, any outstanding amounts borrowed pursuant to the Credit Facilities will immediately mature if any of the following of our senior notes (other than, in the case of amounts borrowed pursuant to the Revolving Credit Facility, the 5.375% Senior notes due 2023 and the 6.00% Senior Notes due 2023) are not refinanced or repaid in full prior to the date that is 91 days prior to the stated maturity date thereof:



Instrument		Maturity Date
7.25% Senior Notes Due 2022		January 15, 2022
5.75% Senior Notes Due 2022		January 15, 2022
5.375% Senior Notes Due 2023		January 15, 2023
6.00% Senior Notes Due 2023		July 15, 2023

The Credit Agreement provides that the borrowers thereunder may incur (i) incremental revolving commitments and/or incremental term loans in an aggregate principal amount of up to: (a) up to $1.0 billion plus (b) an unlimited amount if the pro forma First Lien Net Leverage Ratio (as defined in the Credit Agreement) at the time of incurrence of such incremental commitments or loans after giving effect thereto is less than or equal to 2.50 to 1.00 (assuming for purposes of such calculation that any incremental revolving commitments being incurred are fully drawn and without netting cash proceeds of any incremental facilities or incremental equivalent debt) or, (ii) in lieu of incremental facilities under the Credit Agreement, incremental equivalent debt consisting of pari passu notes or loans (subject to pro forma compliance with a First Lien Net Leverage Ratio of 2.50 to 1.00), junior secured notes or loans (subject to pro forma compliance with a Secured Net Leverage Ratio (as defined in the Credit Agreement) of 3.50 to 1.00) or unsecured notes or loans (subject to pro forma compliance with a Total Net Leverage Ratio (as defined in the Credit Agreement) of 6.50 to 1.00), subject, in each case, to compliance by the borrowers with the documentation and other requirements under the Credit Agreement, without the need for consent from any of the existing lenders under the Credit Agreement.

Borrowings under the Revolving Credit Facility bear interest, at the borrower’s election, at a rate equal to (i) an applicable margin between 1.50% and 3.00% depending on the Company’s Total Net Leverage Ratio plus the London Interbank Offered Rate (LIBOR) or (ii) an applicable margin between 0.50% and 2.00% depending on the Company’s Total Net Leverage Ratio plus the Alternate Base Rate (as defined in the Credit Agreement). In addition, borrowings under our Term Loan Facility bear interest, at the borrower’s election, at a rate equal to (i) 4.25% plus LIBOR, subject to a LIBOR floor of 0.75%, or (ii) 3.75% plus the Alternate Base Rate, subject to an Alternate Base Rate floor of 1.75%.

Senior Notes and Senior Secured Notes

Our various senior notes and senior secured notes mature between 2022 and 2025. The indentures governing these notes generally allow for redemption prior to maturity, in whole or in part, subject to certain restrictions and limitations described therein, in the following ways:

•

Until a date specified in each indenture (the Non-Call Period), the notes may be redeemed, in part or in full, by paying the sum of: (i) 100% of the principal amount being redeemed, (ii) an applicable make-whole premium as described in each indenture and (iii) accrued and unpaid interest. As of December 31, 2018, the Non-Call Period has expired for each of our notes except for the 5.875% Senior Secured Notes due 2024 (the 2024 Notes) and the 6.00% Senior Notes due 2025.

•

After the Non-Call Period specified in each indenture, the notes may be redeemed, in whole or in part, at redemption prices set forth in each indenture, plus accrued and unpaid interest. The redemption prices for each of our notes vary over time. The redemption prices pursuant to this clause range from 101.208% to 104.500% of principal at December 31, 2018; however, these redemption prices generally decrease to 100% of the principal amount of the applicable notes over time as the notes approach maturity pursuant to a step-down schedule set forth in each of the indentures.

•

Until a date specified in each indenture, the notes may be redeemed, in part (up to 35% of the principal amount outstanding) with the net cash proceeds from specified equity offerings at redemption prices set forth in each indenture, plus accrued and unpaid interest. As of December 31, 2018, this clause has expired for each of our notes except for the 2024 Notes, for which the specified redemption premium is 105.875%.

Other than the 2024 Notes, these notes are senior unsecured obligations of the Company’s subsidiaries party to the applicable indentures governing such notes. These notes are issued by certain of the Company’s subsidiaries and are guaranteed on a senior unsecured basis by the subsidiaries of Endo International plc that also guarantee the Credit Agreement, except for a de minimis amount of the 7.25% Senior Notes due 2022, which are issued by EHSI and guaranteed on a senior unsecured basis by the guarantors named in the Fifth Supplemental Indenture relating to such notes. The 2024 Notes are senior secured obligations of Endo International plc and its subsidiaries that are party to the indenture governing such notes. These notes are issued by certain of our subsidiaries and are guaranteed on a senior secured basis by Endo International plc and its subsidiaries that also guarantee our Credit Agreement.

The indentures governing our various senior notes contain affirmative and negative covenants that the Company believes to be usual and customary for similar indentures. Under the senior secured notes indenture, the negative covenants, among other things, restrict the Company’s ability, and the ability of its restricted subsidiaries, to incur certain additional indebtedness and issue preferred stock, make certain dividends, distributions, investments and other restricted payments, sell certain assets, enter into sale and leaseback transactions, agree to payment restrictions on the ability of restricted subsidiaries to make certain payments to Endo International plc or any of its restricted subsidiaries, create certain liens, merge, consolidate or sell all or substantially all of the Company’s or guarantors’ assets, enter into certain transactions with affiliates or designate subsidiaries as unrestricted subsidiaries. Under the senior unsecured notes indentures, the negative covenants, among other things, restrict the ability of Endo Designated Activity Company and its restricted subsidiaries to incur certain additional indebtedness and issue preferred stock, make certain dividends, distributions, investments and other restricted payments, sell certain assets, enter into sale and leaseback transactions, agree to payment restrictions on the ability of restricted subsidiaries to make certain payments to the issuer or any of the restricted subsidiaries, create certain liens, merge, consolidate or sell all or substantially all of Endo Designated Activity Company’s, its co-issuers’ or guarantors’ assets, enter into certain transactions with affiliates or designate subsidiaries as unrestricted subsidiaries. These covenants are subject to a number of exceptions and qualifications, including the fall away or revision of certain of these covenants, and release of collateral in the case of the 2024 Notes, upon the notes receiving investment grade credit ratings. As of December 31, 2018 and 2017, we were in compliance with all such covenants. Additionally, pursuant to the terms of the indentures governing certain of our senior unsecured notes, the restricted subsidiaries of Endo International plc, whose assets comprise substantially all of the Company’s consolidated total assets after intercompany eliminations, are subject to various restrictions limiting their ability to transfer assets in excess of certain thresholds to Endo International plc.

April 2017 Refinancing

The Company and/or certain of its subsidiaries entered into the Credit Agreement and issued the 2024 Notes on April 27, 2017 (the April 2017 Refinancing). The Company used the net proceeds under the Term Loan Facility, together with the net proceeds of the 2024 Notes and cash on hand, to refinance certain of its prior indebtedness and to pay related fees and expenses.

In connection with the April 2017 Refinancing, we incurred new debt issuance costs of approximately $56.7 million, which were allocated among the new debt instruments as follows: (i) $41.3 million to the Term Loan Facility, (ii) $10.5 million to the Revolving Credit Facility and (iii) $4.9 million to the 2024 Notes. These costs, together with $10.1 million of the previously deferred debt issuance costs associated with our prior revolving credit facility, were deferred and are being amortized as interest expense over the terms of the respective instruments. The remaining $51.7 million of deferred debt issuance costs associated with our prior revolving and term loan facilities were charged to expense in the second quarter of 2017. These expenses were included in the Consolidated Statements of Operations as Loss on extinguishment of debt.

Maturities

The following table presents the maturities on our long-term debt for each of the five fiscal years subsequent to December 31, 2018 (in thousands):



	Maturities (1)
2019	$	34,150
2020	$	34,150
2021	$	34,150
2022	$	1,134,150
2023	$	2,419,150

__________

(1)

As described above under the heading “Credit Facilities,” certain amounts borrowed pursuant to the Credit Facilities will immediately mature if certain of our senior notes are not refinanced or repaid in full prior to the date that is 91 days prior to the respective stated maturity dates thereof. Accordingly, we may be required to repay or refinance senior notes with aggregate principal amounts of $1,100.0 million in 2021, despite such notes having stated maturities in 2022, and/or $750.0 million in 2022, despite such notes having stated maturities in 2023. The amounts in this maturities table do not reflect any such early payment; rather, they reflect stated maturity dates.

Commitments And Contingencies

12 Months Ended

Dec. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 15. COMMITMENTS AND CONTINGENCIES

Manufacturing, Supply and Other Service Agreements

Our subsidiaries contract with various third party manufacturers, suppliers and service providers to provide raw materials used in our subsidiaries’ products and semi-finished and finished goods, as well as certain packaging, labeling services, customer service support, warehouse and distribution services. If, for any reason, we are unable to obtain sufficient quantities of any of the finished goods or raw materials or components required for our products or services needed to conduct our business, it could have an adverse effect on our business, financial condition, results of operations and cash flows.

In addition to the manufacturing and supply agreements described above, we have agreements with various companies for clinical development services. Although we have no reason to believe that the parties to these agreements will not meet their obligations, failure by any of these third parties to honor their contractual obligations may have a material adverse effect on our business, financial condition, results of operations and cash flows.

Jubilant HollisterStier Laboratories LLC (JHS)

During the second quarter of 2016, we entered into a new agreement with JHS (the JHS Agreement). Pursuant to the JHS Agreement, JHS fills and lyophilizes the XIAFLEX^®bulk drug substance, which is manufactured by the Company, and produces sterile diluent. The initial term of the JHS Agreement is three years, with automatic renewal provisions thereafter for subsequent one-year terms, unless or until either party provides notification prior to expiration of the then current term of the contract. The Company is required to purchase a specified percentage of its total forecasted volume of XIAFLEX^®from JHS each year, unless JHS is unable to supply XIAFLEX^®within the timeframe established under such forecasts. Amounts purchased pursuant to the JHS Agreement were $7.5 million, $5.6 million and $6.3 million for the years ended December 31, 2018, 2017 and 2016.

Milestones and Royalties

See Note 11. License and Collaboration Agreements for a description of future milestone and royalty commitments pursuant to our material acquisitions, license and collaboration agreements.

Legal Proceedings and Investigations

We and certain of our subsidiaries are involved in various claims, legal proceedings and internal and governmental investigations (collectively, proceedings) that arise from time to time in the ordinary course of our business, including, among others, those relating to product liability, intellectual property, regulatory compliance, consumer protection and commercial matters. While we cannot predict the outcome of these proceedings and we intend to vigorously prosecute or defend our position as appropriate, there can be no assurance that we will be successful or obtain any requested relief, and an adverse outcome in any of these proceedings could have a material adverse effect on our current and future financial position, results of operations and cash flows. Matters that are not being disclosed herein are, in the opinion of our management, immaterial both individually and in the aggregate with respect to our financial position, results of operations and cash flows. If and when such matters, in the opinion of our management, become material, either individually or in the aggregate, we will disclose them.

We believe that certain settlements and judgments, as well as legal defense costs, relating to certain product liability or other matters are or may be covered in whole or in part under our insurance policies with a number of insurance carriers. In certain circumstances, insurance carriers reserve their rights to contest or deny coverage. We intend to contest vigorously any and all disputes with our insurance carriers and to enforce our rights under the terms of our insurance policies. Accordingly, we will record receivables with respect to amounts due under these policies only when the resolution of any dispute has been reached and realization of the potential claim for recovery is considered probable. Amounts recovered under our insurance policies could be materially less than the stated coverage limits and may not be adequate to cover damages and/or costs relating to claims. In addition, there is no guarantee that insurers will pay claims or that coverage will otherwise be available.

As of December 31, 2018, our accrual for loss contingencies totaled $905.1 million, of which $748.6 million relates to our liability accrual for vaginal mesh cases and other mesh-related matters. During the fourth quarter of 2017, the Company recorded a total increase to its liability accrual of approximately $200 million related to testosterone-related product liability matters and LIDODERM^®-related antitrust matters. The accrual for LIDODERM^®-related matters includes an estimated loss for, among other matters, settlement of all remaining claims filed against EPI in multidistrict litigation (MDL) No. 2521 (defined below), which matters are further discussed below under the heading “Other Antitrust Matters.” The testosterone-related accrual includes an estimated loss for, among other matters, all testosterone-related product liability cases filed in MDL No. 2545 (defined below) and in other courts. These cases are further discussed below under the heading “Product Liability and Related Matters.” Although we believe there is a reasonable possibility that a loss in excess of the amount recognized exists, we are unable to estimate the possible loss or range of loss in excess of the amount recognized at this time.

Product Liability and Related Matters

We and certain of our subsidiaries have been named as defendants in numerous lawsuits in various U.S. federal and state courts, as well as in Canada and other countries, alleging personal injury resulting from the use of certain products of our subsidiaries. These and other related matters are described below in more detail.

Vaginal Mesh. Since 2008, we and certain of our subsidiaries, including American Medical Systems Holdings, Inc. (subsequently converted to Astora Women’s Health Holding LLC and merged into Astora Women’s Health LLC and referred to herein as AMS) and/or Astora, have been named as defendants in multiple lawsuits in various state and federal courts in the U.S. (including a federal MDL pending in the U.S. District Court for the Southern District of West Virginia (MDL No. 2325)), and in Canada and other countries, alleging personal injury resulting from the use of transvaginal surgical mesh products designed to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI). In January 2018, a representative proceeding (class action) was filed in the Federal Court of Australia against American Medical Systems, LLC. In the various class action and individual complaints, plaintiffs claim a variety of personal injuries, including chronic pain, incontinence, inability to control bowel function and permanent deformities, and seek compensatory and punitive damages, where available.

We and certain plaintiffs’ counsel representing mesh-related product liability claimants have entered into various Master Settlement Agreements (MSAs) and other agreements to resolve up to approximately 71,000 filed and unfiled mesh claims handled or controlled by the participating counsel. These MSAs and other agreements were entered into at various times between June 2013 and the present, were solely by way of compromise and settlement and were not in any way an admission of liability or fault by us or any of our subsidiaries.

All MSAs are subject to a process that includes guidelines and procedures for administering the settlements and the release of funds. In certain cases, the MSAs provide for the creation of QSFs into which funds may be deposited pursuant to certain schedules set forth in those agreements. All MSAs have participation requirements regarding the claims represented by each law firm party to the MSA. In addition, one agreement gives us a unilateral right of approval regarding which claims may be eligible to participate under that settlement. To the extent fewer claims than are authorized under an agreement participate, the total settlement payment under that agreement will be reduced by an agreed-upon amount for each such non-participating claim. Funds deposited in QSFs are considered restricted cash and/or restricted cash equivalents.

Distribution of funds to any individual claimant is conditioned upon the receipt of documentation substantiating the validity of the claim, a full release and dismissal of the entire action or claim as to all AMS parties and affiliates. Prior to receiving funds, an individual claimant is required to represent and warrant that liens, assignment rights or other claims identified in the claims administration process have been or will be satisfied by the individual claimant. Confidentiality provisions apply to the amount of settlement awards to participating claimants, the claims evaluation process and procedures used in conjunction with award distributions, and the negotiations leading to the settlements.

In June 2017, the MDL court entered a case management order which, among other things, requires plaintiffs in newly-filed MDL cases to provide expert disclosures on specific causation within one hundred twenty (120) days of filing a claim (the Order). Under the Order, a plaintiff's failure to meet the foregoing deadline may be grounds for the entry of judgment against such plaintiff. In July 2017, a similar order was entered in Minnesota state court. In June 2018, at the request of the MDL court, the Judicial Panel on Multidistrict Litigation entered a minute order suspending the transfer of cases into the MDL. Subsequently, the MDL court issued a pretrial order discontinuing the direct filing of claims in MDL No. 2325. The MDL court also issued similar orders in other MDLs involving claims against other mesh manufacturers.

Although the Company believes it has appropriately estimated the probable total amount of loss associated with all matters as of the date of this report, fact and expert discovery is ongoing in certain cases that have not settled, and it is reasonably possible that further claims may be filed or asserted and that adjustments to our liability accrual may be required. This could have a material adverse effect on our business, financial condition, results of operations and cash flows.

The following table presents the changes in the QSFs and mesh liability accrual balances during the year ended December 31, 2018 (in thousands):



	Qualified Settlement Funds			Mesh Liability Accrual
Balance as of January 1, 2018	$	313,814		$	1,087,172
Additional charges	—			34,000
Cash contributions to Qualified Settlement Funds	336,648			—
Cash distributions to settle disputes from Qualified Settlement Funds	(353,032		)	(353,032		)
Cash distributions to settle disputes	—			(25,222		)
Other (1)	2,303			5,688
Balance as of December 31, 2018	$	299,733		$	748,606

__________

(1)

Amounts deposited in the QSFs may earn interest, which is generally used to pay administrative costs of the fund and is reflected in the table above as an increase to the QSF and Mesh Liability Accrual balances. Any interest remaining after all claims have been paid will generally be distributed to the claimants who participated in that settlement. The $5.7 million in the table above also includes a second quarter 2018 reclassification adjustment of $4.4 million for accrued interest amounts previously recorded in Accounts payable and accrued expenses in the Consolidated Balance Sheets.

While the timing of the resolution of certain of the matters included in this mesh liability accrual remains uncertain, as of December 31, 2018, the entire liability accrual amount is classified in the Current portion of the legal settlement accrual in the Consolidated Balance Sheets. Charges related to vaginal mesh liability and associated legal fees and other expenses for all periods presented are reported in Discontinued operations, net of tax in our Consolidated Statements of Operations.

To date, the Company has made total mesh liability payments of approximately $3.3 billion, $299.7 million of which remains in the QSFs as of December 31, 2018. We currently expect to fund into the QSFs the remaining payments under all settlement agreements during 2019. As the funds are disbursed out of the QSFs from time to time, the liability accrual will be reduced accordingly with a corresponding reduction to restricted cash and cash equivalents. In addition, we may pay cash distributions to settle disputes separate from the QSFs, which will also decrease the liability accrual and decrease cash and cash equivalents.

We were contacted in October 2012 regarding a civil investigation initiated by various state attorneys general into mesh products, including transvaginal surgical mesh products designed to treat POP and SUI. In November 2013, we received a subpoena relating to this investigation from the state of California, and we have subsequently received additional subpoenas from California and other states. We are cooperating with these investigations.

We will continue to vigorously defend any unresolved claims and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any additional losses that could be incurred.

Testosterone. Various manufacturers of prescription medications containing testosterone, including our subsidiaries Endo Pharmaceuticals Inc. (EPI) and Auxilium Pharmaceuticals, Inc. (subsequently converted to Auxilium Pharmaceuticals, LLC and hereinafter referred to as Auxilium), have been named as defendants in multiple lawsuits alleging personal injury resulting from the use of such medications, including FORTESTA^® Gel, DELATESTRYL^®, TESTIM^®, TESTOPEL^®, AVEED^® and STRIANT^®. Plaintiffs in these suits generally allege various personal injuries, including pulmonary embolism, stroke or other vascular and/or cardiac injuries, and seek compensatory and/or punitive damages, where available.

As of February 21, 2019, we were aware of approximately 1,105 testosterone cases (some of which may have been filed on behalf of multiple plaintiffs) pending against one or more of our subsidiaries in federal or state court. Most of these cases have been coordinated in a federal MDL pending in the U.S. District Court for the Northern District of Illinois (MDL No. 2545). An MDL trial against Auxilium involving TESTIM^® took place in November 2017 and resulted in a defense verdict. A trial against Auxilium involving TESTIM^® was scheduled for January 2018 in the Philadelphia Court of Common Pleas but resolved prior to trial.

In June 2018, counsel for plaintiffs, on the one hand, and Auxilium and EPI, on the other, executed an MSA allowing for the resolution of all known testosterone replacement therapy product liability claims against our subsidiaries. The MSA was solely by way of compromise and settlement and was not in any way an admission of fault by us or any of our subsidiaries.

The MSA is subject to a process that includes guidelines and procedures for administering the settlement and the release of funds. Among other things, the MSA provides for the creation of a QSF into which the settlement funds will be deposited, establishes participation requirements and allows for a reduction of the total settlement payment in the event the participation threshold is not met. Distribution of funds to any individual claimant is conditioned upon the receipt of documentation substantiating product use and injury as determined by a third-party special master, the dismissal of any lawsuit and the release of the claim as to us and all affiliates. Prior to receiving funds, an individual claimant must represent and warrant that liens, assignment rights or other claims identified in the claims administration process have been or will be satisfied by the individual claimant. Confidentiality provisions apply to the settlement funds, amounts allocated to individual claimants and other terms of the agreement.

Although the Company believes it has appropriately estimated the probable total amount of loss associated with testosterone-related product liability matters as of the date of this report, it is reasonably possible that further claims may be filed or asserted and that adjustments to our liability accrual may be required. This could have a material adverse effect on our business, financial condition, results of operations and cash flows.

The MDL also included a lawsuit filed in November 2014 in the U.S. District for the Northern District of Illinois against EPI, Auxilium and various other manufacturers of testosterone products on behalf of a proposed class of health insurance companies and other third party payers that claim to have paid for certain testosterone products. This lawsuit is not part of the settlement described above. After a series of motions to dismiss, plaintiff filed a third amended complaint in April 2016, asserting civil claims for alleged violations of the Racketeer Influenced and Corrupt Organizations Act and negligent misrepresentation based on defendants’ marketing of certain testosterone products. The court denied a motion to dismiss this complaint in August 2016. In July 2018, the court denied plaintiff’s motion for class certification. In February 2019, the court granted defendants’ motion for summary judgment.

Opioid-Related Matters

Since 2014, multiple U.S. states, counties, other governmental persons or entities and private plaintiffs have filed suit against us and/or certain of our subsidiaries, including Endo Health Solutions Inc. (EHSI), EPI, Par Pharmaceutical, Inc. (PPI), Par Pharmaceutical Companies, Inc., Vintage Pharmaceuticals, LLC, Generics Bidco I, LLC and DAVA Pharmaceuticals, LLC, as well as various other manufacturers, distributors and/or others, asserting claims relating to defendants’ alleged sales, marketing and/or distribution practices with respect to prescription opioid medications, including certain of our products. As of February 21, 2019, the cases of which we were aware include, but are not limited to, approximately 12 cases filed by or on behalf of states; approximately 1,711 cases filed by counties, cities, Native American tribes and/or other government-related persons or entities; approximately 121 cases filed by hospitals, health systems, unions, health and welfare funds or other third-party payers and approximately 56 cases filed by individuals. Certain of the cases have been filed as putative class actions. In addition to the litigation in the U.S., in August 2018, an action against Paladin Labs, EPI, the Company and various other manufacturers and distributors was commenced in British Columbia on behalf of all federal, provincial and territorial governments and agencies in Canada that paid healthcare, pharmaceutical and treatment costs related to opioids.

Many of the U.S. cases have been coordinated in a federal MDL pending in the U.S. District Court for the Northern District of Ohio (MDL No. 2804). In March 2018, the U.S. Department of Justice (DOJ) filed a statement of interest in the case, and in April 2018 it filed a motion to participate in settlement discussions as a friend of the court, which the MDL court has granted. The MDL court has issued a series of case management orders permitting motions to dismiss addressing threshold legal issues in certain cases, setting a trial date in October 2019 for the claims of two Ohio counties, allowing certain discovery and establishing certain other deadlines and procedures, among other things.

Other cases remain pending in various state courts. In some jurisdictions, such as Connecticut, Illinois, New York, Pennsylvania, South Carolina and Texas, certain state court cases have been transferred to a single court within their respective state court systems for coordinated pretrial proceedings. The state cases are generally at the pleading and/or discovery stage with certain of these cases scheduled for trial beginning in 2020.

The complaints in the cases assert a variety of claims including, but not limited to, claims for alleged violations of public nuisance, consumer protection, unfair trade practices, racketeering, Medicaid fraud and/or drug dealer liability statutes and/or common law claims for public nuisance, fraud/misrepresentation, strict liability, negligence and/or unjust enrichment. The claims are generally based on alleged misrepresentations and/or omissions in connection with the sale and marketing of prescription opioid medications and/or an alleged failure to take adequate steps to prevent abuse and diversion. Plaintiffs generally seek declaratory and/or injunctive relief; compensatory, punitive and/or treble damages; restitution, disgorgement, civil penalties, abatement, attorneys’ fees, costs and/or other relief.

We will continue to vigorously defend the foregoing matters and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.

In addition to the lawsuits described above, the Company and/or its subsidiaries have received certain subpoenas, civil investigative demands (CIDs) and informal requests for information concerning the sale, marketing and/or distribution of prescription opioid medications, including the following:

Various state attorneys general have served subpoenas and/or CIDs on EHSI and/or EPI. We are cooperating with these investigations.

In January 2018, our subsidiary EPI received a federal grand jury subpoena from the U.S. District Court for the Southern District of Florida in connection with an investigation being conducted by the U.S. Attorney’s Office for the Southern District of Florida in conjunction with the FDA. The subpoena seeks information related to OPANA^® ER and other oxymorphone products. EPI is cooperating with the investigation.

Similar investigations may be brought by others or the foregoing matters may be expanded or result in litigation. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.

Generic Drug Pricing Matters

In December 2014, we received a grand jury subpoena from the Antitrust Division of the DOJ issued by the U.S. District Court for the Eastern District of Pennsylvania addressed to Par Pharmaceuticals. The subpoena requested documents and information focused primarily on product and pricing information relating to the authorized generic version of Lanoxin (digoxin) oral tablets and generic doxycycline products, and on communications with competitors and others regarding those products. We are cooperating with the investigation.

In May 2018, we and our subsidiary Par Pharmaceutical Companies, Inc. each received a CID from the U.S. Department of Justice in relation to a False Claims Act investigation concerning whether generic pharmaceutical manufacturers engaged in price-fixing and market allocation agreements, paid illegal remuneration and caused the submission of false claims. We are cooperating with the investigation.

Since November 2016, various private plaintiffs and state attorneys general have filed cases against our subsidiary PPI and/or, in some instances, the Company, Generics Bidco I, LLC, DAVA Pharmaceuticals, LLC and/or Par Pharmaceutical Companies, Inc., as well as other pharmaceutical manufacturers and, in some instances, other corporate and/or individual defendants, alleging price-fixing and other anticompetitive conduct with respect to generic pharmaceutical products. These cases, which include proposed class actions filed on behalf of direct purchasers, end-payers and indirect purchaser resellers, have been consolidated and/or coordinated for pretrial proceedings in a federal MDL pending in the U.S. District Court for the Eastern District of Pennsylvania under the caption In re Generic Pharmaceuticals Pricing Antitrust Litigation (MDL No. 2724).

The various complaints generally assert claims under federal and/or state antitrust law, state consumer protection statutes and/or state common law, and seek damages, treble damages, civil penalties, disgorgement, declaratory and injunctive relief, costs and attorneys’ fees. Some claims are based on alleged product-specific conspiracies. With respect to our subsidiaries, the allegations in the various complaints focus on amitriptyline, baclofen, digoxin, divalproex ER, doxycycline hyclate, doxycycline monohydrate, nystatin, propranolol and/or zoledronic acid. Other claims allege broader, multiple-product conspiracies involving various combinations of these and/or other products. Under these overarching conspiracy theories, plaintiffs seek to hold all alleged participants in a particular conspiracy jointly and severally liable for all harms caused by the alleged conspiracy, not just harms related to the products manufactured and/or sold by a particular defendant.

In October 2018, the MDL court denied defendants’ motions to dismiss federal antitrust claims relating to digoxin, divalproex ER and doxycycline hyclate, among other products. In February 2019, the MDL dismissed certain state law claims but allowed others to proceed. In February 2019, the defendants moved to dismiss plaintiffs’ overarching conspiracy claims. The MDL court has also allowed certain discovery.

Other Antitrust Matters

Beginning in November 2013, multiple direct and indirect purchasers of LIDODERM^® filed a number of cases against our subsidiary EPI and other pharmaceutical companies generally alleging that they had entered into an anticompetitive agreement to restrain trade through the settlement of patent infringement litigation concerning U.S. Patent No. 5,827,529 (the ‘529 patent) and other patents. The complaints asserted claims under Sections 1 and 2 of the Sherman Act (15 U.S.C. §§ 1, 2), and/or various state antitrust and consumer protection statutes, as well as common law claims, and generally sought damages, treble damages, disgorgement of profits, restitution, injunctive relief and attorneys’ fees. The cases were consolidated and/or coordinated in April 2014 in a federal MDL in the U.S. District Court for the Northern District of California (MDL No. 2521). The MDL court certified classes of direct and indirect purchasers in February 2017. EPI settled with certain opt-out retailer plaintiffs in October 2017. In September 2018, the court approved EPI’s settlement with the class plaintiffs and entered judgment dismissing the class cases with prejudice. In connection with the settlements, several indirect purchasers which previously had opted out were permitted to rejoin the class. The class settlement agreements provide for aggregate payments of approximately $100 million. As of February 21, 2019, EPI had paid approximately $70 million of this total, including approximately $60 million in 2018 and approximately $10 million in February 2019.

Beginning in June 2014, multiple direct and indirect purchasers of OPANA^® ER filed cases against our subsidiaries EHSI and EPI and other pharmaceutical companies, including Impax Laboratories, LLC (formerly Impax Laboratories, Inc. and referred to herein as Impax) and Penwest Pharmaceuticals Co., which our subsidiary EPI had acquired. Some cases were filed on behalf of putative classes of direct and indirect purchasers, while others were filed on behalf of individual retailers or health care benefit plans. All cases have been consolidated and/or coordinated for pretrial proceedings in a federal MDL pending in the U.S. District Court for the Northern District of Illinois (MDL No. 2580). Plaintiffs generally allege that an agreement reached by EPI and Impax to settle patent infringement litigation concerning multiple patents pertaining to OPANA^® ER and EPI’s introduction of reformulated OPANA^® ER violated antitrust laws. The complaints assert claims under Sections 1 and 2 of the Sherman Act, various state antitrust and consumer protection statutes and/or state common law. Plaintiffs generally seek damages, treble damages, disgorgement of profits, restitution, injunctive relief and attorneys’ fees. In February 2016, the MDL court issued orders (i) denying defendants’ motion to dismiss the claims of the direct purchasers, (ii) denying in part and granting in part defendants’ motion to dismiss the claims of the indirect purchasers, but giving them permission to file amended complaints and (iii) granting defendants’ motion to dismiss the complaints filed by certain retailers, but giving them permission to file amended complaints. In response to the MDL court’s orders, the indirect purchasers filed an amended complaint to which the defendants filed a renewed motion to dismiss certain claims, and certain retailers also filed amended complaints. The court has dismissed the indirect purchaser unjust enrichment claims arising under the laws of the states of California, Rhode Island and Illinois. The cases are currently in discovery. We will continue to vigorously defend these matters and to explore other options as appropriate in our best interests.

Beginning in February 2009, the FTC and certain private plaintiffs, including distributors and retailers, filed suit against our subsidiary Par Pharmaceutical Companies, Inc. (since June 2016, Endo Generics Holdings, Inc., and referred to in this Commitments and Contingencies note as EGHI) and other pharmaceutical companies alleging violations of antitrust law arising out of their settlement of certain patent litigation concerning the generic version of AndroGel^®. Generally, the complaints seek damages, treble damages, equitable relief and attorneys’ fees and costs. The cases have been consolidated and/or coordinated for pretrial proceedings in a federal MDL pending in the U.S. District Court for the Northern District of Georgia (MDL No. 2084). In September 2012, the MDL court granted summary judgment to defendants on plaintiffs’ claims of sham litigation. In May 2016, plaintiffs representing a putative class of indirect purchasers voluntarily dismissed their claims with prejudice. In February 2017, the FTC voluntarily dismissed its claims against EGHI with prejudice. Claims by certain alleged direct purchasers or their assignees are still pending against EGHI and other defendants. In June 2018, the MDL court granted in part and denied in part various summary judgment and evidentiary motions filed by defendants. In particular, the court rejected two of direct purchasers’ three causation theories, rejected damages claims related to AndroGel^® 1.62% and granted in part a motion seeking to exclude part of plaintiffs’ proposed manufacturing expert’s opinions. The motions were denied in all other respects, and the court denied a motion for reconsideration, or in the alternative leave to file an interlocutory appeal, in October 2018. In July 2018, the district court denied certain plaintiffs’ motion for certification of a direct purchaser class. We will continue to vigorously defend these matters and to explore other options as appropriate in our best interests.

Beginning in May 2018, multiple alleged direct and indirect purchasers filed complaints in the U.S. District Court for the Southern District of New York against PPI, EPI and/or us, as well as others, alleging a conspiracy to delay generic competition and monopolize the market for Exforge^® (amlodipine/valsartan) and its generic equivalents. Some cases were filed on behalf of putative classes of direct and indirect purchasers; others were filed on behalf of individual retailers. The plaintiffs generally assert claims under Sections 1 and 2 of the Sherman Act, various state antitrust and consumer protection statutes and state common law and seek damages, treble damages, equitable relief and attorneys’ fees and costs. In September 2018, the putative class plaintiffs stipulated to the dismissal without prejudice of their claims against EPI and us, and the retailer plaintiffs did the same in November and December 2018. PPI filed a partial motion to dismiss certain claims in September 2018, which has not yet been ruled upon. We intend to vigorously defend these matters and to explore other options as appropriate in our best interests.

In November 2014, EPI received a CID from Florida’s Office of the Attorney General seeking documents and other information concerning EPI’s agreement with Actavis settling the LIDODERM^® patent litigation, as well as information concerning marketing and sales of LIDODERM^®. EPI and/or EHSI later received similar CIDs from other states. A CID from Alaska’s Office of the Attorney General in February 2015 included requests for documents and information concerning agreements with Actavis and Impax settling the OPANA^® ER patent litigation. We are cooperating with these investigations.

In February 2015, EGHI and affiliates received a CID from the Office of the Attorney General for the state of Alaska seeking production of certain documents and information regarding EGHI’s settlement of the AndroGel^® patent litigation as well as documents produced in the aforementioned litigation filed by the FTC. We are cooperating with this investigation.

Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any additional losses that could be incurred.

Securities Litigation

In May 2016, a putative class action entitled Craig Friedman v. Endo International plc, Rajiv Kanishka Liyanaarchchie de Silva and Suketu P. Upadhyay was filed in the U.S. District Court for the Southern District of New York by an individual shareholder on behalf of himself and all similarly situated shareholders. In August 2016, the court appointed Steamfitters’ Industry Pension Fund and Steamfitters’ Industry Security Benefit Fund as lead plaintiffs in the action. In October 2016, plaintiffs filed a second amended complaint that, among other things, added Paul Campanelli as a defendant, and we filed a motion to dismiss. In response, and without resolving the motion, the court permitted lead plaintiffs to file a third amended complaint. The amended complaint alleged violations of Sections 10(b) and 20(a) of the Exchange Act based on the Company’s revision of its 2016 earnings guidance and certain disclosures about its generics business, the integration of Par Pharmaceutical Holdings, Inc. and its subsidiaries, certain other alleged business issues and the receipt of a CID from the U.S. Attorney’s Office for the Southern District of New York regarding contracts with pharmacy benefit managers concerning FROVA^®. Lead plaintiffs sought class certification, damages in an unspecified amount and attorneys’ fees and costs. We filed a motion to dismiss the third amended complaint in December 2016. In January 2018, the court granted our motion and dismissed the case with prejudice. In February 2018, lead plaintiffs filed a motion for relief from the judgment and leave to file a fourth amended complaint; the court denied this motion in April 2018. Lead plaintiffs appealed to the U.S. Court of Appeals for the Second Circuit; that appeal is still pending.

In February 2017, a putative class action entitled Public Employees’ Retirement System of Mississippi v. Endo International plc was filed in the Court of Common Pleas of Chester County, Pennsylvania by an institutional purchaser of shares in our June 2, 2015 public offering, on behalf of itself and all similarly situated purchasers. The lawsuit alleges violations of Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 against Endo, certain of its current and former directors and officers, and the underwriters who participated in the offering, based on certain disclosures about Endo’s generics business. In March 2017, defendants removed the case to the U.S. District Court for the Eastern District of Pennsylvania. In August 2017, the court remanded the case back to the Chester County Court of Common Pleas. In October 2017, plaintiff filed an amended complaint. In December 2017, defendants filed preliminary objections to the amended complaint. The court denied those preliminary objections in April 2018. The case is currently in discovery. Plaintiff filed its motion for class certification in July 2018.

In April 2017, a putative class action entitled Phaedra A. Makris v. Endo International plc, Rajiv Kanishka Liyanaarchchie de Silva and Suketu P. Upadhyay was filed in the Superior Court of Justice in Ontario, Canada by an individual shareholder on behalf of herself and similarly-situated Canadian-based investors who purchased Endo’s securities between January 11 and May 5, 2016. The statement of claim generally seeks class certification, declaratory relief, damages, interest and costs based on alleged violations of the Ontario Securities Act. The statement of claim alleges negligent misrepresentations concerning the Company’s revenues, profit margins and earnings per share; its receipt of a subpoena from the state of Connecticut regarding doxycycline hyclate, amitriptyline hydrochloride, doxazosin mesylate, methotrexate sodium and oxybutynin chloride; and the erosion of the Company’s U.S. generic pharmaceuticals business. In January 2019, plaintiff amended her statement of claim to add a claim on behalf of herself and similarly-situated Canadian investors who purchased Endo’s securities between January 11, 2016 and June 8, 2017. This new claim is based on the Company’s decision to remove reformulated OPANA^® ER from the market.

In August 2017, a putative class action entitled Bier v. Endo International plc, et al. was filed in the U.S. District Court for the Eastern District of Pennsylvania by an individual shareholder on behalf of himself and all similarly situated shareholders. The original complaint alleged violations of Section 10(b) and 20(a) of the Exchange Act against Endo and four current and former directors and officers, based on the Company’s decision to remove reformulated OPANA^® ER from the market. In December 2017, the court appointed SEB Investment Management AB lead plaintiff in the action. In February 2018, the lead plaintiff filed an amended complaint, which added claims alleging violations of Sections 11 and 15 of the Securities Act in connection with the June 2015 offering. The amended complaint named the Company, EHSI and 20 current and former directors, officers and employees of Endo as defendants. In April 2018, the defendants moved to dismiss the amended complaint. In December 2018, the court dismissed the plaintiff’s claims against four individual defendants, but otherwise denied the motion to dismiss.

In November 2017, a putative class action entitled Pelletier v. Endo International plc, Rajiv Kanishka Liyanaarchchie De Silva, Suketu P. Upadhyay, and Paul V. Campanelli was filed in the U.S. District Court for the Eastern District of Pennsylvania by an individual shareholder on behalf of himself and all similarly situated shareholders. The lawsuit alleges violations of Section 10(b) and 20(a) of the Exchange Act relating to the pricing of various generic pharmaceutical products. In June 2018, the court appointed Park Employees’ Annuity and Benefit Fund of Chicago lead plaintiff in the action. In August 2018, the lead plaintiff filed an amended complaint. In September 2018, the defendants moved to dismiss the amended complaint. That motion remains pending.

VASOSTRICT^®Related Matters

In July 2016, Fresenius Kabi USA, LLC (Fresenius) filed a complaint against Par Pharmaceutical Companies, Inc. and its affiliate Par Sterile Products, LLC (PSP) in the U.S. District Court for the District of New Jersey alleging that Par Pharmaceutical Companies, Inc. and its affiliate engaged in an anticompetitive scheme to exclude competition from the market for vasopressin solution for intravenous injection in view of Par Pharmaceutical Companies, Inc.’s VASOSTRICT^® (vasopressin) product. The complaint alleges violations of Sections 1 and 2 of the Sherman Antitrust Act, as well as state antitrust and common law, based on assertions that Par Pharmaceutical Companies, Inc. and its affiliate entered into exclusive supply agreements with one or more active pharmaceutical ingredient (API) manufacturers and that, as a result, Fresenius has been unable to obtain vasopressin API in order to file an ANDA to obtain FDA approval for its own vasopressin product. Fresenius seeks actual, treble and punitive damages, attorneys’ fees and costs and injunctive relief. In September 2016, Par Pharmaceutical Companies, Inc. and its affiliate filed a motion to dismiss, which the district court denied in February 2017. The case is currently in discovery.

In August 2017, our subsidiaries PPI and PSP filed a complaint for actual, exemplary and punitive damages, injunctive relief and other relief against QuVa Pharma, Inc. (QuVa), Stuart Hinchen, Peter Jenkins and Mike Rutkowski in the U.S. District Court for the District of New Jersey. The complaint alleges misappropriation in violation of the federal Defend Trade Secrets Act, New Jersey’s Trade Secrets Act and New Jersey common law, as well as unfair competition, breach of contract, breach of fiduciary duty, breach of the duty of loyalty, tortious interference with contractual relations and breach of the duty of confidence in connection with VASOSTRICT^®, a vasopressin-based cardiopulmonary drug. In October 2017, defendants answered the complaint and QuVa asserted counterclaims against PPI and PSP alleging unfair competition under New Jersey common law and seeking declaratory judgment of non-infringement as to five U.S. Patents assigned to PPI that are listed in FDA’s Orange Book for VASOSTRICT^®. The counterclaims seek actual, exemplary and punitive damages, injunctive relief and other relief. We filed a motion to dismiss the unfair competition counterclaim in November 2017. Also in November 2017, we filed a motion for preliminary injunction seeking various forms of relief. In January 2018, we filed a first amended complaint adding four former employees and one consultant of PSP as defendants and numerous causes of action against some or all of those individuals, including misappropriation under the federal Defend Trade Secrets Act, New Jersey’s Trade Secrets Act and New Jersey common law, as well as breach of contract, breach of the duty of loyalty and breach of the duty of confidence. In March 2018, the court granted in part our motion for preliminary injunction and enjoined QuVa from marketing and releasing its planned vasopressin product through the conclusion of trial. We subsequently deposited a bond to the court’s interest-bearing account to secure the preliminary injunction. Defendants filed a motion asking the court to reconsider the bond amount, which the court denied. Also in March 2018, QuVa and seven of the individual defendants filed a motion to dismiss the New Jersey common law claims, four of the individual defendants filed a motion to dismiss for lack of personal jurisdiction and one of the individuals filed a motion to dismiss the breach of contract claim. In April 2018, another individual defendant filed a motion to dismiss asserting numerous arguments, including lack of personal jurisdiction, improper venue and choice of law. Discovery began in May 2018. Also in May 2018, defendants filed a notice of appeal to the Third Circuit Court of Appeal indicating intent to appeal the court’s preliminary injunction. In October 2018, defendants filed their opening appellate brief, in December 2018, we filed our response brief and in January 2019, defendants filed their reply brief. Also in January 2019, the court denied all four of defendants’ pending motions to dismiss, as well as our pending motion to dismiss, which the court found was moot in light of the first amended complaint. In February 2019, the defendants filed their answers and affirmative defenses, and certain defendants also filed counterclaims.

In October 2017, Endo Par Innovation Company, LLC (EPIC) and PSP filed a complaint in the United States District Court for the District of Columbia challenging the legality of the FDA’s Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act (January 2017) with respect to the listing of vasopressin in Category 1 of the Interim Policy. The complaint contends that the Interim Policy is unlawful because it is inconsistent with the Federal Food, Drug, and Cosmetic Act, including, but not limited to, Section 503B of that Act. The complaint seeks (i) a declaration that FDA’s Interim Policy and its listing of vasopressin in Category 1 of the Interim Policy are unlawful, and (ii) an order enjoining and vacating the Interim Policy and the FDA’s listing of vasopressin in Category 1 of the Interim Policy. In January 2018, EPIC and PSP agreed to a temporary 60-day stay of the litigation in light of the FDA’s announcement that forthcoming guidance would address the concerns set forth in the Company’s complaint. In March 2018, the FDA released new draft guidance for industry entitled “Evaluation of Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act.” Shortly thereafter, the parties agreed to extend the temporary stay for an additional 180 days. In August 2018, before the 180-day stay period expired, Athenex Pharma Solutions, LLC and Athenex Pharmaceutical Division, LLC announced they had commenced bulk compounding of vasopressin, and moved to intervene in EPIC and PSP’s case against the FDA. Later that month, EPIC and PSP invoked their ability to terminate the stay and filed a Motion for Preliminary Injunction. Before responding to the Motion for Preliminary Injunction, the FDA issued a notice containing a proposed finding that there is no clinical need to bulk compound vasopressin under Section 503B in August 2018. In September 2018, the FDA advised EPIC and PSP that it would agree to use its best efforts to finalize the vasopressin clinical need rulemaking by December 31, 2018, if the case were again stayed. EPIC and PSP agreed to the requested stay. In December 2018, the appropriations act that had been funding the Department of Justice and components of the FDA expired, resulting in a lapse of appropriations; therefore, the FDA moved the court for a further stay of the case until appropriations were restored. The court granted the motion in January 2019, ordering the FDA to file a notification with the court within three business days of Department of Justice operations resuming. After government appropriations were restored, the FDA advised that it would use its best efforts to finalize the vasopressin clinical need determination by March 15, 2019. Based on that commitment, EPIC and PSP agreed not to oppose the FDA’s request to stay the case again until the earliest of March 15, 2019, the publication of a final clinical need determination for vasopressin or a substantial change in circumstances necessitating a decision on EPIC and PSP’s Motion for Preliminary Injunction. EPIC and PSP cannot currently be certain whether the FDA will request a further stay of the litigation, of the date on which the FDA will finalize its clinical need determination or of the date on which the litigation will be resolved.

In August 2018, Athenex filed a declaratory judgment action in the U.S. District Court for the Western District of New York, a case styled Athenex v. Par, alleging non-infringement and/or invalidity of the patents the Company has listed in the Orange Book in view of VASOSTRICT^®. The Company moved to dismiss Athenex’s case on multiple grounds in October 2018, which motion was opposed by Athenex in December 2018. The Company responded to this opposition in December 2018. This motion has not yet been decided.

In April 2018, PSP and PPI received a notice letter from Eagle Pharmaceuticals, Inc. (Eagle) advising of the filing by such company of an ANDA for a generic version of VASOSTRICT^® (vasopressin IV solution (infusion)) 20 units/ml. In May 2018, PSP and PPI received a second notice letter from Eagle advising of the same filing, but adding an additional patent. The Paragraph IV notices refer to U.S. Patent Nos. 9,375,478; 9,687,526; 9,744,209; 9,744,239; 9,750,785; and 9,937,223, which variously cover either vasopressin-containing pharmaceutical compositions or methods of using a vasopressin-containing dosage form to increase blood pressure in humans. In May 2018, PPI, PSP and EPIC filed a lawsuit against Eagle in the United States District Court for the District of Delaware within the 45-day deadline to invoke a 30-month stay of FDA approval pursuant to the Hatch-Waxman legislative scheme. In August 2018, Eagle filed an answer and a counterclaim for non-infringement and invalidity of asserted patents. A claim construction hearing is scheduled for May 2019, with a bench trial scheduled for May 2020.

In September 2018, PSP and PPI received a notice letter from Sandoz Inc. (Sandoz) advising of the filing by such company of an ANDA for a generic version of VASOSTRICT^® (vasopressin IV solution (infusion)) 200 units/10 ml. In October 2018, PPI, PSP and EPIC filed a lawsuit against Sandoz in the United States District Court for the District of New Jersey within the 45-day deadline to invoke a 30-month stay of FDA approval pursuant to the Hatch-Waxman legislative scheme. In October 2018, PSP and PPI received an additional notice letter from Sandoz advising of the filing by such company of an ANDA for a generic version of the 20 units/1 ml presentation for VASOSTRICT^®. In November 2018, the complaint was amended to add a claim for the additional notice letter, within the 45-day deadline to invoke a 30-month stay of FDA approval pursuant to the Hatch-Waxman legislative scheme. The Company continues to vigorously defend its intellectual property.

In November 2018, PSP and PPI received a notice letter from Amphastar Pharmaceuticals, Inc. (Amphastar) advising of the filing by such company of an ANDA for a generic version of VASOSTRICT^® (vasopressin IV solution (infusion)) 20 units/1 ml. In December 2018, PPI, PSP and EPIC filed a lawsuit against Amphastar in the U.S. District Court for the District of Delaware within the 45-day deadline to invoke a 30-month stay of FDA approval pursuant to the Hatch-Waxman legislative scheme. The Company continues to vigorously defend its intellectual property.

The Company’s legal reserves include, among other things, an estimated accrual for certain VASOSTRICT^®-related matters. We will continue to vigorously defend or prosecute the foregoing matters as appropriate, to protect our intellectual property rights, to pursue all available legal and regulatory avenues and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any additional losses that could be incurred.

Paragraph IV Certifications on OPANA^® ER

In August 2014 and October 2014, the U.S. Patent Office issued U.S. Patent Nos. 8,808,737 (the ‘737 patent) and 8,871,779 (the ‘779 patent) respectively, which cover a method of using OPANA^® ER and a highly pure version of the API of OPANA^® ER. In November 2014, EPI filed lawsuits against Teva, ThoRx, Actavis, Impax, Ranbaxy, Roxane, Amneal and Sandoz Inc. based on their ANDAs filed against both the INTAC^® technology and non-INTAC^® technology versions of OPANA^® ER. Those lawsuits were filed in the U.S. District Court for the District of Delaware alleging infringement of these new patents, which expire in 2027 and 2029, respectively. On November 17, 2015, the District Court held the ‘737 patent invalid for claiming unpatentable subject matter. That patent has been dismissed from all suits and the suits administratively closed as to that patent, subject to appeal at the end of the case on the ‘779 patent. In July 2016, a three-day trial was held in the U.S. District Court for the District of Delaware against Teva and Amneal for infringement of the ‘779 patent. In October 2016, the District Court issued an opinion holding that the defendants infringed the claims of U.S. Patent No. 8,871,779. The opinion also held that the defendants had failed to show that the ‘779 patent was invalid. The District Court issued an Order enjoining the defendants from launching their generic products until the expiration of the ‘779 patent in November 2029. A trial for infringement of the ‘779 patent by Actavis was held in February 2017 in the same court (U.S. District Court for the District of Delaware) in front of the same judge. In August 2017, the District Court issued an opinion holding that Actavis infringed the claims of the ‘779 patent and that Actavis had failed to show that the ‘779 patent was invalid. Teva, Amneal and Actavis have appealed these holdings. We have appealed the holding that the ‘737 patent is invalid. A hearing on those appeals took place in December 2018.We are awaiting decisions on those appeals.

We will continue to vigorously defend or prosecute the foregoing matter as appropriate, to protect our intellectual property rights, to pursue all available legal and regulatory avenues and to explore other options as appropriate in our best interests in defense of our intellectual property, including enforcement of the product’s intellectual property rights and approved labeling. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.

Other Proceedings and Investigations

Proceedings similar to those described above may also be brought in the future. Additionally, we are involved in, or have been involved in, arbitrations or various other proceedings that arise from the normal course of our business. We cannot predict the timing or outcome of these other proceedings. Currently, neither we nor our subsidiaries are involved in any other proceedings that we expect to have a material effect on our business, financial condition, results of operations and cash flows.

Leases

We lease certain fixed assets under capital leases that expire through 2032. We lease automobiles, machinery and equipment and facilities under certain noncancelable operating leases that expire through 2028. These leases are renewable at our option.

On October 28, 2011, our subsidiary EPI entered into a lease agreement for a new Company headquarters in Malvern, Pennsylvania. The initial term of the lease is through 2024 and includes three renewal options, each for an additional 60-month period. This lease is accounted for as a direct financing arrangement whereby the Company recorded, over the construction period, the full cost of the asset in Property, plant and equipment, net. A corresponding liability was also recorded, net of leasehold improvements paid for by the Company, and is being amortized over the expected lease term through monthly rental payments using an effective interest method. At December 31, 2018, there was a liability of $33.8 million related to this arrangement, $4.9 million of which is included in Accounts payable and accrued expenses and $28.9 million of which is included in Other liabilities in the accompanying Consolidated Balance Sheet.

A summary of minimum future rental payments required under capital and operating leases as of December 31, 2018 are as follows (in thousands):



	Capital Leases (1)(2)		Operating Leases
2019	$	6,884	$	15,800
2020	6,819		14,519
2021	6,921		12,883
2022	7,072		12,454
2023	7,225		9,945
Thereafter	9,127		20,573
Total minimum lease payments	$	44,048	$	86,174
Less: Amount representing interest	4,084
Total present value of minimum payments	$	39,964
Less: Current portion of such obligations	5,845
Long-term capital lease obligations	$	34,119

__________


(1)	The direct financing arrangement is included under Capital Leases.

(2)

We have entered into agreements to sublease certain properties. Most significantly, we sublease approximately 140,000 square feet of our Malvern, Pennsylvania headquarters and substantially all of our Chesterbrook, Pennsylvania facility. As of December 31, 2018, we expect to receive approximately $29.7 million in future minimum rental payments over the remaining terms of the Malvern and Chesterbrook subleases through 2024. Amounts included in this table have not been reduced by the minimum sublease rentals.

Expenses incurred under operating leases were approximately $18.7 million, $18.7 million and $22.2 million for the years ended December 31, 2018, 2017 and 2016, respectively.

Other Comprehensive (Loss) Income

12 Months Ended

Dec. 31, 2018

Equity [Abstract]

Other Comprehensive (Loss) Income

NOTE 16. OTHER COMPREHENSIVE (LOSS) INCOME

Set forth below are the tax effects allocated to each component of Other comprehensive (loss) income for the years ended December 31, 2018, 2017 and 2016 (in thousands):



	2018								2017								2016
	Before-Tax Amount			Tax (Expense) Benefit		Net-of-Tax Amount			Before-Tax Amount			Tax Benefit (Expense)		Net-of-Tax Amount			Before-Tax Amount			Tax Benefit (Expense)		Net-of-Tax Amount
Net unrealized loss on securities:
Unrealized loss arising during the period	$	—		$	—	$	—		$	(811	)	$	296	$	(515	)	$	(1,588	)	$	674	$	(914	)
Less: reclassification adjustments for (gain) loss realized in net loss	—			—		—			—			—		—			(6		)	—		(6		)
Net unrealized gains (losses) on securities	$	—		$	—	$	—		$	(811	)	$	296	$	(515	)	$	(1,594	)	$	674	$	(920	)
Net unrealized (loss) gain on foreign currency:
Foreign currency translation (loss) gain arising during the period	(19,408		)	—		(19,408		)	31,202			—		31,202			18,267			13,462		31,729
Less: reclassification adjustments for loss realized in net loss	—			—		—			112,926			—		112,926			—			—		—
Foreign currency translation (loss) gain	$	(19,408	)	$	—	$	(19,408	)	$	144,128		$	—	$	144,128		$	18,267		$	13,462	$	31,729
Other comprehensive (loss) income	$	(19,408	)	$	—	$	(19,408	)	$	143,317		$	296	$	143,613		$	16,673		$	14,136	$	30,809

Reclassification adjustments out of Other comprehensive (loss) income related to foreign currency translation were recorded upon the liquidation of Litha and Somar during 2017.

Substantially all of the Company’s Accumulated other comprehensive loss at December 31, 2018 and December 31, 2017 consists of Foreign currency translation loss.

Shareholders' (Deficit) Equity Shareholders' (Deficit) Equity	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Shareholders' (Deficit) Equity	NOTE 17. SHAREHOLDERS' (DEFICIT) EQUITY The Company has issued 4,000,000 euro deferred shares of $0.01 each at par. The euro deferred shares are held by nominees in order to satisfy an Irish legislative requirement to maintain a minimum level of issued share capital denominated in euro and to have at least seven registered shareholders. The euro deferred shares carry no voting rights and are not entitled to receive any dividend or distribution. Effects of Changes in Accounting Principles The Company early adopted ASU No. 2016-16, “Intra-Entity Transfers of Assets Other Than Inventory” (ASU 2016-16) on January 1, 2017, resulting in, among other effects, the elimination of previously recorded deferred charges that were established in 2016. Specifically, effective January 1, 2017, the Company eliminated $372.8 million of deferred charges and recorded a corresponding increase to its accumulated deficit. As further discussed in Note 2. Summary of Significant Accounting Policies, the Company also adopted ASC 606 on January 1, 2018, resulting in a net decrease of $3.1 million to its accumulated deficit at January 1, 2018. Share Repurchase Program Pursuant to Article 11 of the Company’s Articles of Association, the Company has broad shareholder authority to conduct ordinary share repurchases by way of redemptions. The Company’s authority to repurchase ordinary shares is subject to legal limitations and the existence of sufficient distributable reserves. For example, the Companies Act requires Irish companies to have distributable reserves equal to or greater than the amount of any proposed ordinary share repurchase amount. Unless we are able to generate sufficient distributable reserves or create distributable reserves by reducing our share premium account, we will not be able to repurchase our ordinary shares. As permitted by Irish Law and the Company’s Articles of Association, any ordinary shares redeemed shall be cancelled upon redemption. The Board of Directors has approved a share buyback program (the 2015 Share Buyback Program) that authorizes the Company to redeem, in the aggregate, $2.5 billion of its outstanding ordinary shares. To date, the Company has redeemed and cancelled approximately 4.4 million of its ordinary shares under the 2015 Share Buyback Program for $250.0 million, not including related fees.

Shared-based Compensation

12 Months Ended

Dec. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Shared-based Compensation

NOTE 18. SHARE-BASED COMPENSATION

As discussed in Note 3. Discontinued Operations and Divestitures, the operating results of the Company’s Astora businesses are reported as Discontinued operations, net of tax in the Consolidated Statements of Operations for all periods presented. However, as share-based compensation is not material for these businesses, amounts in this Note 18. Share-based Compensation have not been adjusted to exclude the impact of these businesses.

Stock Incentive Plans

In June 2015, the Company’s shareholders approved the 2015 Stock Incentive Plan (the 2015 Plan), which has subsequently been amended, as approved by the Company’s shareholders, on multiple occasions, including in 2017 and 2018. Under the 2015 Plan, stock options (including incentive stock options), stock appreciation rights, restricted stock awards, performance awards and other share- or cash-based awards may be issued at the discretion of the Board of Directors from time to time. No ordinary shares are to be granted under previously approved plans, including the Company’s 2000, 2004, 2007, 2010 and Assumed Stock Incentive Plans. All awards previously granted and outstanding under these prior plans remain subject to the terms of those prior plans.

During the third quarter of 2017, the Company issued approximately 1.0 million stock options and 0.1 million restricted stock units that were initially subject to shareholder approval and were subsequently approved by shareholders on June 7, 2018 at the Company’s Annual General Meeting of Shareholders. The options have an exercise price equal to the closing share price on their issuance date in August 2017. For accounting and disclosure purposes, these stock options and restricted stock units were considered to have been granted in 2018 upon approval by shareholders.

As further described below, certain of the Company’s outstanding Performance Share Units (PSUs) are measured upon the completion of three independent successive one-year performance targets, which are generally established for each performance period during the first quarter of that calendar year. The determination of the grant-date(s) underlying such PSUs depends in part on the date(s) on which each of the performance targets with respect to those PSUs are approved. Therefore, for certain PSUs, a single unit may give rise to multiple grant dates depending, in part, on the dates on which the respective performance targets are approved. As of December 31, 2018, there are 0.5 million PSUs outstanding, representing target amounts, for which a grant date has not yet been established. No fair value has been ascribed to these awards as no grant date has been established.

Beginning in 2017, long-term cash incentive (LTCI) awards were provided to certain employees. LTCI awards were designed to vest ratably, in equal amounts, over a three-year service period. Upon vesting, each vested LTCI unit would be settled in cash in an amount equal to the price of Endo’s ordinary shares on the vest date. As of September 30, 2018, approximately 3.0 million unvested LTCI awards were outstanding for approximately 570 employees. The outstanding awards had a weighted average remaining requisite service period of 2.3 years. A corresponding liability of $14.9 million was recorded as of September 30, 2018 in Accounts payable and accrued expenses and Other liabilities in the Company’s Condensed Consolidated Balance Sheets. On October 1, 2018, the Compensation Committee of the Board of Directors authorized the Company to settle each of the outstanding unvested LTCI awards in shares, rather than cash, upon vesting in accordance with the original vesting terms of the awards. With the authorization of the Compensation Committee, management’s intent to settle the awards in shares rather than cash is a modification that changes the awards’ classification from liability to equity, effective October 1, 2018. The accounting for the modification occurred in the fourth quarter of 2018. Prior to this modification, LTCI awards were excluded from amounts in this Note 18. Share-based Compensation. Subsequent to this modification, LTCI awards are generally treated the same as restricted stock units (RSUs), including for accounting, financial statement classification and disclosure purposes. However, adjustments to pre-modification amounts of LTCI expense that are recorded in the Consolidated Statements of Operations subsequent to this modification, including adjustments related to actual or estimated forfeitures, are excluded from the determination of share-based compensation expense.

At December 31, 2018, approximately 5.5 million ordinary shares were reserved for future grants under the 2015 Plan. As of December 31, 2018, stock options, restricted stock awards, PSUs, RSUs and LTCI awards have been granted under the stock incentive plans.

Generally, the grant-date fair value of each award is recognized as expense over the requisite service period. However, expense recognition differs in the case of certain performance share units where the ultimate payout is performance-based. For these awards, at each reporting period, the Company estimates the ultimate payout and adjusts the cumulative expense based on its estimate and the percent of the requisite service period that has elapsed.

Presented below are the components of total share-based compensation as recorded in our Consolidated Statements of Operations for the years ended December 31, 2018, 2017 and 2016 (in thousands).



	2018		2017		2016
Selling, general and administrative expenses	$	44,454	$	38,292	$	54,176
Research and development expenses	2,251		4,197		2,440
Cost of revenues	7,366		7,660		2,040
Discontinued operations (Note 3)	—		—		1,113
Total share-based compensation expense	$	54,071	$	50,149	$	59,769

As of December 31, 2018, the total remaining unrecognized compensation cost related to all non-vested share-based compensation awards for which a grant date has been established as of December 31, 2018 amounted to $68.3 million.

Stock Options

From time to time, the Company grants stock options to its employees as part of their annual share compensation awards and, in certain circumstances, on an ad hoc basis or upon their commencement of service with the Company.

Employee stock options generally vest ratably, in equal amounts, over a three or four-year service period and expire ten years from the grant date. The fair value of option grants is estimated at the date of grant using the Black-Scholes option-pricing model. This model utilizes assumptions related to volatility, the risk-free interest rate, the dividend yield (which is assumed to be zero as the Company has not paid cash dividends to date and does not currently expect to pay cash dividends) and the expected term of the option. Expected volatilities utilized in the model are based mainly on the historical volatility of the Company’s share price over a period commensurate with the expected life of the share option as well as other factors. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. We estimate the expected term of options granted based on our historical experience with our employees’ exercise of stock options and other factors.

A summary of the activity for each of the years ended December 31, 2018, 2017 and 2016 is presented below:



	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value (1)
Outstanding as of January 1, 2016	2,768,567		$	51.56
Granted	2,578,105		$	35.45
Exercised	(62,589	)	$	31.19
Forfeited	(858,556	)	$	52.27
Expired	(100,318	)	$	60.71
Outstanding as of December 31, 2016	4,325,209		$	41.70
Granted	5,288,675		$	10.42
Forfeited	(623,987	)	$	28.32
Expired	(741,767	)	$	40.29
Outstanding as of December 31, 2017	8,248,130		$	22.79
Granted	971,590		$	7.55
Exercised	(94,392	)	$	9.89
Forfeited	(605,737	)	$	19.01
Expired	(446,873	)	$	36.80
Outstanding as of December 31, 2018	8,072,718		$	20.62	7.12	$	—
Vested and expected to vest as of December 31, 2018	7,833,930		$	20.86	7.08	$	—
Exercisable as of December 31, 2018	3,550,777		$	28.07	6.00	$	—

__________


(1)	The intrinsic value of a stock option is the excess, if any, of the closing price of the Company’s ordinary shares on the last trading day of the fiscal year over the exercise price. The aggregate intrinsic values presented in the table above represent sum of the intrinsic values of all corresponding stock options that are “in-the-money,” if any.

The range of exercise prices for the above stock options outstanding at December 31, 2018 is from $7.55 to $89.68.

No options were exercised during the year ended December 31, 2017. The total intrinsic value of options exercised during the years ended December 31, 2018 and 2016 was $0.6 million and $1.3 million, respectively. No tax benefits from stock option exercises were realized during the years ended December 31, 2018, 2017 and 2016. The weighted average grant-date fair value of the stock options granted in the years ended December 31, 2018, 2017 and 2016 was $3.97, $4.73 and $11.46 per option, respectively, determined using the following average assumptions:



	2018		2017		2016
Expected term (years)	4.0		4.0		4.0
Risk-free interest rate	2.7	%	1.7	%	1.1	%
Dividend yield	—		—		—
Expected volatility	63	%	58	%	43	%

As of December 31, 2018, the weighted average remaining requisite service period of non-vested stock options was 1.7 years and the total remaining unrecognized compensation cost related to non-vested stock options amounted to $9.4 million.

Restricted Stock Units and Performance Share Units

For PSUs for which a grant date has not yet occurred, such as those described above, no fair value has been established and these awards are not reflected in any of the amounts in this “Restricted Stock Units and Performance Share Units” section.

From time to time, the Company grants RSUs and PSUs to its employees as part of their annual share compensation awards and, in certain circumstances, on an ad hoc basis or upon their commencement of service with the Company.

RSUs vest ratably, in equal amounts, over a three or four-year service period. PSUs vest in full after a three-year service period and are conditional upon the achievement of performance and/or market conditions established by the Compensation Committee of the Board of Directors.

PSUs awarded in 2018 and 2017 were based upon two discrete measures: relative total shareholder return (TSR) and a free cash flow performance metric. The free cash flow performance metric, which accounts for 50% of the PSU award upon issuance, is measured upon the completion of three independent successive one-year performance targets, which are generally established for each performance period during the first quarter of that calendar year. The remaining 50% of the PSU award is tied exclusively to relative TSR performance, which will be measured against the three-year TSR of a custom index of companies. The actual number of shares awarded is adjusted to between zero and 200% of the target award amount based upon achievement of certain goals. In addition to meeting the performance conditions, grant recipients are also generally subject to being employed by the Company until the conclusion of the three-year vesting period in order to receive the awards. TSR relative to peers is considered a market condition under applicable authoritative guidance, while the free cash flow measure is considered performance condition.

In 2016, PSU grants are tied to relative TSR performance, which will be measured against the three-year TSR of a custom index of companies, with maximum payout levels also based on absolute compounded annual growth rate (CAGR) share price objectives. Each award covered a three-year performance cycle. The actual number of shares awarded is adjusted to between zero and 300% of the target award amount based upon achievement of pre-determined relative TSR and CAGR share price goals. TSR relative to peers is considered a market condition under applicable authoritative guidance.

RSUs are valued based on the closing price of Endo’s ordinary shares on the date of grant. PSUs with TSR conditions are valued using a Monte-Carlo variant valuation model, while those with adjusted free cash flow conditions are valued taking into consideration the probability of achieving the specified performance goal. The Monte-Carlo variant valuation model considered a variety of potential future share prices for Endo as well as our peer companies in a selected market index.

A summary of our non-vested RSUs and PSUs for the years ended December 31, 2018, 2017 and 2016 is presented below:



	Number of Shares		Aggregate Intrinsic Value (1)
Non-vested as of January 1, 2016	1,806,853
Granted	1,582,429
Forfeited	(975,994	)
Vested	(728,228	)
Non-vested as of December 31, 2016	1,685,060
Granted	4,168,477
Forfeited	(552,981	)
Vested	(575,883	)
Non-vested as of December 31, 2017	4,724,673
Granted	5,609,561
LTCI modification (2)	2,989,965
Forfeited	(753,653	)
Vested	(1,551,074	)
Non-vested as of December 31, 2018	11,019,472		$	80,442,146
Vested and expected to vest as of December 31, 2018	10,250,560		$	74,829,088

__________


(1)	The aggregate intrinsic values of RSUs and PSUs presented in the table above are calculated by multiplying the closing price of the Company’s ordinary shares on the last trading day of the fiscal year by the corresponding number of RSUs and PSUs.


(2)	As a result of the October 1, 2018 modification to the Company’s LTCI awards described above, modified LTCI awards are treated as RSUs for disclosure purposes; thus, the table above reflects an increase to the non-vested number of shares on the modification date.

As of December 31, 2018, the weighted average remaining requisite service period of the units presented in the table above was 1.9 years and the corresponding total remaining unrecognized compensation cost amounted to $54.2 million in the case of RSUs and LTCI awards and $4.7 million in the case of PSUs. The weighted average grant-date fair value of the units granted during the years ended December 31, 2018, 2017 and 2016 was $6.88, $11.42 and $43.52 per unit, respectively.

Other Income, Net

12 Months Ended

Dec. 31, 2018

Component of Operating Income [Abstract]

OTHER INCOME, NET

NOTE 19. OTHER INCOME, NET

The components of Other income, net for the years ended December 31, 2018, 2017 and 2016 are as follows (in thousands):



	2018			2017			2016
Net (gain) loss on sale of business and other assets	$	(45,155	)	$	(13,809	)	$	3,192
Foreign currency (gain) loss, net	(3,762		)	(2,801		)	2,991
Net loss (gain) from our investments in the equity of other companies	3,444			898			(1,190		)
Other miscellaneous, net	(6,480		)	(1,311		)	(5,331		)
Other income, net	$	(51,953	)	$	(17,023	)	$	(338	)

In 2018, Net (gain) loss on sale of business and other assets primarily relates to proceeds received from the 2018 sales of various ANDAs and of the Huntsville facilities, as further discussed in Note 4. Restructuring.

In 2017, Net (gain) loss on sale of business and other assets includes a $10.1 million gain resulting from the sale of Litha, as further described in Note 3. Discontinued Operations and Divestitures.

Amounts of Foreign currency (gain) loss, net result from the remeasurement of the Company’s foreign currency denominated assets and liabilities. Net loss (gain) from our investments in the equity of other companies includes the income statement impacts of our investments in the equity of other companies, including those accounted for under the equity method and those classified as marketable securities.

Income Taxes

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 20. INCOME TAXES

Tax Reform

The TCJA, which was signed into law on December 22, 2017, has resulted in significant changes to the U.S. corporate income tax system. In addition to the reduction of the U.S. statutory federal corporate income tax rate from 35% to 21% effective January 1, 2018, the TCJA contains a broad range of domestic and international provisions, many of which differ significantly from those contained in previous U.S. tax law. Although the rate of U.S. federal income tax was reduced prospectively, changes in tax rates and laws are accounted for in the period of enactment. Therefore, during the year ended December 31, 2017, we recorded a benefit of $36.2 million as our provisional estimate of the impact of the TCJA in accordance with Staff Accounting Bulletin (SAB) 118. This benefit, which is primarily related to remeasurement of deferred tax liabilities related to tax deductible goodwill, has been recorded in our Consolidated Statements of Operations as Income tax benefit. The Company has completed its accounting for the tax effects of the TCJA in accordance with SAB 118. There were no significant adjustments to the provisional amounts recorded.

Income (Loss) Before Income Taxes

Our operations are conducted through our various subsidiaries in numerous jurisdictions throughout the world. We have provided for income taxes based upon the tax laws and rates in the jurisdictions in which our operations are conducted.

The components of our Loss from continuing operations before income tax by geography for the years ended December 31, 2018, 2017 and 2016 are as follows (in thousands):



	2018			2017			2016
United States	$	(1,342,860	)	$	(1,866,222	)	$	(4,309,211	)
International	404,028			383,218			385,355
Total (loss) income from continuing operations before income tax	$	(938,832	)	$	(1,483,004	)	$	(3,923,856	)

Income tax from continuing operations consists of the following for the years ended December 31, 2018, 2017 and 2016 (in thousands):



	2018			2017			2016
Current:
U.S. Federal	$	6,236		$	(86,478	)	$	18,369
U.S. State	2,864			(6,462		)	9,501
International	8,278			(1,224		)	22,851
Total current income tax	$	17,378		$	(94,164	)	$	50,721
Deferred:
U.S. Federal	$	10,084		$	(124,682	)	$	(661,484	)
U.S. State	(778		)	(3,225		)	(239		)
International	(3,749		)	(28,222		)	(83,619		)
Total deferred income tax	$	5,557		$	(156,129	)	$	(745,342	)
Excess tax benefits of stock compensation exercised	—			—			(5,463		)
Total income tax	$	22,935		$	(250,293	)	$	(700,084	)

Tax Rate

A reconciliation of income tax from continuing operations at the U.S. federal statutory income tax rate to the total income tax provision from continuing operations for the years ended December 31, 2018, 2017 and 2016 is as follows (in thousands):



	2018			2017			2016
Notional U.S. federal income tax provision at the statutory rate	$	(197,155	)	$	(519,051	)	$	(1,373,350	)
State income tax, net of federal benefit	494			(11,473		)	5,182
U.S. tax reform impact	5,664			(36,216		)	—
Uncertain tax positions	46,317			58,120			(18,111		)
Residual tax on non-U.S. net earnings	(638,724		)	(1,350,811		)	(301,666		)
Effects of outside basis differences	—			—			(636,134		)
Non-deductible goodwill impairment	109,189			60,808			926,881
Change in valuation allowance	752,008			1,648,836			762,604
Intra-entity transfers of assets	(63,335		)	(53,509		)	(92,859		)
International Pharmaceuticals segment divestitures	—			(56,092		)	—
Other	8,477			9,095			27,369
Income tax	$	22,935		$	(250,293	)	$	(700,084	)

During the year ended December 31, 2018, the tax expense primarily related to the establishment of a valuation allowance against certain U.S. deferred tax assets. During the year ended December 31, 2017, the tax benefit primarily related to pre-tax losses incurred by certain U.S. subsidiaries. During the year ended December 31, 2016, the Company recorded a $636.1 million net tax benefit related to worthless stock deductions that are reflected as a component of benefits from outside basis differences.

Deferred Tax Assets and Liabilities

Deferred income taxes result from temporary differences between the amount of assets and liabilities recognized for financial reporting and tax purposes. The significant components of the net deferred income tax liability shown on the balance sheets as of December 31, 2018 and 2017 are as follows (in thousands):



	December 31, 2018			December 31, 2017
Deferred tax assets:
Accrued expenses and customer allowances	$	185,910		$	299,142
Deferred interest expense	240,736			46,230
Fixed assets and intangible assets	604,385			484,313
Loss on capital assets	62,033			49,585
Net operating loss carryforward	8,751,544			7,183,651
Other	65,266			56,828
Research and development and other tax credit carryforwards	9,551			6,354
Total gross deferred income tax assets	$	9,919,425		$	8,126,103
Deferred tax liabilities:
Other	$	(1,965	)	$	(2,042	)
Outside basis difference	(73,652		)	(92,635		)
Total gross deferred income tax liabilities	$	(75,617	)	$	(94,677	)
Valuation allowance	(9,877,617		)	(8,062,975		)
Net deferred income tax liability	$	(33,809	)	$	(31,549	)

At December 31, 2018, the Company had the following significant deferred tax assets for net operating and capital loss carryforwards, net of unrecognized tax benefits (in thousands):



Jurisdiction	Amount		Begin to Expire
Ireland	$	13,254	indefinite
Luxembourg	$	8,378,742	2034
United States:
Federal-ordinary losses	$	176,695	2020
Federal-capital losses	$	35,673	2022
State-ordinary losses	$	178,732	2019
State-capital losses	$	25,524	2026

A valuation allowance is required when it is more likely than not that all or a portion of a deferred tax asset will not be realized. The Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. The amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable income during the carryforward period are reduced or increased, or if objective negative evidence, in the form of cumulative losses, is no longer present and additional weight may be given to subjective evidence, such as projections for growth.

The Company has recorded a valuation allowance against certain jurisdictional net operating loss carryforwards and other tax attributes. As of December 31, 2018 and 2017, the total valuation allowance was $9,877.6 million and $8,063.0 million, respectively. During the years ended December 31, 2018 and 2017, the Company increased its valuation allowance in the amount of $1,814.6 million and $3,221.8 million, respectively.

The net increase in the Company’s valuation allowance in 2018 was primarily driven by losses within jurisdictions unable to support recognition of a deferred tax asset, of which the largest jurisdiction was Luxembourg, where the Company had significant interest expense and losses on its investments in the equity of consolidated subsidiaries.

The net increase in the Company’s valuation allowance in 2017 was primarily driven by: (i) $3,310.8 million related to losses within jurisdictions unable to support recognition of a deferred tax asset, of which the largest jurisdiction was Luxembourg, where the Company recognized a significant loss on its investment in the equity of consolidated subsidiaries, (ii) the establishment of a $479.7 million valuation allowance offsetting net deferred tax assets that was created in connection with the January 1, 2017 adoption of ASU No. 2016-16, “Intra-Entity Transfers of Assets Other Than Inventory” and that primarily relates to certain intangibles and tax deductible goodwill and (iii) $21.5 million relating to state tax benefits. This increase was partially offset by a $590.2 million reduction related to remeasurement of certain deferred tax assets resulting from the TCJA.

At December 31, 2018, the Company had the following significant valuation allowances (in thousands):



Jurisdiction	December 31, 2018
Ireland	$	160,867
Luxembourg	$	8,378,742
United States	$	1,334,463

We have provided income taxes for earnings that are currently distributed as well as the taxes associated with certain earnings that are expected to be distributed in the future. No additional provision has been made for Irish and non-Irish income taxes on the undistributed earnings of subsidiaries or for unrecognized deferred tax liabilities for temporary differences related to basis differences in investments in subsidiaries as such earnings are expected to be indefinitely reinvested, the investments in subsidiaries are essentially permanent in duration. As of December 31, 2018, certain subsidiaries had approximately $1,231.8 million of cumulative undistributed earnings that have been permanently reinvested because our plans do not demonstrate a need to repatriate such earnings. A liability could arise if our intention to indefinitely reinvest such earnings were to change and amounts are distributed by such subsidiaries or if such subsidiaries are ultimately disposed. It is not practicable to estimate the additional income taxes related to indefinitely reinvested earnings or the basis differences related to investments in subsidiaries.

Uncertain Tax Positions

The Company and its subsidiaries are subject to income taxes in the U.S., various states and numerous foreign jurisdictions with varying statutes as to which tax years are subject to examination by the tax authorities. The Company has taken positions on its tax returns that may be challenged by various tax authorities for which reserves have been established for tax-related uncertainties. The Company endeavors to resolve matters with a tax authority at the examination level and could reach agreement with a tax authority at any time. The accruals for tax-related uncertainties are based on the Company’s best estimate of the potential tax exposures. When particular matters arise, a number of years may elapse before such matters are audited and finally resolved, and the final outcome with a tax authority may result in a tax liability that is more or less than that reflected in our financial statements. Favorable resolution of such matters could be recognized as a reduction of the Company’s effective tax rate in the year of resolution, while a resolution that is not favorable could increase the effective tax rate and may require the use of cash in the year of resolution. Uncertain tax positions are reviewed quarterly and adjusted as necessary when events occur that affect potential tax liabilities, such as lapsing of applicable statutes of limitations, proposed assessments by tax authorities, identification of new issues and issuance of new legislation, regulations or case law.

As of December 31, 2018, the Company had total unrecognized income tax benefits of $479.4 million. If recognized in future years, $304.3 million of these currently unrecognized income tax benefits would impact the income tax provision and effective tax rate. As of December 31, 2017, the Company had total unrecognized tax benefits of $435.1 million. If recognized in future years, $289.9 million of these unrecognized income tax benefits would have impacted the income tax provision and effective tax rate. The following table summarizes the activity related to unrecognized income tax benefits during the years ended December 31, 2018, 2017 and 2016 (in thousands):



	Unrecognized Tax Benefit Federal, State, and Foreign Tax
UTB Balance at January 1, 2016	$	316,247
Gross additions for current year positions	142,778
Gross reductions for prior period positions	(35,888		)
Gross additions for prior period positions	2,111
Decrease due to lapse of statute of limitations	(3,085		)
Additions related to acquisitions	2,350
Currency translation adjustment	88
UTB Balance at December 31, 2016	$	424,601
Gross additions for current year positions	44,293
Gross reductions for prior period positions	(64,887		)
Gross additions for prior period positions	22,765
Decrease due to lapse of statute of limitations	(13,151		)
Currency translation adjustment	2,330
UTB Balance at December 31, 2017	$	415,951
Gross additions for current year positions	36,088
Gross reductions for prior period positions	(3,570		)
Gross additions for prior period positions	7,950
Decrease due to lapse of statute of limitations	(2,129		)
Currency translation adjustment	(2,600		)
UTB Balance at December 31, 2018	$	451,690
Accrued interest and penalties	27,739
Total UTB balance including accrued interest and penalties	$	479,429

The Company records accrued interest as well as penalties related to uncertain tax positions as part of the provision for income taxes. As of December 31, 2018 and 2017, $27.7 million and $19.2 million, respectively, of corresponding accrued interest and penalties is included in the Consolidated Balance Sheets, all of which is recorded in income taxes.

During the years ended December 31, 2018, 2017, and 2016, we recognized expense of $8.6 million, $1.4 million and $5.1 million, respectively, related to interest and penalties. The current portion of our UTB liability of $6.5 million is included in our Consolidated Balance Sheet as Accounts payable and accrued expenses. The non-current portion of our UTB liability is included in our Consolidated Balance Sheet as Other liabilities or, if and to the extent appropriate, as a reduction to Deferred tax assets.

Our subsidiaries file income tax returns in the countries in which they have operations. Generally, these countries have statutes of limitations ranging from 3 to 5 years. Certain subsidiary tax returns are currently under examination by taxing authorities, including U.S. tax returns for the 2011 through 2015 tax years by the Internal Revenue Service.

It is expected that the amount of unrecognized tax benefits will change during the next twelve months; however, the Company does not anticipate any adjustments that would lead to a material impact on our results of operations or our financial position.

As of December 31, 2018, we may be subject to examination in the following major tax jurisdictions:



Jurisdiction		Open Years
Canada		2013 through 2018
India		2013 through 2018
Ireland		2014 through 2018
Luxembourg		2014 through 2018
United States - federal, state and local		2006 through 2018

Net Loss Per Share

12 Months Ended

Dec. 31, 2018

Earnings Per Share [Abstract]

NET LOSS PER SHARE

NOTE 21. NET LOSS PER SHARE

The following is a reconciliation of the numerator and denominator of basic and diluted net loss per share attributable to Endo International plc ordinary shareholders for the years ended December 31, 2018, 2017 and 2016 (in thousands):



	2018			2017			2016
Numerator:
Loss from continuing operations	$	(961,767	)	$	(1,232,711	)	$	(3,223,772	)
Less: Net income from continuing operations attributable to noncontrolling interests	—			—			16
Loss from continuing operations attributable to Endo International plc	$	(961,767	)	$	(1,232,711	)	$	(3,223,788	)
Loss from discontinued operations, net of tax attributable to Endo International plc	(69,702		)	(802,722		)	(123,278		)
Net loss attributable to Endo International plc	$	(1,031,469	)	$	(2,035,433	)	$	(3,347,066	)
Denominator:
For basic per share data—weighted average shares	223,960			223,198			222,651
Dilutive effect of ordinary share equivalents	—			—			—
For diluted per share data—weighted average shares	223,960			223,198			222,651

Basic net loss per share attributable to Endo International plc ordinary shareholders amounts are computed based on the weighted average number of ordinary shares outstanding during the period. Diluted net loss per share attributable to Endo International plc ordinary shareholders amounts are computed based on the weighted average number of ordinary shares outstanding and, if there is net income from continuing operations attributable to Endo International plc during the period, the dilutive impact of ordinary share equivalents outstanding during the period.

The dilutive effect of ordinary share equivalents is measured using the treasury stock method. Stock options and awards that have been issued but for which a grant date has not yet been established, such as the performance share units discussed in Note 18. Share-based Compensation, are not considered in the calculation of basic or diluted weighted average shares.

All potentially dilutive items were excluded from the diluted share calculation for the years ended December 31, 2018, 2017 and 2016 because their effect would have been anti-dilutive, as the Company was in a loss position.

Savings And Investment Plan And Deferred Compensation Plans	12 Months Ended
	Dec. 31, 2018
Savings And Investment Plan And Deferred Compensation Plans [Abstract]
Savings And Investment Plan And Deferred Compensation Plans	NOTE 22. SAVINGS AND INVESTMENT PLAN AND DEFERRED COMPENSATION PLANS Savings and Investment Plan The Company maintains a defined contribution Savings and Investment Plan (the Endo 401(k) Plan) covering all U.S.-based eligible employees. The Company matches 100% of the first 3% of eligible cash compensation that a participant contributes to the Endo 401(k) Plan plus 50% of the next 2% for a total of up to 4%, subject to statutory limitations. Participants are immediately vested with respect to their own contributions and the Company’s matching contributions, except that, for employees hired after 2017, the Company’s matching contributions will vest ratably over a two-year period. Costs incurred for contributions made by the Company to the Endo 401(k) Plan amounted to $6.4 million, $9.4 million and $11.5 million for the years ended December 31, 2018, 2017 and 2016, respectively. Directors Stock Election Plan The Company maintains a directors stock election plan. The purpose of this plan is to provide non-employee directors the opportunity to have their cash retainer fees, or a portion thereof, delivered in the form of Endo ordinary shares. The amount of shares will be determined by dividing the portion of cash fees elected to be received as shares by the closing price of the shares on the day the payment would have otherwise been paid in cash.

Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2018

Quarterly Financial Data [Abstract]

Quarterly Financial Data (Unaudited)

NOTE 23. QUARTERLY FINANCIAL DATA (UNAUDITED)

The following table presents select unaudited financial data for each of the three-month periods ending March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018, as well as the comparable 2017 periods (in thousands, except per share data):



	Quarter Ended
	March 31,			June 30,			September 30,			December 31,
2018 (1)
Total revenues	$	700,527		$	714,696		$	745,466		$	786,389
Gross profit	$	296,929		$	332,791		$	332,501		$	353,175
Loss from continuing operations	$	(497,738	)	$	(52,479	)	$	(146,071	)	$	(265,479	)
Discontinued operations, net of tax	$	(7,751	)	$	(8,388	)	$	(27,134	)	$	(26,429	)
Net loss attributable to Endo International plc	$	(505,489	)	$	(60,867	)	$	(173,205	)	$	(291,908	)
Net loss per share attributable to Endo International plc ordinary shareholders—Basic:
Continuing operations	$	(2.23	)	$	(0.23	)	$	(0.65	)	$	(1.18	)
Discontinued operations	(0.03		)	(0.04		)	(0.12		)	(0.12		)
Basic	$	(2.26	)	$	(0.27	)	$	(0.77	)	$	(1.30	)
Net loss per share attributable to Endo International plc ordinary shareholders—Diluted:
Continuing operations	$	(2.23	)	$	(0.23	)	$	(0.65	)	$	(1.18	)
Discontinued operations	(0.03		)	(0.04		)	(0.12		)	(0.12		)
Diluted	$	(2.26	)	$	(0.27	)	$	(0.77	)	$	(1.30	)
Weighted average shares—Basic	223,521			223,834			224,132			224,353
Weighted average shares—Diluted	223,521			223,834			224,132			224,353
2017 (2)
Total revenues	$	1,037,600		$	875,731		$	786,887		$	768,640
Gross profit	$	368,638		$	336,330		$	272,365		$	262,995
Loss from continuing operations	$	(165,423	)	$	(696,020	)	$	(99,687	)	$	(271,581	)
Discontinued operations, net of tax	$	(8,405	)	$	(700,498	)	$	3,017		$	(96,836	)
Net loss attributable to Endo International plc	$	(173,828	)	$	(1,396,518	)	$	(96,670	)	$	(368,417	)
Net loss per share attributable to Endo International plc ordinary shareholders—Basic:
Continuing operations	$	(0.74	)	$	(3.12	)	$	(0.45	)	$	(1.22	)
Discontinued operations	(0.04		)	(3.14		)	0.02			(0.43		)
Basic	$	(0.78	)	$	(6.26	)	$	(0.43	)	$	(1.65	)
Net loss per share attributable to Endo International plc ordinary shareholders—Diluted:
Continuing operations	$	(0.74	)	$	(3.12	)	$	(0.45	)	$	(1.22	)
Discontinued operations	(0.04		)	(3.14		)	0.02			(0.43		)
Diluted	$	(0.78	)	$	(6.26	)	$	(0.43	)	$	(1.65	)
Weighted average shares—Basic	223,014			223,158			223,299			223,322
Weighted average shares—Diluted	223,014			223,158			223,299			223,322

__________

(1)

Loss from continuing operations for the year ended December 31, 2018 was impacted by (i) acquisition-related and integration items of $6.8 million, $5.2 million, $1.3 million and $8.6 million during the first, second, third and fourth quarters, respectively, including charges due to changes in the fair value of contingent consideration of $6.8 million, $4.1 million, $0.8 million and $8.2 million, respectively, (ii) asset impairment charges of $448.4 million, $22.8 million, $142.2 million and $303.5 million during the first, second, third and fourth quarters, respectively, (iii) certain cost reductions and separation benefits incurred in connection with continued efforts to enhance the Company’s operations and other miscellaneous costs of $49.0 million, $29.2 million, $4.0 million and $4.2 million during the first, second, third and fourth quarters, respectively, (iv) charges/(benefits) related to litigation-related and other contingent matters totaling $(2.5) million, $19.6 million, $(1.8) million and $(1.6) million during the first, second, third and fourth quarters, respectively, and (v) (gains) on sales of businesses and other assets of $(2.4) million, $(24.6) million, $(2.9) million and $(15.3) million during the first, second, third and fourth quarters, respectively.

(2)

Loss from continuing operations for the year ended December 31, 2017 was impacted by (i) acquisition-related and integration items of $10.9 million, $4.2 million, $16.6 million and $26.4 million during the first, second, third and fourth quarters, respectively, including charges due to changes in the fair value of contingent consideration of $6.2 million, $2.0 million, $15.4 million and $26.4 million, respectively, (ii) asset impairment charges of $204.0 million, $725.0 million, $94.9 million and $130.4 million during the first, second, third and fourth quarters, respectively, (iii) certain cost reductions and separation benefits incurred in connection with continued efforts to enhance the Company’s operations and other miscellaneous costs of $22.7 million, $24.6 million, $80.7 million and $84.5 million during the first, second, third and fourth quarters, respectively, (iv) charges/(benefits) related to litigation-related and other contingent matters totaling $0.9 million, $(2.6) million, $(12.4) million and $200.0 million during the first, second, third and fourth quarters, respectively, (v) loss on extinguishment of debt of $51.7 million during the second quarter and (vi) (gains) on sales of businesses and other assets of $(2.3) million, $(2.8) million and $(8.7) million during the first, third and fourth quarters, respectively. As previously reported in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, the third quarter numbers above reflect a $14.2 million correcting entry to increase asset impairment charges resulting from certain assets that should have been impaired during the second quarter.

Quarterly and year-to-date computations of per share amounts are made independently, therefore, the sum of the per share amounts for the quarters may not equal the per share amounts for the year.

As further described in Note 3. Discontinued Operations and Divestitures, we sold our Litha business in July 2017 and our Somar business in October 2017. Both of these businesses were part of our International Pharmaceuticals segment. Neither business met the requirements for presentation as discontinued operations. The operating results of the Astora business are reported as Discontinued operations, net of tax in the Consolidated Statements of Operations for all periods presented. For additional information, see Note 3. Discontinued Operations and Divestitures.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Consolidation and Basis of Presentation

Consolidation and Basis of Presentation. The Consolidated Financial Statements include the accounts of wholly owned subsidiaries after the elimination of intercompany accounts and transactions.

Reclassifications

Reclassifications. Certain prior period amounts have been reclassified to conform to the current period presentation.

Use of Estimates

Customer Product And Supplier Concentration

Revenues

Rebates—Our provision for rebates, sales incentives and other allowances can generally be categorized into the following four types:


•	direct rebates;


•	indirect rebates;


•	governmental rebates, including those for Medicaid, Medicare and TRICARE, among others; and


•	managed-care rebates.

Research and Development (R&D)

Cash and Cash Equivalents

Restricted Cash and Cash Equivalents

Marketable Securities

Marketable Securities. The Company has equity securities, which consist of investments in the stock of publicly traded companies.

Accounts Receivable

Concentrations of Credit Risk

Inventories

Property, Plant and Equipment

Computer Software

Lease Accounting

Finite-Lived Intangible Assets

License Rights

Long-Lived Asset Impairment Test

In-Process Research and Development Assets (IPR&D)

Goodwill

Contingencies

Contingent Consideration

Share Repurchases

Advertising Costs

Advertising Costs. Advertising costs are expensed as incurred and included in Selling, general and administrative expenses in the Consolidated Statements of Operations.

Share-based Compensation

Foreign Currency

Income Taxes

Comprehensive Income

Recently Issued and Adopted Accounting Pronouncements

Recently Issued Accounting Pronouncements Not Yet Adopted at December 31, 2018

Recent Accounting Pronouncements Adopted or Otherwise Effective as of December 31, 2018

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” (ASU 2014-09), which was subsequently amended and supplemented by several additional ASUs including:


•	ASU No. 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” (issued in August 2015), which deferred the effective date of ASU 2014-09 by one year, such that ASU 2014-09 became effective for Endo for annual and interim reporting periods beginning after December 15, 2017;


•	ASU No. 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Consideration (Reporting Revenue Gross versus Net)” (issued in March 2016), which clarified the guidance on reporting revenue as a principal versus agent;


•	ASU No. 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing” (issued in April 2016), which clarified the guidance on identifying performance obligations and accounting for intellectual property licenses; and


•	ASU No. 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients” and ASU No. 2016-20, “Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers,” (issued in May 2016 and December 2016, respectively), which amended certain narrow aspects of Topic 606.

The current year impact of adoption on our Consolidated Statements of Operations and Consolidated Balance Sheets is as follows (in thousands, except per share amounts):



	Year Ended December 31, 2018
Statement of Operations:	Amounts reported under ASC 606			Amounts assuming continued application of ASC 605			Effect of adoption of ASC 606 (1)
Total revenues	$	2,947,078		$	2,947,930		$	(852	)
Cost of revenues	$	1,631,682		$	1,633,294		$	(1,612	)
Other income, net	$	(51,953	)	$	(50,953	)	$	(1,000	)
Loss from continuing operations	$	(961,767	)	$	(963,527	)	$	1,760
Net loss attributable to Endo International plc	$	(1,031,469	)	$	(1,033,229	)	$	1,760
Net loss per share attributable to Endo International plc ordinary shareholders—Basic:
Continuing operations	$	(4.29	)	$	(4.30	)	$	0.01
Total basic	$	(4.61	)	$	(4.61	)	$	—
Net loss per share attributable to Endo International plc ordinary shareholders—Diluted:
Continuing operations	$	(4.29	)	$	(4.30	)	$	0.01
Total diluted	$	(4.61	)	$	(4.61	)	$	—

__________


(1)	Amounts may not add due to rounding.



	At December 31, 2018
Balance Sheet:	Amounts reported under ASC 606			Amounts assuming continued application of ASC 605			Effect of adoption of ASC 606
Assets:
Inventories, net	$	322,179		$	329,684		$	(7,505	)
Prepaid expenses and other current assets	$	56,139		$	46,832		$	9,307
Other assets	$	66,993		$	64,235		$	2,758
Liabilities:
Accounts payable and accrued expenses	$	1,009,200		$	1,009,476		$	(276	)
Shareholders' (deficit) equity:
Accumulated deficit	$	(9,124,932	)	$	(9,129,768	)	$	4,836

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Schedules of concentration of risk, by risk factor

Total revenues from direct customers that accounted for 10% or more of our total consolidated revenues during the years ended December 31, 2018, 2017 and 2016 are as follows:



	2018		2017		2016
AmerisourceBergen Corporation	32	%	25	%	25	%
McKesson Corporation	27	%	25	%	27	%
Cardinal Health, Inc.	26	%	25	%	26	%

Estimated useful lives

Depreciation is based on the following estimated useful lives, as of December 31, 2018:



	Range of Useful Lives, from:
Buildings	10 years	to	30 years
Machinery and equipment	2 years	to	15 years
Leasehold improvements	Shorter of useful life or lease term
Computer equipment and software	1 year	to	7 years
Assets under capital lease	Shorter of useful life or lease term
Furniture and fixtures	3 years	to	10 years

Changes in the amount of Property, plant and equipment for the year ended December 31, 2018 are set forth in the table below (in thousands).



Cost:	Land and Buildings			Machinery and Equipment			Leasehold Improvements			Computer Equipment and Software			Assets under Capital Lease			Furniture and Fixtures			Assets under Construction			Total
At January 1, 2018	$	331,466		$	267,818		$	60,464		$	131,451		$	4,896		$	13,124		$	119,035		$	928,254
Additions	20,317			34,570			12,925			18,660			2,286			490			5,549			94,797
Disposals, transfers, impairments and other	(126,961		)	(90,795		)	(4,030		)	(32,602		)	(1,969		)	(1,101		)	(3,545		)	(261,003		)
Effect of currency translation	—			(102		)	(103		)	(375		)	—			(18		)	(15		)	(613		)
At December 31, 2018	$	224,822		$	211,491		$	69,256		$	117,134		$	5,213		$	12,495		$	121,024		$	761,435
Accumulated Depreciation:
At January 1, 2018	$	(149,402	)	$	(134,741	)	$	(26,867	)	$	(82,792	)	$	(4,161	)	$	(6,320	)	$	—		$	(404,283	)
Additions	(39,253		)	(32,273		)	(6,583		)	(21,105		)	(670		)	(1,484		)	—			(101,368		)
Disposals, transfers and other	121,861			83,037			2,806			32,235			1,969			842			—			242,750
Effect of currency translation	—			71			44			225			—			18			—			358
At December 31, 2018	$	(66,794	)	$	(83,906	)	$	(30,600	)	$	(71,437	)	$	(2,862	)	$	(6,944	)	$	—		$	(262,543	)
Net Book Amount:
At December 31, 2018	$	158,028		$	127,585		$	38,656		$	45,697		$	2,351		$	5,551		$	121,024		$	498,892
At December 31, 2017	$	182,064		$	133,077		$	33,597		$	48,659		$	735		$	6,804		$	119,035		$	523,971

Schedule of new accounting pronouncements and changes in accounting principles

The current year impact of adoption on our Consolidated Statements of Operations and Consolidated Balance Sheets is as follows (in thousands, except per share amounts):



	Year Ended December 31, 2018
Statement of Operations:	Amounts reported under ASC 606			Amounts assuming continued application of ASC 605			Effect of adoption of ASC 606 (1)
Total revenues	$	2,947,078		$	2,947,930		$	(852	)
Cost of revenues	$	1,631,682		$	1,633,294		$	(1,612	)
Other income, net	$	(51,953	)	$	(50,953	)	$	(1,000	)
Loss from continuing operations	$	(961,767	)	$	(963,527	)	$	1,760
Net loss attributable to Endo International plc	$	(1,031,469	)	$	(1,033,229	)	$	1,760
Net loss per share attributable to Endo International plc ordinary shareholders—Basic:
Continuing operations	$	(4.29	)	$	(4.30	)	$	0.01
Total basic	$	(4.61	)	$	(4.61	)	$	—
Net loss per share attributable to Endo International plc ordinary shareholders—Diluted:
Continuing operations	$	(4.29	)	$	(4.30	)	$	0.01
Total diluted	$	(4.61	)	$	(4.61	)	$	—

__________


(1)	Amounts may not add due to rounding.



	At December 31, 2018
Balance Sheet:	Amounts reported under ASC 606			Amounts assuming continued application of ASC 605			Effect of adoption of ASC 606
Assets:
Inventories, net	$	322,179		$	329,684		$	(7,505	)
Prepaid expenses and other current assets	$	56,139		$	46,832		$	9,307
Other assets	$	66,993		$	64,235		$	2,758
Liabilities:
Accounts payable and accrued expenses	$	1,009,200		$	1,009,476		$	(276	)
Shareholders' (deficit) equity:
Accumulated deficit	$	(9,124,932	)	$	(9,129,768	)	$	4,836

Discontinued Operations and Divestitures (Tables)

12 Months Ended

Dec. 31, 2018

Discontinued Operations and Disposal Groups [Abstract]

Schedule of disposal groups, including discontinued operations, income statement, balance sheet and additional disclosures

The following table provides the operating results of Astora Discontinued operations, net of tax, for the years ended December 31, 2018, 2017 and 2016 (in thousands):



	2018			2017			2016
Revenue	$	—		$	338		$	30,101
Litigation-related and other contingencies, net	$	34,000		$	775,474		$	20,115
Asset impairment charges	$	—		$	—		$	21,328
Loss from discontinued operations before income taxes	$	(69,702	)	$	(816,426	)	$	(123,164	)
Income tax benefit	$	—		$	(13,704	)	$	—
Discontinued operations, net of tax	$	(69,702	)	$	(802,722	)	$	(123,164	)

Schedule of restructuring and related costs

A summary of expenses related to the Astora Restructuring Initiative is included below for the year ended December 31, 2016 (in thousands):



	2016
Employee separation, retention and other benefit-related costs	$	20,476
Asset impairment charges	21,328
Contract termination-related items	8,074
Other wind-down costs	10,972
Total	$	60,850

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

Restructuring (Tables)

12 Months Ended

Dec. 31, 2018

Restructuring and Related Activities [Abstract]

Schedule of restructuring reserve by type of cost



	Employee Separation and Other Benefit-Related Costs			Other Restructuring Costs			Total
Liability balance as of January 1, 2018	$	—		$	650		$	650
Expenses	21,754			1,764			23,518
Cash distributions	(20,925		)	(2,094		)	(23,019		)
Liability balance as of December 31, 2018	$	829		$	320		$	1,149

Changes to this liability during the year ended December 31, 2017 were as follows (in thousands):



	Employee Separation and Other Benefit-Related Costs			Contract Termination Charges			Total
Liability balance as of January 1, 2017	$	16,544		$	5,224		$	21,768
Cash distributions	(16,544		)	(5,224		)	(21,768		)
Liability balance as of December 31, 2017	$	—		$	—		$	—



	Total
Liability balance as of January 1, 2017	$	—
Expenses	15,072
Cash distributions	(12,391		)
Liability balance as of December 31, 2017	$	2,681
Cash distributions	(2,681		)
Liability balance as of December 31, 2018	$	—



	Employee Separation and Other Benefit-Related Costs			Other Restructuring Costs			Total
Liability balance as of January 1, 2017	$	—		$	—		$	—
Expenses	29,553			13,724			43,277
Cash distributions	(6,578		)	(12,114		)	(18,692		)
Liability balance as of December 31, 2017	$	22,975		$	1,610		$	24,585
Expenses	9,090			11,294			20,384
Cash distributions	(27,826		)	(12,856		)	(40,682		)
Liability balance as of December 31, 2018	$	4,239		$	48		$	4,287

Substantially all cash payments are expected to be made by the end of the third quarter in 2019.

Segment Results (Tables)

12 Months Ended

Dec. 31, 2018

Segment Reporting [Abstract]

Schedule of reportable segments information

The following represents selected information for the Company’s reportable segments for the years ended December 31, 2018, 2017 and 2016 (in thousands):



	2018		2017		2016
Net revenues from external customers:
U.S. Branded - Specialty & Established Pharmaceuticals	$	862,832	$	957,525	$	1,166,294
U.S. Branded - Sterile Injectables	929,566		750,471		576,399
U.S. Generic Pharmaceuticals	1,012,215		1,530,530		1,988,214
International Pharmaceuticals (1)	142,465		230,332		279,367
Total net revenues from external customers	$	2,947,078	$	3,468,858	$	4,010,274
Adjusted income from continuing operations before income tax:
U.S. Branded - Specialty & Established Pharmaceuticals	$	368,790	$	485,515	$	553,806
U.S. Branded - Sterile Injectables	695,363		563,103		426,170
U.S. Generic Pharmaceuticals	317,892		501,249		653,309
International Pharmaceuticals	59,094		58,308		84,337
Total segment adjusted income from continuing operations before income tax	$	1,441,139	$	1,608,175	$	1,717,622

__________


(1)	Revenues generated by our International Pharmaceuticals segment are primarily attributable to external customers located in Canada and, prior to the sale of Litha in July 2017 and Somar in October 2017, South Africa and Latin America.



	2018			2017			2016
Total consolidated loss from continuing operations before income tax	$	(938,832	)	$	(1,483,004	)	$	(3,923,856	)
Interest expense, net	521,656			488,228			452,679
Corporate unallocated costs (1)	200,592			165,298			189,043
Amortization of intangible assets	622,339			773,766			876,451
Inventory step-up and certain manufacturing costs that will be eliminated pursuant to integration plans	261			390			125,699
Upfront and milestone payments to partners	45,108			9,483			8,330
Separation benefits and other cost reduction initiatives (2)	86,295			212,448			107,491
Impact of VOLTAREN® Gel generic competition	—			—			(7,750		)
Certain litigation-related and other contingencies, net (3)	13,809			185,990			23,950
Asset impairment charges (4)	916,939			1,154,376			3,781,165
Acquisition-related and integration items (5)	21,914			58,086			87,601
Loss on extinguishment of debt	—			51,734			—
Foreign currency impact related to the remeasurement of intercompany debt instruments	(5,486		)	(1,403		)	366
Other, net (6)	(43,456		)	(7,217		)	(3,547		)
Total segment adjusted income from continuing operations before income tax	$	1,441,139		$	1,608,175		$	1,717,622

__________


(1)	Amounts include certain corporate overhead costs, such as headcount, facility and corporate litigation expenses and certain other income and expenses.

(2)


(3)	Amounts include adjustments for Litigation-related and other contingencies, net as further described in Note 15. Commitments and Contingencies.


(4)	Amounts primarily relate to charges to impair goodwill and intangible assets as further described in Note 10. Goodwill and Other Intangibles as well as charges to write down certain property, plant and equipment as further described in Note 4. Restructuring, Note 7. Fair Value Measurements and Note 9. Property, Plant and Equipment.


(5)	Amounts include charges due to changes in the fair value of contingent consideration of $19.9 million, $49.9 million and $23.8 million, respectively. All other amounts are directly related to costs associated with acquisition and integration efforts.


(6)	Amounts in 2018 primarily relate to gains on sales of businesses and other assets, as further described in Note 19. Other Income, Net.

The following represents depreciation expense for our reportable segments for the years ended December 31, 2018, 2017 and 2016 (in thousands):



	2018		2017		2016
U.S. Branded - Specialty & Established Pharmaceuticals	$	14,542	$	16,957	$	16,294
U.S. Branded - Sterile Injectables	10,500		8,411		9,023
U.S. Generic Pharmaceuticals	66,016		174,652		70,816
International Pharmaceuticals	4,925		3,332		2,557
Corporate unallocated	5,385		6,647		8,168
Total depreciation expense	$	101,368	$	209,999	$	106,858

Disaggregation of revenue



	2018		2017		2016
U.S. Branded - Specialty & Established Pharmaceuticals:
Specialty Products:
XIAFLEX®	$	264,638	$	213,378	$	189,689
SUPPRELIN® LA	81,707		86,211		78,648
Other Specialty (1)	156,607		153,384		138,483
Total Specialty Products	$	502,952	$	452,973	$	406,820
Established Products:
PERCOCET®	$	122,901	$	125,231	$	139,211
VOLTAREN® Gel	57,700		68,780		100,642
OPANA® ER	—		83,826		158,938
Other Established (2)	179,279		226,715		360,683
Total Established Products	$	359,880	$	504,552	$	759,474
Total U.S. Branded - Specialty & Established Pharmaceuticals (3)	$	862,832	$	957,525	$	1,166,294
U.S. Branded - Sterile Injectables:
VASOSTRICT®	$	453,767	$	399,909	$	343,468
ADRENALIN®	143,489		76,523		22,172
Ertapenem for injection	57,668		—		—
Other Sterile Injectables (4)	274,642		274,039		210,759
Total U.S. Branded - Sterile Injectables (3)	$	929,566	$	750,471	$	576,399
Total U.S. Generic Pharmaceuticals (5)	$	1,012,215	$	1,530,530	$	1,988,214
Total International Pharmaceuticals (6)	$	142,465	$	230,332	$	279,367
Total Revenues	$	2,947,078	$	3,468,858	$	4,010,274

__________


(1)	Products included within Other Specialty include NASCOBAL^®Nasal Spray, TESTOPEL^® and AVEED^®.


(2)	Products included within Other Established include, but are not limited to, LIDODERM^®, FORTESTA^® Gel, EDEX^® and TESTIM^® including the authorized generics of TESTIM^® and FORTESTA^® Gel.


(3)	Individual products presented above represent the top two performing products in each product category and/or any product having revenues in excess of $100 million during any of the years ended December 31, 2018, 2017 and 2016 or $25 million during any quarterly period in 2018.


(4)	Products included within Other Sterile Injectables include, but are not limited to, APLISOL^® and ephedrine sulfate injection.

(5)


(6)	The International Pharmaceuticals segment, which accounted for 5%, 7% and 7% of consolidated total revenues in 2018, 2017 and 2016, respectively, includes a variety of specialty pharmaceutical products sold outside the U.S., primarily in Canada through our operating company Paladin. This segment also included Litha, which was sold in July 2017, and Somar, which was sold in October 2017.

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2018

Fair Value Disclosures [Abstract]

Restrictions on Cash and Cash Equivalents

The following table presents current and non-current restricted cash and cash equivalent balances at December 31, 2018 and 2017 (in thousands):



	2018		2017
Restricted cash and cash equivalents—current portion (1)	$	305,368	$	320,453
Restricted cash and cash equivalents—noncurrent portion (2)	22,356		3,956
Restricted cash and cash equivalents—total (3)	$	327,724	$	324,409

__________


(1)	These amounts are reported in our Consolidated Balance Sheets as Restricted cash and cash equivalents.


(2)	These amounts are reported in our Consolidated Balance Sheets as Other assets.

(3)

Financial assets and liabilities measured at fair value on recurring basis

The Company’s financial assets and liabilities measured at fair value on a recurring basis at December 31, 2018 and 2017 were as follows (in thousands):



	Fair Value Measurements at December 31, 2018 using:
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets:
Money market funds	$	137,215	$	—	$	—	$	137,215
Equity securities	738		—		—		738
Total	$	137,953	$	—	$	—	$	137,953
Liabilities:
Acquisition-related contingent consideration—short-term	$	—	$	—	$	36,514	$	36,514
Acquisition-related contingent consideration—long-term	—		—		80,189		80,189
Total	$	—	$	—	$	116,703	$	116,703



	Fair Value Measurements at December 31, 2017 using:
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets:
Money market funds	$	439,831	$	—	$	—	$	439,831
Time deposits	—		303,410		—		303,410
Equity securities	1,456		—		—		1,456
Total	$	441,287	$	303,410	$	—	$	744,697
Liabilities:
Acquisition-related contingent consideration—short-term	$	—	$	—	$	70,543	$	70,543
Acquisition-related contingent consideration—long-term	—		—		119,899		119,899
Total	$	—	$	—	$	190,442	$	190,442

Changes to liability for acquisition-related contingent consideration

The following table presents changes to the Company’s liability for acquisition-related contingent consideration during the year ended December 31, 2018 by acquisition (in thousands):



	Balance as of December 31, 2017		Fair Value Adjustments and Accretion			Payments and Other			Balance as of December 31, 2018
Auxilium acquisition	$	13,061	$	2,941		$	(1,845	)	$	14,157
Lehigh Valley Technologies, Inc. acquisitions	63,001		19,146			(47,447		)	34,700
VOLTAREN® Gel acquisition	98,124		9			(41,893		)	56,240
Other	16,256		(2,186		)	(2,464		)	11,606
Total	$	190,442	$	19,910		$	(93,649	)	$	116,703

The following table presents changes to the Company’s liability for acquisition-related contingent consideration during the year ended December 31, 2017 by acquisition (in thousands):



	Balance as of December 31, 2016		Fair Value Adjustments and Accretion			Payments and Other			Balance as of December 31, 2017
Auxilium acquisition	$	21,097	$	467		$	(8,503	)	$	13,061
Lehigh Valley Technologies, Inc. acquisitions	96,000		40,016			(73,015		)	63,001
VOLTAREN^® Gel acquisition	118,395		18,586			(38,857		)	98,124
Other	26,621		(9,120		)	(1,245		)	16,256
Total	$	262,113	$	49,949		$	(121,620	)	$	190,442



	2018			2017
Beginning of period	$	190,442		$	262,113
Amounts settled	(92,627		)	(122,559		)
Changes in fair value recorded in earnings	19,910			49,949
Effect of currency translation	(1,022		)	939
End of period	$	116,703		$	190,442

Summary of nonrecurring fair value measurements

The Company’s financial assets and liabilities measured at fair value on a nonrecurring basis during the years ended December 31, 2018 and 2017 were as follows (in thousands):



	Fair Value Measurements during the Year Ended December 31, 2018 (1) using:						Total Expense for the Year Ended December 31, 2018
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Expense for the Year Ended December 31, 2018
Assets:
Intangible assets, excluding goodwill (Note 10)	$	—	$	—	$	239,857	$	(230,418	)
Certain property, plant and equipment (2)	—		—		—		(6,521		)
Total	$	—	$	—	$	239,857	$	(236,939	)



	Fair Value Measurements during the Year Ended December 31, 2017 (1) using:						Total Expense for the Year Ended December 31, 2017
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Expense for the Year Ended December 31, 2017
Assets:
Intangible assets, excluding goodwill (Note 10)	$	—	$	—	$	423,258	$	(799,957	)
Certain property, plant and equipment (2)	—		—		—		(65,676		)
Total	$	—	$	—	$	423,258	$	(865,633	)

__________


(1)	The fair value amounts are presented as of the date of the fair value measurement as these assets are not measured at fair value on a recurring basis. Such measurements generally occur in connection with our quarter-end financial reporting close procedures.

(2)

Inventories (Tables)

12 Months Ended

Dec. 31, 2018

Inventory Disclosure [Abstract]

Schedule of inventory

Inventories consist of the following at December 31, 2018 and December 31, 2017 (in thousands):



	December 31, 2018		December 31, 2017
Raw materials (1)	$	122,825	$	124,685
Work-in-process (1)	70,458		109,897
Finished goods (1)	128,896		156,855
Total	$	322,179	$	391,437

__________

(1) The components of inventory shown in the table above are net of allowance for obsolescence.

Property, Plant And Equipment (Tables)

12 Months Ended

Dec. 31, 2018

Property, Plant and Equipment [Abstract]

Schedule of property, plant and equipment

Depreciation is based on the following estimated useful lives, as of December 31, 2018:



	Range of Useful Lives, from:
Buildings	10 years	to	30 years
Machinery and equipment	2 years	to	15 years
Leasehold improvements	Shorter of useful life or lease term
Computer equipment and software	1 year	to	7 years
Assets under capital lease	Shorter of useful life or lease term
Furniture and fixtures	3 years	to	10 years

Changes in the amount of Property, plant and equipment for the year ended December 31, 2018 are set forth in the table below (in thousands).



Cost:	Land and Buildings			Machinery and Equipment			Leasehold Improvements			Computer Equipment and Software			Assets under Capital Lease			Furniture and Fixtures			Assets under Construction			Total
At January 1, 2018	$	331,466		$	267,818		$	60,464		$	131,451		$	4,896		$	13,124		$	119,035		$	928,254
Additions	20,317			34,570			12,925			18,660			2,286			490			5,549			94,797
Disposals, transfers, impairments and other	(126,961		)	(90,795		)	(4,030		)	(32,602		)	(1,969		)	(1,101		)	(3,545		)	(261,003		)
Effect of currency translation	—			(102		)	(103		)	(375		)	—			(18		)	(15		)	(613		)
At December 31, 2018	$	224,822		$	211,491		$	69,256		$	117,134		$	5,213		$	12,495		$	121,024		$	761,435
Accumulated Depreciation:
At January 1, 2018	$	(149,402	)	$	(134,741	)	$	(26,867	)	$	(82,792	)	$	(4,161	)	$	(6,320	)	$	—		$	(404,283	)
Additions	(39,253		)	(32,273		)	(6,583		)	(21,105		)	(670		)	(1,484		)	—			(101,368		)
Disposals, transfers and other	121,861			83,037			2,806			32,235			1,969			842			—			242,750
Effect of currency translation	—			71			44			225			—			18			—			358
At December 31, 2018	$	(66,794	)	$	(83,906	)	$	(30,600	)	$	(71,437	)	$	(2,862	)	$	(6,944	)	$	—		$	(262,543	)
Net Book Amount:
At December 31, 2018	$	158,028		$	127,585		$	38,656		$	45,697		$	2,351		$	5,551		$	121,024		$	498,892
At December 31, 2017	$	182,064		$	133,077		$	33,597		$	48,659		$	735		$	6,804		$	119,035		$	523,971

Goodwill And Other Intangibles (Tables)

12 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of changes in the carrying amount of goodwill

The carrying amounts of goodwill at December 31, 2018 and December 31, 2017 are net of the following accumulated impairments (in thousands):



	U.S. Branded - Specialty & Established Pharmaceuticals		U.S. Branded - Sterile Injectables		U.S. Generic Pharmaceuticals		International Pharmaceuticals		Total
Accumulated impairment losses as of December 31, 2017	$	855,810	$	—	$	2,342,549	$	463,545	$	3,661,904
Accumulated impairment losses as of December 31, 2018	$	855,810	$	—	$	2,991,549	$	456,408	$	4,303,767

Changes in the carrying amount of our goodwill for the years ended December 31, 2018 and 2017 were as follows (in thousands):



	U.S. Branded - Specialty & Established Pharmaceuticals			U.S. Branded - Sterile Injectables		U.S. Generic Pharmaceuticals			International Pharmaceuticals			Total
Goodwill as of December 31, 2016	$	1,009,248		$	—	$	3,531,301		$	188,846		$	4,729,395
Effect of currency translation	—			—		—			9,431			9,431
Goodwill impairment charges	(180,430		)	—		—			(108,314		)	(288,744		)
Goodwill as of December 31, 2017	$	828,818		$	—	$	3,531,301		$	89,963		$	4,450,082
Allocation to current segments (1)	—			2,731,193		(2,731,193		)	—			—
Effect of currency translation	—			—		—			(5,446		)	(5,446		)
Goodwill impairment charges	—			—		(649,000		)	(31,000		)	(680,000		)
Goodwill as of December 31, 2018	$	828,818		$	2,731,193	$	151,108		$	53,517		$	3,764,636

__________


(1)	This allocation relates to the change in segments described in Note 6. Segment Results. The amount of goodwill initially attributed to the new U.S. Branded - Sterile Injectables and U.S. Generic Pharmaceuticals segments was determined using a relative fair value methodology in accordance with U.S. GAAP.

Schedule of other intangible assets

Changes in the amount of other intangible assets for the year ended December 31, 2018 are set forth in the table below (in thousands).



Cost basis:	Balance as of December 31, 2017			Acquisitions			Impairments			Other (1)			Effect of Currency Translation			Balance as of December 31, 2018
Indefinite-lived intangibles:
In-process research and development	$	347,200		$	—		$	(87,900	)	$	(165,400	)	$	—		$	93,900
Total indefinite-lived intangibles	$	347,200		$	—		$	(87,900	)	$	(165,400	)	$	—		$	93,900
Finite-lived intangibles:
Licenses (weighted average life of 12 years)	$	457,402		$	—		$	—		$	—		$	—		$	457,402
Tradenames	6,409			—			—			—			—			6,409
Developed technology (weighted average life of 11 years)	6,187,764			3,000			(142,518		)	154,753			(20,984		)	6,182,015
Total finite-lived intangibles (weighted average life of 11 years)	$	6,651,575		$	3,000		$	(142,518	)	$	154,753		$	(20,984	)	$	6,645,826
Total other intangibles	$	6,998,775		$	3,000		$	(230,418	)	$	(10,647	)	$	(20,984	)	$	6,739,726

Accumulated amortization:	Balance as of December 31, 2017			Amortization			Impairments			Other (1)			Effect of Currency Translation			Balance as of December 31, 2018
Finite-lived intangibles:
Licenses	$	(370,221	)	$	(27,961	)	$	—		$	—		$	—		$	(398,182	)
Tradenames	(6,409		)	—			—			—			—			(6,409		)
Developed technology	(2,304,461		)	(594,378		)	—			10,647			10,363			(2,877,829		)
Total other intangibles	$	(2,681,091	)	$	(622,339	)	$	—		$	10,647		$	10,363		$	(3,282,420	)
Net other intangibles	$	4,317,684														$	3,457,306

__________


(1)	Other adjustments relate to reclassification adjustments of $165.4 million for certain developed technology intangible assets, previously classified as in-process research and development, that were placed in service during the year ended December 31, 2018 and the removal of certain fully amortized intangible assets.

Schedule of future amortization expense

Estimated amortization of intangibles for the five fiscal years subsequent to December 31, 2018 is as follows (in thousands):



2019	$	550,574
2020	$	479,358
2021	$	445,215
2022	$	418,844
2023	$	384,223

Schedule of intangible asset impairment charges including goodwill

During the years ended December 31, 2018, 2017 and 2016, the Company incurred the following goodwill and other intangible asset impairment charges (in thousands):



	2018		2017		2016
Goodwill impairment charges	$	680,000	$	288,745	$	2,676,350
Other intangible asset impairment charges	$	230,418	$	799,955	$	1,088,903

Contract Assets and Liabilities (Tables)

12 Months Ended

Dec. 31, 2018

Contract with Customer, Asset and Liability [Abstract]

Contract Assets and Liabilities

The following table shows the opening and closing balances of contract assets and contract liabilities from contracts with customers (dollars in thousands):



	December 31, 2018		January 1, 2018		$ Change			% Change
Contract assets, net (1)	$	12,065	$	11,287	$	778		7	%
Contract liabilities, net (2)	$	19,217	$	20,954	$	(1,737	)	(8	)%

__________

(1)

(2)

Debt (Tables)

12 Months Ended

Dec. 31, 2018

Debt Disclosure [Abstract]

Schedule of long-term debt instruments

The following table presents information about the Company’s total indebtedness at December 31, 2018 and December 31, 2017 (dollars in thousands):



	December 31, 2018						December 31, 2017
	Effective Interest Rate		Principal Amount		Carrying Amount		Effective Interest Rate		Principal Amount		Carrying Amount
7.25% Senior Notes due 2022	7.91	%	$	400,000	$	392,947	7.91	%	$	400,000	$	390,974
5.75% Senior Notes due 2022	6.04	%	700,000		694,464		6.04	%	700,000		692,855
5.375% Senior Notes due 2023	5.62	%	750,000		743,438		5.62	%	750,000		742,048
6.00% Senior Notes due 2023	6.28	%	1,635,000		1,616,817		6.28	%	1,635,000		1,613,446
5.875% Senior Secured Notes due 2024	6.14	%	300,000		296,062		6.14	%	300,000		295,513
6.00% Senior Notes due 2025	6.27	%	1,200,000		1,183,415		6.27	%	1,200,000		1,181,243
Term Loan B Facility Due 2024	7.02	%	3,363,775		3,331,276		6.09	%	3,397,925		3,360,103
Other debt			—		—		1.50	%	55		55
Total long-term debt, net			$	8,348,775	$	8,258,419			$	8,382,980	$	8,276,237
Less current portion, net			34,150		34,150				34,205		34,205
Total long-term debt, less current portion, net			$	8,314,625	$	8,224,269			$	8,348,775	$	8,242,032

Schedule of Maturities of Long-term Debt [Table Text Block]

The following table presents the maturities on our long-term debt for each of the five fiscal years subsequent to December 31, 2018 (in thousands):



	Maturities (1)
2019	$	34,150
2020	$	34,150
2021	$	34,150
2022	$	1,134,150
2023	$	2,419,150

__________

(1)

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Commitments And Contingencies (Tables)

12 Months Ended

Dec. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Changes in Qualified Settlement Funds accounts and product liability balance

The following table presents the changes in the QSFs and mesh liability accrual balances during the year ended December 31, 2018 (in thousands):



	Qualified Settlement Funds			Mesh Liability Accrual
Balance as of January 1, 2018	$	313,814		$	1,087,172
Additional charges	—			34,000
Cash contributions to Qualified Settlement Funds	336,648			—
Cash distributions to settle disputes from Qualified Settlement Funds	(353,032		)	(353,032		)
Cash distributions to settle disputes	—			(25,222		)
Other (1)	2,303			5,688
Balance as of December 31, 2018	$	299,733		$	748,606

__________

(1)

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

A summary of minimum future rental payments required under capital and operating leases as of December 31, 2018 are as follows (in thousands):



	Capital Leases (1)(2)		Operating Leases
2019	$	6,884	$	15,800
2020	6,819		14,519
2021	6,921		12,883
2022	7,072		12,454
2023	7,225		9,945
Thereafter	9,127		20,573
Total minimum lease payments	$	44,048	$	86,174
Less: Amount representing interest	4,084
Total present value of minimum payments	$	39,964
Less: Current portion of such obligations	5,845
Long-term capital lease obligations	$	34,119

__________


(1)	The direct financing arrangement is included under Capital Leases.

(2)

- Definition

Tabular disclosure of the loss contingencies that were reported in the period or disclosed as of the balance sheet date.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14472-108349

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14453-108349

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14615-108349

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=115931803&loc=d3e12021-110248

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14394-108349

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=115931803&loc=d3e12053-110248

+ Details

Other Comprehensive (Loss) Income (Tables)

12 Months Ended

Dec. 31, 2018

Equity [Abstract]

Schedule of tax effects allocated to each component of other comprehensive income

Set forth below are the tax effects allocated to each component of Other comprehensive (loss) income for the years ended December 31, 2018, 2017 and 2016 (in thousands):



	2018								2017								2016
	Before-Tax Amount			Tax (Expense) Benefit		Net-of-Tax Amount			Before-Tax Amount			Tax Benefit (Expense)		Net-of-Tax Amount			Before-Tax Amount			Tax Benefit (Expense)		Net-of-Tax Amount
Net unrealized loss on securities:
Unrealized loss arising during the period	$	—		$	—	$	—		$	(811	)	$	296	$	(515	)	$	(1,588	)	$	674	$	(914	)
Less: reclassification adjustments for (gain) loss realized in net loss	—			—		—			—			—		—			(6		)	—		(6		)
Net unrealized gains (losses) on securities	$	—		$	—	$	—		$	(811	)	$	296	$	(515	)	$	(1,594	)	$	674	$	(920	)
Net unrealized (loss) gain on foreign currency:
Foreign currency translation (loss) gain arising during the period	(19,408		)	—		(19,408		)	31,202			—		31,202			18,267			13,462		31,729
Less: reclassification adjustments for loss realized in net loss	—			—		—			112,926			—		112,926			—			—		—
Foreign currency translation (loss) gain	$	(19,408	)	$	—	$	(19,408	)	$	144,128		$	—	$	144,128		$	18,267		$	13,462	$	31,729
Other comprehensive (loss) income	$	(19,408	)	$	—	$	(19,408	)	$	143,317		$	296	$	143,613		$	16,673		$	14,136	$	30,809

Shared-based Compensation (Tables)

12 Months Ended

Dec. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of allocation of stock-based compensation

Presented below are the components of total share-based compensation as recorded in our Consolidated Statements of Operations for the years ended December 31, 2018, 2017 and 2016 (in thousands).



	2018		2017		2016
Selling, general and administrative expenses	$	44,454	$	38,292	$	54,176
Research and development expenses	2,251		4,197		2,440
Cost of revenues	7,366		7,660		2,040
Discontinued operations (Note 3)	—		—		1,113
Total share-based compensation expense	$	54,071	$	50,149	$	59,769

Summary of activity under stock incentive plans

A summary of the activity for each of the years ended December 31, 2018, 2017 and 2016 is presented below:



	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value (1)
Outstanding as of January 1, 2016	2,768,567		$	51.56
Granted	2,578,105		$	35.45
Exercised	(62,589	)	$	31.19
Forfeited	(858,556	)	$	52.27
Expired	(100,318	)	$	60.71
Outstanding as of December 31, 2016	4,325,209		$	41.70
Granted	5,288,675		$	10.42
Forfeited	(623,987	)	$	28.32
Expired	(741,767	)	$	40.29
Outstanding as of December 31, 2017	8,248,130		$	22.79
Granted	971,590		$	7.55
Exercised	(94,392	)	$	9.89
Forfeited	(605,737	)	$	19.01
Expired	(446,873	)	$	36.80
Outstanding as of December 31, 2018	8,072,718		$	20.62	7.12	$	—
Vested and expected to vest as of December 31, 2018	7,833,930		$	20.86	7.08	$	—
Exercisable as of December 31, 2018	3,550,777		$	28.07	6.00	$	—

__________


(1)	The intrinsic value of a stock option is the excess, if any, of the closing price of the Company’s ordinary shares on the last trading day of the fiscal year over the exercise price. The aggregate intrinsic values presented in the table above represent sum of the intrinsic values of all corresponding stock options that are “in-the-money,” if any.

Stock option assumption

The weighted average grant-date fair value of the stock options granted in the years ended December 31, 2018, 2017 and 2016 was $3.97, $4.73 and $11.46 per option, respectively, determined using the following average assumptions:



	2018		2017		2016
Expected term (years)	4.0		4.0		4.0
Risk-free interest rate	2.7	%	1.7	%	1.1	%
Dividend yield	—		—		—
Expected volatility	63	%	58	%	43	%

Summary of restricted and performance stock units activity

A summary of our non-vested RSUs and PSUs for the years ended December 31, 2018, 2017 and 2016 is presented below:



	Number of Shares		Aggregate Intrinsic Value (1)
Non-vested as of January 1, 2016	1,806,853
Granted	1,582,429
Forfeited	(975,994	)
Vested	(728,228	)
Non-vested as of December 31, 2016	1,685,060
Granted	4,168,477
Forfeited	(552,981	)
Vested	(575,883	)
Non-vested as of December 31, 2017	4,724,673
Granted	5,609,561
LTCI modification (2)	2,989,965
Forfeited	(753,653	)
Vested	(1,551,074	)
Non-vested as of December 31, 2018	11,019,472		$	80,442,146
Vested and expected to vest as of December 31, 2018	10,250,560		$	74,829,088

__________


(1)	The aggregate intrinsic values of RSUs and PSUs presented in the table above are calculated by multiplying the closing price of the Company’s ordinary shares on the last trading day of the fiscal year by the corresponding number of RSUs and PSUs.


(2)	As a result of the October 1, 2018 modification to the Company’s LTCI awards described above, modified LTCI awards are treated as RSUs for disclosure purposes; thus, the table above reflects an increase to the non-vested number of shares on the modification date.

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Schedule of income before income tax, domestic and foreign

The components of our Loss from continuing operations before income tax by geography for the years ended December 31, 2018, 2017 and 2016 are as follows (in thousands):



	2018			2017			2016
United States	$	(1,342,860	)	$	(1,866,222	)	$	(4,309,211	)
International	404,028			383,218			385,355
Total (loss) income from continuing operations before income tax	$	(938,832	)	$	(1,483,004	)	$	(3,923,856	)

Schedule of of components of income tax expense (benefit)

Income tax from continuing operations consists of the following for the years ended December 31, 2018, 2017 and 2016 (in thousands):



	2018			2017			2016
Current:
U.S. Federal	$	6,236		$	(86,478	)	$	18,369
U.S. State	2,864			(6,462		)	9,501
International	8,278			(1,224		)	22,851
Total current income tax	$	17,378		$	(94,164	)	$	50,721
Deferred:
U.S. Federal	$	10,084		$	(124,682	)	$	(661,484	)
U.S. State	(778		)	(3,225		)	(239		)
International	(3,749		)	(28,222		)	(83,619		)
Total deferred income tax	$	5,557		$	(156,129	)	$	(745,342	)
Excess tax benefits of stock compensation exercised	—			—			(5,463		)
Total income tax	$	22,935		$	(250,293	)	$	(700,084	)

Schedule of effective income tax rate reconciliation



	2018			2017			2016
Notional U.S. federal income tax provision at the statutory rate	$	(197,155	)	$	(519,051	)	$	(1,373,350	)
State income tax, net of federal benefit	494			(11,473		)	5,182
U.S. tax reform impact	5,664			(36,216		)	—
Uncertain tax positions	46,317			58,120			(18,111		)
Residual tax on non-U.S. net earnings	(638,724		)	(1,350,811		)	(301,666		)
Effects of outside basis differences	—			—			(636,134		)
Non-deductible goodwill impairment	109,189			60,808			926,881
Change in valuation allowance	752,008			1,648,836			762,604
Intra-entity transfers of assets	(63,335		)	(53,509		)	(92,859		)
International Pharmaceuticals segment divestitures	—			(56,092		)	—
Other	8,477			9,095			27,369
Income tax	$	22,935		$	(250,293	)	$	(700,084	)

Schedule of deferred tax assets and liabilities



	December 31, 2018			December 31, 2017
Deferred tax assets:
Accrued expenses and customer allowances	$	185,910		$	299,142
Deferred interest expense	240,736			46,230
Fixed assets and intangible assets	604,385			484,313
Loss on capital assets	62,033			49,585
Net operating loss carryforward	8,751,544			7,183,651
Other	65,266			56,828
Research and development and other tax credit carryforwards	9,551			6,354
Total gross deferred income tax assets	$	9,919,425		$	8,126,103
Deferred tax liabilities:
Other	$	(1,965	)	$	(2,042	)
Outside basis difference	(73,652		)	(92,635		)
Total gross deferred income tax liabilities	$	(75,617	)	$	(94,677	)
Valuation allowance	(9,877,617		)	(8,062,975		)
Net deferred income tax liability	$	(33,809	)	$	(31,549	)

Summary of tax credit carryforwards

At December 31, 2018, the Company had the following significant deferred tax assets for net operating and capital loss carryforwards, net of unrecognized tax benefits (in thousands):



Jurisdiction	Amount		Begin to Expire
Ireland	$	13,254	indefinite
Luxembourg	$	8,378,742	2034
United States:
Federal-ordinary losses	$	176,695	2020
Federal-capital losses	$	35,673	2022
State-ordinary losses	$	178,732	2019
State-capital losses	$	25,524	2026

Summary of valuations allowance

At December 31, 2018, the Company had the following significant valuation allowances (in thousands):



Jurisdiction	December 31, 2018
Ireland	$	160,867
Luxembourg	$	8,378,742
United States	$	1,334,463

Schedule of reconciliation of change in uncertain tax benefits

The following table summarizes the activity related to unrecognized income tax benefits during the years ended December 31, 2018, 2017 and 2016 (in thousands):



	Unrecognized Tax Benefit Federal, State, and Foreign Tax
UTB Balance at January 1, 2016	$	316,247
Gross additions for current year positions	142,778
Gross reductions for prior period positions	(35,888		)
Gross additions for prior period positions	2,111
Decrease due to lapse of statute of limitations	(3,085		)
Additions related to acquisitions	2,350
Currency translation adjustment	88
UTB Balance at December 31, 2016	$	424,601
Gross additions for current year positions	44,293
Gross reductions for prior period positions	(64,887		)
Gross additions for prior period positions	22,765
Decrease due to lapse of statute of limitations	(13,151		)
Currency translation adjustment	2,330
UTB Balance at December 31, 2017	$	415,951
Gross additions for current year positions	36,088
Gross reductions for prior period positions	(3,570		)
Gross additions for prior period positions	7,950
Decrease due to lapse of statute of limitations	(2,129		)
Currency translation adjustment	(2,600		)
UTB Balance at December 31, 2018	$	451,690
Accrued interest and penalties	27,739
Total UTB balance including accrued interest and penalties	$	479,429

Summary of income tax examinations

As of December 31, 2018, we may be subject to examination in the following major tax jurisdictions:



Jurisdiction		Open Years
Canada		2013 through 2018
India		2013 through 2018
Ireland		2014 through 2018
Luxembourg		2014 through 2018
United States - federal, state and local		2006 through 2018

Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2018

Quarterly Financial Data [Abstract]

Schedule of Quarterly Financial Information



	Quarter Ended
	March 31,			June 30,			September 30,			December 31,
2018 (1)
Total revenues	$	700,527		$	714,696		$	745,466		$	786,389
Gross profit	$	296,929		$	332,791		$	332,501		$	353,175
Loss from continuing operations	$	(497,738	)	$	(52,479	)	$	(146,071	)	$	(265,479	)
Discontinued operations, net of tax	$	(7,751	)	$	(8,388	)	$	(27,134	)	$	(26,429	)
Net loss attributable to Endo International plc	$	(505,489	)	$	(60,867	)	$	(173,205	)	$	(291,908	)
Net loss per share attributable to Endo International plc ordinary shareholders—Basic:
Continuing operations	$	(2.23	)	$	(0.23	)	$	(0.65	)	$	(1.18	)
Discontinued operations	(0.03		)	(0.04		)	(0.12		)	(0.12		)
Basic	$	(2.26	)	$	(0.27	)	$	(0.77	)	$	(1.30	)
Net loss per share attributable to Endo International plc ordinary shareholders—Diluted:
Continuing operations	$	(2.23	)	$	(0.23	)	$	(0.65	)	$	(1.18	)
Discontinued operations	(0.03		)	(0.04		)	(0.12		)	(0.12		)
Diluted	$	(2.26	)	$	(0.27	)	$	(0.77	)	$	(1.30	)
Weighted average shares—Basic	223,521			223,834			224,132			224,353
Weighted average shares—Diluted	223,521			223,834			224,132			224,353
2017 (2)
Total revenues	$	1,037,600		$	875,731		$	786,887		$	768,640
Gross profit	$	368,638		$	336,330		$	272,365		$	262,995
Loss from continuing operations	$	(165,423	)	$	(696,020	)	$	(99,687	)	$	(271,581	)
Discontinued operations, net of tax	$	(8,405	)	$	(700,498	)	$	3,017		$	(96,836	)
Net loss attributable to Endo International plc	$	(173,828	)	$	(1,396,518	)	$	(96,670	)	$	(368,417	)
Net loss per share attributable to Endo International plc ordinary shareholders—Basic:
Continuing operations	$	(0.74	)	$	(3.12	)	$	(0.45	)	$	(1.22	)
Discontinued operations	(0.04		)	(3.14		)	0.02			(0.43		)
Basic	$	(0.78	)	$	(6.26	)	$	(0.43	)	$	(1.65	)
Net loss per share attributable to Endo International plc ordinary shareholders—Diluted:
Continuing operations	$	(0.74	)	$	(3.12	)	$	(0.45	)	$	(1.22	)
Discontinued operations	(0.04		)	(3.14		)	0.02			(0.43		)
Diluted	$	(0.78	)	$	(6.26	)	$	(0.43	)	$	(1.65	)
Weighted average shares—Basic	223,014			223,158			223,299			223,322
Weighted average shares—Diluted	223,014			223,158			223,299			223,322

__________

(1)

(2)

Summary of Significant Accounting Policies - Customer Concentration Risk (Details) - Customer Concentration Risk	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
AmerisourceBergen Corporation
Product Information [Line Items]
Concentration risk, percentage	32.00%	25.00%	25.00%
McKesson Corporation
Product Information [Line Items]
Concentration risk, percentage	27.00%	25.00%	27.00%
Cardinal Health, Inc.
Product Information [Line Items]
Concentration risk, percentage	26.00%	25.00%	26.00%

Summary of Significant Accounting Policies - Narrative (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2018 USD ($) customer	Dec. 31, 2017 USD ($) customer	Dec. 31, 2016 USD ($)	Jan. 01, 2018 USD ($)
Product Information [Line Items]
Allowance for sales returns and allowances	$ 772,300	$ 942,800
Advertising expense	49,600	42,000	$ 47,900
Accumulated deficit	$ (9,124,932)	$ (8,096,539)
Sales Revenue, Net \| Product Concentration Risk
Product Information [Line Items]
Concentration risk, percentage	15.00%	12.00%
Trade Accounts Receivable \| Credit Concentration Risk
Product Information [Line Items]
Concentration risk, percentage	87.00%	89.00%
Number of customers \| customer	3	3
Minimum
Product Information [Line Items]
Performance obligation, payment term	30 days
Maximum
Product Information [Line Items]
Performance obligation, payment term	90 days
Weighted Average
Product Information [Line Items]
Intangible life (years)	11 years
Developed technology \| Minimum
Product Information [Line Items]
Intangible life (years)	4 years
Developed technology \| Maximum
Product Information [Line Items]
Intangible life (years)	20 years
Developed technology \| Weighted Average
Product Information [Line Items]
Intangible life (years)	11 years
Licensing Agreements \| Minimum
Product Information [Line Items]
Intangible life (years)	10 years
Licensing Agreements \| Maximum
Product Information [Line Items]
Intangible life (years)	15 years
Licensing Agreements \| Weighted Average
Product Information [Line Items]
Intangible life (years)	12 years
Effect of adoption of ASC 606 \| ASC 606
Product Information [Line Items]
Accumulated deficit	$ 4,836			$ 3,100

Summary of Significant Accounting Policies - Estimated Useful Lives (Details)	12 Months Ended
	Dec. 31, 2018
Buildings \| Minimum
Property, Plant and Equipment [Line Items]
PP&E Useful life	10 years
Buildings \| Maximum
Property, Plant and Equipment [Line Items]
PP&E Useful life	30 years
Machinery and equipment \| Minimum
Property, Plant and Equipment [Line Items]
PP&E Useful life	2 years
Machinery and equipment \| Maximum
Property, Plant and Equipment [Line Items]
PP&E Useful life	15 years
Computer equipment and software \| Minimum
Property, Plant and Equipment [Line Items]
PP&E Useful life	1 year
Computer equipment and software \| Maximum
Property, Plant and Equipment [Line Items]
PP&E Useful life	7 years
Furniture and fixtures \| Minimum
Property, Plant and Equipment [Line Items]
PP&E Useful life	3 years
Furniture and fixtures \| Maximum
Property, Plant and Equipment [Line Items]
PP&E Useful life	10 years

Summary of Significant Accounting Policies - Schedule of Impact of ASC 606 (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Jan. 01, 2018
Statement of Operations:
TOTAL REVENUES	$ 786,389	$ 745,466	$ 714,696	$ 700,527	$ 768,640	$ 786,887	$ 875,731	$ 1,037,600	$ 2,947,078	$ 3,468,858	$ 4,010,274
Cost of revenues									1,631,682	2,228,530	2,634,973
OTHER EXPENSE (INCOME), NET									(51,953)	(17,023)	(338)
Loss from continuing operations									(961,767)	(1,232,711)	(3,223,772)
NET LOSS ATTRIBUTABLE TO ENDO INTERNATIONAL PLC	$ (291,908)	$ (173,205)	$ (60,867)	$ (505,489)	$ (368,417)	$ (96,670)	$ (1,396,518)	$ (173,828)	$ (1,031,469)	$ (2,035,433)	$ (3,347,066)
NET LOSS PER SHARE ATTRIBUTABLE TO ENDO INTERNATIONAL PLC ORDINARY SHAREHOLDERS—BASIC:
Continuing operations (in dollars per share)	$ (1.18)	$ (0.65)	$ (0.23)	$ (2.23)	$ (1.22)	$ (0.45)	$ (3.12)	$ (0.74)	$ (4.29)	$ (5.52)	$ (14.48)
Basic (in dollars per share)	(1.30)	(0.77)	(0.27)	(2.26)	(1.65)	(0.43)	(6.26)	(0.78)	(4.61)	(9.12)	(15.03)
Net loss per share attributable to Endo International plc ordinary shareholders—Diluted:
Continuing operations (in dollars per share)	(1.18)	(0.65)	(0.23)	(2.23)	(1.22)	(0.45)	(3.12)	(0.74)	(4.29)	(5.52)	(14.48)
Diluted (in dollars per share)	$ (1.30)	$ (0.77)	$ (0.27)	$ (2.26)	$ (1.65)	$ (0.43)	$ (6.26)	$ (0.78)	$ (4.61)	$ (9.12)	$ (15.03)
ASSETS
Inventories, net	$ 322,179				$ 391,437				$ 322,179	$ 391,437
Prepaid expenses and other current assets	56,139				43,098				56,139	43,098
OTHER ASSETS	66,993				59,728				66,993	59,728
Liabilities:
Accounts payable and accrued expenses	1,009,200				1,096,825				1,009,200	1,096,825
Shareholders' (deficit) equity:
Accumulated deficit	(9,124,932)				$ (8,096,539)				(9,124,932)	$ (8,096,539)
Amounts assuming continued application of ASC 605
Statement of Operations:
TOTAL REVENUES									2,947,930
Cost of revenues									1,633,294
OTHER EXPENSE (INCOME), NET									(50,953)
Loss from continuing operations									(963,527)
NET LOSS ATTRIBUTABLE TO ENDO INTERNATIONAL PLC									$ (1,033,229)
NET LOSS PER SHARE ATTRIBUTABLE TO ENDO INTERNATIONAL PLC ORDINARY SHAREHOLDERS—BASIC:
Continuing operations (in dollars per share)									$ (4.30)
Basic (in dollars per share)									(4.61)
Net loss per share attributable to Endo International plc ordinary shareholders—Diluted:
Continuing operations (in dollars per share)									(4.30)
Diluted (in dollars per share)									$ (4.61)
ASSETS
Inventories, net	329,684								$ 329,684
Prepaid expenses and other current assets	46,832								46,832
OTHER ASSETS	64,235								64,235
Liabilities:
Accounts payable and accrued expenses	1,009,476								1,009,476
Shareholders' (deficit) equity:
Accumulated deficit	(9,129,768)								(9,129,768)
Effect of adoption of ASC 606 \| ASC 606
Statement of Operations:
TOTAL REVENUES									(852)
Cost of revenues									(1,612)
OTHER EXPENSE (INCOME), NET									(1,000)
Loss from continuing operations									1,760
NET LOSS ATTRIBUTABLE TO ENDO INTERNATIONAL PLC									$ 1,760
NET LOSS PER SHARE ATTRIBUTABLE TO ENDO INTERNATIONAL PLC ORDINARY SHAREHOLDERS—BASIC:
Continuing operations (in dollars per share)									$ 0.01
Basic (in dollars per share)									0.00
Net loss per share attributable to Endo International plc ordinary shareholders—Diluted:
Continuing operations (in dollars per share)									0.01
Diluted (in dollars per share)									$ 0.00
ASSETS
Inventories, net	(7,505)								$ (7,505)
Prepaid expenses and other current assets	9,307								9,307
OTHER ASSETS	2,758								2,758
Liabilities:
Accounts payable and accrued expenses	(276)								(276)
Shareholders' (deficit) equity:
Accumulated deficit	$ 4,836								$ 4,836			$ 3,100

Discontinued Operations and Divestitures - Astora - Discontinued Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued operations, net of tax	$ (69,702)	$ (802,722)	$ (123,278)
Discontinued Operations, Disposed of by Means Other than Sale, Abandonment \| Astora
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue	0	338	30,101
Litigation-related and other contingencies, net	34,000	775,474	20,115
Asset impairment charges	0	0	21,328
Loss from discontinued operations before income taxes	(69,702)	(816,426)	(123,164)
Income tax benefit	0	(13,704)	0
Discontinued operations, net of tax	$ (69,702)	$ (802,722)	$ (123,164)

- Definition

Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details

- Definition

Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.

+ References + Details

- Definition

Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details

Discontinued Operations and Divestitures - Astora (Narrative) (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2016 employee	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Restructuring Cost and Reserve [Line Items]
Income (loss) from discontinued operations, net of tax		$ (69,702,000)	$ (802,722,000)	$ (123,278,000)
Astora Restructuring
Restructuring Cost and Reserve [Line Items]
Number of positions reduced \| employee	250
Expected restructuring costs remaining		0
Discontinued Operations, Disposed of by Means Other than Sale, Abandonment \| Astora
Restructuring Cost and Reserve [Line Items]
Income (loss) from discontinued operations, net of tax		(69,702,000)	(802,722,000)	(123,164,000)
Cash used in investing activities		0	0	0
Depreciation and amortization		$ 0	$ 0	$ 0

- Definition

+ References + Details

Discontinued Operations and Divestitures - Summary of Astora Restructuring Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Other wind down costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	$ 16,500	$ 22,000	$ 25,100
Astora Restructuring
Restructuring Cost and Reserve [Line Items]
Restructuring expenses			60,850
Astora Restructuring \| Employee separation, retention and other benefit-related costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses			20,476
Astora Restructuring \| Asset impairment charges
Restructuring Cost and Reserve [Line Items]
Restructuring expenses			21,328
Astora Restructuring \| Contract termination-related items
Restructuring Cost and Reserve [Line Items]
Restructuring expenses			8,074
Astora Restructuring \| Other wind down costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses			$ 10,972

Discontinued Operations and Divestitures - Lithia (Narrative) (Details) - USD ($)		1 Months Ended		12 Months Ended
	Jul. 03, 2017	Dec. 31, 2017	Oct. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of business, net				$ 70,369,000	$ 223,237,000	$ 10,870,000
Litha Healthcare Group Limited \| Disposal Group, Disposed of by Sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of business, net	$ 94,200,000
Consideration receivable			$ 4,400,000
Gain on sale of business	$ 0	$ 10,100,000

Discontinued Operations and Divestitures - Somar (Narrative) (Details) - USD ($) $ in Thousands		3 Months Ended							12 Months Ended
	Oct. 25, 2017	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on sale of business		$ (15,300)	$ (2,900)	$ (24,600)	$ (2,400)	$ (8,700)	$ (2,800)	$ (2,300)	$ (45,155)	$ (13,809)	$ 3,192
Somar \| Disposal Group, Disposed of by Sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Aggregate purchase price	$ 124,000
Gain on sale of business	$ 1,300

Restructuring - 2016 Restructuring Initiative (Narrative) (Details) $ in Thousands		3 Months Ended									12 Months Ended
	Oct. 31, 2016 USD ($)	Dec. 31, 2018 USD ($)	Sep. 30, 2018 USD ($)	Jun. 30, 2018 USD ($)	Mar. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Sep. 30, 2017 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2016 USD ($) position_eliminated	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Restructuring Cost and Reserve [Line Items]
Asset impairment charges		$ 303,500	$ 142,200	$ 22,800	$ 448,400	$ 130,400	$ 94,900	$ 725,000	$ 204,000		$ 916,939	$ 1,154,376	$ 3,781,165
US Generic Pharmaceuticals Restructuring 2016
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost												1,000	173,900
US Branded Pharmaceuticals Restructuring 2016
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost										$ 61,500
Number of positions reduced \| position_eliminated										375
Asset Impairment Charges \| US Generic Pharmaceuticals Restructuring 2016
Restructuring Cost and Reserve [Line Items]
Asset impairment charges													107,200
Asset Impairment Charges \| US Branded Pharmaceuticals Restructuring 2016
Restructuring Cost and Reserve [Line Items]
Restructuring expenses										$ 36,800
Inventory Write-Offs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses											2,900	13,700	24,500
Inventory Write-Offs \| US Branded Pharmaceuticals Restructuring 2016
Restructuring Cost and Reserve [Line Items]
Restructuring expenses										3,000
Employee Separation, Retention, and Other Benefit Related Costs \| US Branded Pharmaceuticals Restructuring 2016
Restructuring Cost and Reserve [Line Items]
Restructuring expenses										16,500
Other restructuring charges
Restructuring Cost and Reserve [Line Items]
Restructuring expenses											$ 16,500	$ 22,000	25,100
Contract Termination Charges \| US Branded Pharmaceuticals Restructuring 2016
Restructuring Cost and Reserve [Line Items]
Restructuring expenses										$ 5,200
U.S. Generic Pharmaceuticals \| Inventory Write-Offs \| US Generic Pharmaceuticals Restructuring 2016
Restructuring Cost and Reserve [Line Items]
Restructuring expenses													33,300
U.S. Generic Pharmaceuticals \| Employee Separation, Retention, and Other Benefit Related Costs \| US Generic Pharmaceuticals Restructuring 2016
Restructuring Cost and Reserve [Line Items]
Restructuring expenses													17,000
U.S. Generic Pharmaceuticals \| Accelerated Depreciation \| US Generic Pharmaceuticals Restructuring 2016
Restructuring Cost and Reserve [Line Items]
Restructuring expenses													10,200
U.S. Generic Pharmaceuticals \| Other restructuring charges \| US Generic Pharmaceuticals Restructuring 2016
Restructuring Cost and Reserve [Line Items]
Restructuring expenses													$ 6,200
Charlotte, North Carolina Facility \| US Generic Pharmaceuticals Restructuring 2016
Restructuring Cost and Reserve [Line Items]
Proceeds from sale of property, plant and equipment	$ 14,000

Restructuring - 2017 Restructuring Initiatives (Narrative) (Details) $ in Thousands		1 Months Ended	12 Months Ended
	Jan. 26, 2017 position	Jun. 30, 2018 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Other restructuring charges
Restructuring Cost and Reserve [Line Items]
Restructuring expenses			$ 16,500	$ 22,000	$ 25,100
January 2017 Restructuring
Restructuring Cost and Reserve [Line Items]
Expected number of positions \| position	90
Restructuring expenses				15,072
January 2017 Restructuring \| Corporate unallocated costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses				4,900
January 2017 Restructuring \| U.S. Branded - Specialty & Established Pharmaceuticals \| Operating Segments
Restructuring Cost and Reserve [Line Items]
Restructuring expenses				6,900
January 2017 Restructuring \| U.S. Generic Pharmaceuticals \| Operating Segments
Restructuring Cost and Reserve [Line Items]
Restructuring expenses				3,300
January 2017 Restructuring \| Employee Separation, Retention, and Other Benefit Related Costs \| Operating Segments
Restructuring Cost and Reserve [Line Items]
Restructuring expenses				15,100
2017 US Generic Pharmaceuticals Restructuring
Restructuring Cost and Reserve [Line Items]
Restructuring expenses			20,384	43,277
2017 US Generic Pharmaceuticals Restructuring \| U.S. Generic Pharmaceuticals
Restructuring Cost and Reserve [Line Items]
Restructuring expenses			61,600	286,700
2017 US Generic Pharmaceuticals Restructuring \| Employee Separation, Retention, and Other Benefit Related Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses			9,100	29,600
2017 US Generic Pharmaceuticals Restructuring \| Accelerated Depreciation
Restructuring Cost and Reserve [Line Items]
Restructuring expenses			35,200	123,300
2017 US Generic Pharmaceuticals Restructuring \| Asset Impairment Charges
Restructuring Cost and Reserve [Line Items]
Restructuring expenses			2,600
2017 US Generic Pharmaceuticals Restructuring \| Other restructuring charges
Restructuring Cost and Reserve [Line Items]
Restructuring expenses			11,294	13,724
Restructuring charges			$ 14,700	17,000
2017 US Generic Pharmaceuticals Restructuring \| Property, Plant and Equipment Impairment Charges
Restructuring Cost and Reserve [Line Items]
Restructuring expenses				104,700
2017 US Generic Pharmaceuticals Restructuring \| Inventory Reserve
Restructuring Cost and Reserve [Line Items]
Restructuring charges				$ 12,100
Huntsville, Alabama Manufacturing and Distributing Facility \| Disposal Group, Disposed of by Sale, Not Discontinued Operations \| 2017 US Generic Pharmaceuticals Restructuring \| Facility Closing
Restructuring Cost and Reserve [Line Items]
Proceeds from sale of property, plant and equipment		$ 23,100
Net gain on disposal		$ 12,500

Restructuring - January 2018 Restructuring Initiative (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
January 2018 Restructuring Initiative
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	$ 23,518
Employee Separation, Retention, and Other Benefit Related Costs \| January 2018 Restructuring Initiative
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	21,700
Other restructuring charges
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	16,500	$ 22,000	$ 25,100
Other restructuring charges \| January 2018 Restructuring Initiative
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	1,764
Restructuring charges	1,800	600
Asset Impairment Charges \| January 2018 Restructuring Initiative
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		2,000
U.S. Generic Pharmaceuticals \| January 2018 Restructuring Initiative
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	23,500	$ 2,600
Operating Segments \| U.S. Generic Pharmaceuticals \| January 2018 Restructuring Initiative
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	10,600
Operating Segments \| U.S. Branded - Sterile Injectables \| January 2018 Restructuring Initiative
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	3,900
Operating Segments \| International Pharmaceuticals \| January 2018 Restructuring Initiative
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	3,100
Operating Segments \| U.S. Branded - Specialty & Established Pharmaceuticals \| January 2018 Restructuring Initiative
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	700
Corporate unallocated costs \| January 2018 Restructuring Initiative
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	$ 5,200

Restructuring - Schedule of Restructuring Roll Forward (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Other Restructuring Costs
Restructuring Reserve [Roll Forward]
Expenses	$ 16,500	$ 22,000	$ 25,100
US Branded Pharmaceuticals Restructuring 2016
Restructuring Reserve [Roll Forward]
Beginning liability balance	0	21,768
Cash distributions		(21,768)
Ending liability balance		0	21,768
US Branded Pharmaceuticals Restructuring 2016 \| Employee separation, retention and other benefit-related costs
Restructuring Reserve [Roll Forward]
Beginning liability balance	0	16,544
Cash distributions		(16,544)
Ending liability balance		0	16,544
US Branded Pharmaceuticals Restructuring 2016 \| Other Restructuring Costs
Restructuring Reserve [Roll Forward]
Beginning liability balance	0	5,224
Cash distributions		(5,224)
Ending liability balance		0	5,224
January 2017 Restructuring
Restructuring Reserve [Roll Forward]
Beginning liability balance	2,681	0
Expenses		15,072
Cash distributions	(2,681)	(12,391)
Ending liability balance	0	2,681	0
2017 US Generic Pharmaceuticals Restructuring
Restructuring Reserve [Roll Forward]
Beginning liability balance	24,585	0
Expenses	20,384	43,277
Cash distributions	(40,682)	(18,692)
Ending liability balance	4,287	24,585	0
2017 US Generic Pharmaceuticals Restructuring \| Employee separation, retention and other benefit-related costs
Restructuring Reserve [Roll Forward]
Beginning liability balance	22,975	0
Expenses	9,090	29,553
Cash distributions	(27,826)	(6,578)
Ending liability balance	4,239	22,975	0
2017 US Generic Pharmaceuticals Restructuring \| Other Restructuring Costs
Restructuring Reserve [Roll Forward]
Beginning liability balance	1,610	0
Expenses	11,294	13,724
Cash distributions	(12,856)	(12,114)
Ending liability balance	48	1,610	$ 0
January 2018 Restructuring Initiative
Restructuring Reserve [Roll Forward]
Beginning liability balance	650
Expenses	23,518
Cash distributions	(23,019)
Ending liability balance	1,149	650
January 2018 Restructuring Initiative \| Employee separation, retention and other benefit-related costs
Restructuring Reserve [Roll Forward]
Beginning liability balance	0
Expenses	21,754
Cash distributions	(20,925)
Ending liability balance	829	0
January 2018 Restructuring Initiative \| Other Restructuring Costs
Restructuring Reserve [Roll Forward]
Beginning liability balance	650
Expenses	1,764
Cash distributions	(2,094)
Ending liability balance	$ 320	$ 650

Acquisitions (Voltaren Gel) (Narrative) (Details) - USD ($)	Jul. 01, 2016	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Goodwill		$ 3,764,636,000	$ 4,450,082,000	$ 4,729,395,000
VOLTAREN® Gel
Business Acquisition [Line Items]
Aggregate consideration transferred	$ 162,700,000
Payments to acquire business	16,200,000
Contingent consideration	146,000,000
Goodwill	$ 0
Estimated useful life	7 years

Segment Results - Schedule Of Reportable Segments Information (Details) $ in Thousands		3 Months Ended								12 Months Ended
	Dec. 31, 2017 Reportable_Business_Segments	Dec. 31, 2018 USD ($)	Sep. 30, 2018 USD ($)	Jun. 30, 2018 USD ($)	Mar. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Sep. 30, 2017 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2018 USD ($) Reportable_Business_Segments	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments \| Reportable_Business_Segments	3									4
Total net revenues from external customers		$ 786,389	$ 745,466	$ 714,696	$ 700,527	$ 768,640	$ 786,887	$ 875,731	$ 1,037,600	$ 2,947,078	$ 3,468,858	$ 4,010,274
Total segment adjusted income from continuing operations before income tax										1,441,139	1,608,175	1,717,622
U.S. Branded - Specialty & Established Pharmaceuticals
Segment Reporting Information [Line Items]
Total net revenues from external customers										862,832	957,525	1,166,294
Total segment adjusted income from continuing operations before income tax										368,790	485,515	553,806
U.S. Branded - Sterile Injectables
Segment Reporting Information [Line Items]
Total net revenues from external customers										929,566	750,471	576,399
Total segment adjusted income from continuing operations before income tax										695,363	563,103	426,170
U.S. Generic Pharmaceuticals
Segment Reporting Information [Line Items]
Total net revenues from external customers										1,012,215	1,530,530	1,988,214
Total segment adjusted income from continuing operations before income tax										317,892	501,249	653,309
International Pharmaceuticals
Segment Reporting Information [Line Items]
Total net revenues from external customers										142,465	230,332	279,367
Total segment adjusted income from continuing operations before income tax										$ 59,094	$ 58,308	$ 84,337

Segment Results - Schedule Of Reconciliations Of Consolidated Adjusted Income (Loss) Before Income Tax (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Segment Reporting Information [Line Items]
Total consolidated loss from continuing operations before income tax									$ (938,832)	$ (1,483,004)	$ (3,923,856)
Interest expense, net									521,656	488,228	452,679
Amortization of intangible assets									622,339	773,800	876,500
Asset impairment charges	$ 303,500	$ 142,200	$ 22,800	$ 448,400	$ 130,400	$ 94,900	$ 725,000	$ 204,000	916,939	1,154,376	3,781,165
Acquisition-related costs	8,600	1,300	5,200	6,800	26,400	16,600	4,200	10,900	21,914	58,086	87,601
Loss on extinguishment of debt									0	51,734	0
Severance costs	4,200	4,000	29,200	49,000	84,500	80,700	24,600	22,700	31,700	53,000	60,200
Accelerated depreciation									35,200	123,700
Change in fair value of contingent consideration	$ 8,200	$ 800	$ 4,100	$ 6,800	$ 26,400	$ 15,400	$ 2,000	$ 6,200	19,910	49,949	23,823
Inventory Write-Offs
Segment Reporting Information [Line Items]
Restructuring expenses									2,900	13,700	24,500
Other restructuring charges
Segment Reporting Information [Line Items]
Restructuring expenses									16,500	22,000	25,100
Segment Reconciling Items
Segment Reporting Information [Line Items]
Interest expense, net									521,656	488,228	452,679
Corporate unallocated costs									200,592	165,298	189,043
Amortization of intangible assets									622,339	773,766	876,451
Inventory step-up and certain manufacturing costs that will be eliminated pursuant to integration plans									261	390	125,699
Upfront and milestone payments to partners									45,108	9,483	8,330
Separation benefits and other cost reduction initiatives									86,295	212,448	107,491
Impact of VOLTAREN® Gel generic competition									0	0	(7,750)
Certain litigation-related and other contingencies, net									13,809	185,990	23,950
Asset impairment charges									916,939	1,154,376	3,781,165
Acquisition-related costs									21,914	58,086	87,601
Loss on extinguishment of debt									0	51,734	0
Foreign currency impact related to the remeasurement of intercompany debt instruments									(5,486)	(1,403)	366
Other, net									(43,456)	(7,217)	(3,547)
Operating Segments
Segment Reporting Information [Line Items]
Total consolidated loss from continuing operations before income tax									$ 1,441,139	$ 1,608,175	$ 1,717,622

Segment Results - Schedule of Disaggregation of Revenues (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disaggregation of Revenue [Line Items]
TOTAL REVENUES	$ 786,389	$ 745,466	$ 714,696	$ 700,527	$ 768,640	$ 786,887	$ 875,731	$ 1,037,600	$ 2,947,078	$ 3,468,858	$ 4,010,274
Product line revenue reporting threshold	$ 25,000								100,000	100,000	100,000
U.S. Branded - Specialty & Established Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES									862,832	957,525	1,166,294
U.S. Branded - Sterile Injectables
Disaggregation of Revenue [Line Items]
TOTAL REVENUES									929,566	750,471	576,399
U.S. Generic Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES									1,012,215	1,530,530	1,988,214
International Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES									142,465	230,332	279,367
XIAFLEX® \| U.S. Branded - Specialty & Established Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES									264,638	213,378	189,689
SUPPRELIN® LA \| U.S. Branded - Specialty & Established Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES									81,707	86,211	78,648
Other Specialty \| U.S. Branded - Specialty & Established Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES									156,607	153,384	138,483
Total Specialty Products \| U.S. Branded - Specialty & Established Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES									502,952	452,973	406,820
PERCOCET® \| U.S. Branded - Specialty & Established Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES									122,901	125,231	139,211
VOLTAREN® Gel \| U.S. Branded - Specialty & Established Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES									57,700	68,780	100,642
OPANA® ER \| U.S. Branded - Specialty & Established Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES									0	83,826	158,938
Other Established \| U.S. Branded - Specialty & Established Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES									179,279	226,715	360,683
Total Established Products \| U.S. Branded - Specialty & Established Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES									359,880	504,552	759,474
Vasostrict® \| U.S. Branded - Sterile Injectables
Disaggregation of Revenue [Line Items]
TOTAL REVENUES									453,767	399,909	343,468
ADRENALIN® \| U.S. Branded - Sterile Injectables
Disaggregation of Revenue [Line Items]
TOTAL REVENUES									143,489	76,523	22,172
Ertapenem for injection \| U.S. Branded - Sterile Injectables
Disaggregation of Revenue [Line Items]
TOTAL REVENUES									57,668	0	0
Other Sterile Injectables \| U.S. Branded - Sterile Injectables
Disaggregation of Revenue [Line Items]
TOTAL REVENUES									$ 274,642	$ 274,039	$ 210,759
Product Concentration Risk \| International Pharmaceuticals
Disaggregation of Revenue [Line Items]
Concentration risk, percentage									5.00%	7.00%	7.00%
Product Concentration Risk \| Ezetimibe and Quetiapine ER Tablets \| U.S. Generic Pharmaceuticals
Disaggregation of Revenue [Line Items]
Concentration risk, percentage										7.00%	7.00%

Segment Results Schedule of Depreciation Expense for Reportable Segments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Segment Reporting Information [Line Items]
Depreciation expense	$ 101,368	$ 209,999	$ 106,858
Operating Segments \| U.S. Branded - Specialty & Established Pharmaceuticals
Segment Reporting Information [Line Items]
Depreciation expense	14,542	16,957	16,294
Operating Segments \| U.S. Branded - Sterile Injectables
Segment Reporting Information [Line Items]
Depreciation expense	10,500	8,411	9,023
Operating Segments \| U.S. Generic Pharmaceuticals
Segment Reporting Information [Line Items]
Depreciation expense	66,016	174,652	70,816
Operating Segments \| International Pharmaceuticals
Segment Reporting Information [Line Items]
Depreciation expense	4,925	3,332	2,557
Corporate unallocated
Segment Reporting Information [Line Items]
Depreciation expense	$ 5,385	$ 6,647	$ 8,168

Fair Value Measurements - Restricted Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash and cash equivalents, current	$ 305,368	$ 320,453
Restricted cash and cash equivalents, noncurrent	22,356	3,956
Restricted cash and cash equivalents	327,724	324,409
Vaginal Mesh Cases
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash and cash equivalents		313,800
Settlement funds	$ 299,733	$ 313,814

Fair Value Measurements (Narrative) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Goodwill impairment charges	$ 680,000	$ 288,745	$ 2,676,350
Money market funds \| Restricted cash and cash equivalents
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Settlement funds	$ 86,900	$ 35,600
Measurement Input, Discount Rate \| Minimum
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate applied	0.095
Measurement Input, Discount Rate \| Maximum
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate applied	0.170
Measurement Input, Discount Rate \| Weighted Average
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate applied	0.132

Fair Value Measurements - Financial Liabilities Measured At Fair Value On Recurring Basis Using Significant Unobservable Inputs (Details) - Acquisition-related contingent consideration - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period	$ 190,442	$ 262,113
Amounts settled	(92,627)	(122,559)
Changes in fair value recorded in earnings	19,910	49,949
Effect of currency translation	(1,022)	939
Fair Value Adjustments and Accretion	19,910	49,949
Payments and Other	(93,649)	(121,620)
End of period	116,703	190,442
Auxilium acquisition
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period	13,061	21,097
Fair Value Adjustments and Accretion	2,941	467
Payments and Other	(1,845)	(8,503)
End of period	14,157	13,061
Lehigh Valley Technologies, Inc. acquisitions
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period	63,001	96,000
Fair Value Adjustments and Accretion	19,146	40,016
Payments and Other	(47,447)	(73,015)
End of period	34,700	63,001
VOLTAREN® Gel acquisition
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period	98,124	118,395
Fair Value Adjustments and Accretion	9	18,586
Payments and Other	(41,893)	(38,857)
End of period	56,240	98,124
Other
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period	16,256	26,621
Fair Value Adjustments and Accretion	(2,186)	(9,120)
Payments and Other	(2,464)	(1,245)
End of period	$ 11,606	$ 16,256

Fair Value Measurements - Fair Value Measurements (Schedule of Financial Assets Measured At Fair Value On A Nonrecurring Basis) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Assets:
Total expense for the year	$ (303,500)	$ (142,200)	$ (22,800)	$ (448,400)	$ (130,400)	$ (94,900)	$ (725,000)	$ (204,000)	$ (916,939)	$ (1,154,376)	$ (3,781,165)
2017 US Generic Pharmaceuticals Restructuring
Assets:
Total expense for the year										(47,200)
Restructuring expenses									20,384	43,277
2017 US Generic Pharmaceuticals Restructuring \| Asset impairment charges
Assets:
Restructuring expenses									2,600
Fair value, measurements, nonrecurring
Assets:
Total expense for the year									(236,939)	(865,633)
Fair value, measurements, nonrecurring \| Intangible assets
Assets:
Total expense for the year									(230,418)	(799,957)
Fair value, measurements, nonrecurring \| Certain property, plant and equipment
Assets:
Total expense for the year									(6,521)	(65,676)
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Fair value, measurements, nonrecurring
Assets:
Intangible assets, excluding goodwill	0				0				0	0
Certain property, plant and equipment	0				0				0	0
Total	0				0				0	0
Significant Other Observable Inputs (Level 2) \| Fair value, measurements, nonrecurring
Assets:
Intangible assets, excluding goodwill	0				0				0	0
Certain property, plant and equipment	0				0				0	0
Total	0				0				0	0
Significant Unobservable Inputs (Level 3) \| Fair value, measurements, nonrecurring
Assets:
Intangible assets, excluding goodwill	239,857				423,258				239,857	423,258
Certain property, plant and equipment	0				0				0	0
Total	$ 239,857				$ 423,258				$ 239,857	423,258
Disposal Group, Held-for-sale, Not Discontinued Operations \| Somar
Assets:
Total expense for the year										$ (11,900)

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 122,825	$ 124,685
Work-in-process	70,458	109,897
Finished goods	128,896	156,855
Total	322,179	391,437
Long-term inventory	8,100	17,100
Inventories not yet available for sale	$ 12,500	$ 5,900

Property, Plant And Equipment - Schedule Of Property, Plant And Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cost:
Beginning Balance	$ 928,254
Additions	94,797
Disposals, transfers, impairments and other	(261,003)
Effect of currency translation	(613)
Ending Balance	761,435
Accumulated Depreciation:
Beginning Balance	(404,283)
Additions	(101,368)
Disposals, transfers and other	242,750
Effect of currency translation	358
Ending Balance	(262,543)
Net Book Amount:	498,892	$ 523,971
Land and Buildings
Cost:
Beginning Balance	331,466
Additions	20,317
Disposals, transfers, impairments and other	(126,961)
Effect of currency translation	0
Ending Balance	224,822
Accumulated Depreciation:
Beginning Balance	(149,402)
Additions	(39,253)
Disposals, transfers and other	121,861
Effect of currency translation	0
Ending Balance	(66,794)
Net Book Amount:	158,028	182,064
Machinery and Equipment
Cost:
Beginning Balance	267,818
Additions	34,570
Disposals, transfers, impairments and other	(90,795)
Effect of currency translation	(102)
Ending Balance	211,491
Accumulated Depreciation:
Beginning Balance	(134,741)
Additions	(32,273)
Disposals, transfers and other	83,037
Effect of currency translation	71
Ending Balance	(83,906)
Net Book Amount:	127,585	133,077
Leasehold Improvements
Cost:
Beginning Balance	60,464
Additions	12,925
Disposals, transfers, impairments and other	(4,030)
Effect of currency translation	(103)
Ending Balance	69,256
Accumulated Depreciation:
Beginning Balance	(26,867)
Additions	(6,583)
Disposals, transfers and other	2,806
Effect of currency translation	44
Ending Balance	(30,600)
Net Book Amount:	38,656	33,597
Computer Equipment and Software
Cost:
Beginning Balance	131,451
Additions	18,660
Disposals, transfers, impairments and other	(32,602)
Effect of currency translation	(375)
Ending Balance	117,134
Accumulated Depreciation:
Beginning Balance	(82,792)
Additions	(21,105)
Disposals, transfers and other	32,235
Effect of currency translation	225
Ending Balance	(71,437)
Net Book Amount:	45,697	48,659
Assets under Capital Lease
Cost:
Beginning Balance	4,896
Additions	2,286
Disposals, transfers, impairments and other	(1,969)
Effect of currency translation	0
Ending Balance	5,213
Accumulated Depreciation:
Beginning Balance	(4,161)
Additions	(670)
Disposals, transfers and other	1,969
Effect of currency translation	0
Ending Balance	(2,862)
Net Book Amount:	2,351	735
Furniture and Fixtures
Cost:
Beginning Balance	13,124
Additions	490
Disposals, transfers, impairments and other	(1,101)
Effect of currency translation	(18)
Ending Balance	12,495
Accumulated Depreciation:
Beginning Balance	(6,320)
Additions	(1,484)
Disposals, transfers and other	842
Effect of currency translation	18
Ending Balance	(6,944)
Net Book Amount:	5,551	6,804
Assets under Construction
Cost:
Beginning Balance	119,035
Additions	5,549
Disposals, transfers, impairments and other	(3,545)
Effect of currency translation	(15)
Ending Balance	121,024
Accumulated Depreciation:
Beginning Balance	0
Additions	0
Disposals, transfers and other	0
Effect of currency translation	0
Ending Balance	0
Net Book Amount:	$ 121,024	$ 119,035

Property, Plant And Equipment (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total depreciation expense									$ 101,368	$ 209,999	$ 106,858
Asset impairment charges of long-lived assets									6,500	65,700	15,900
Asset impairment charges	$ 303,500	$ 142,200	$ 22,800	$ 448,400	$ 130,400	$ 94,900	$ 725,000	$ 204,000	$ 916,939	1,154,376	$ 3,781,165
Somar \| Disposal Group, Held-for-sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset impairment charges										11,900
2017 US Generic Pharmaceuticals Restructuring
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset impairment charges										$ 47,200

Goodwill And Other Intangibles - Schedule Of Changes In The Carrying Amount Of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 4,450,082	$ 4,729,395
Effect of currency translation	(5,446)	9,431
Goodwill impairment charges	(680,000)	(288,745)	$ (2,676,350)
Allocation to current segments	0
Goodwill, ending balance	3,764,636	4,450,082	4,729,395
U.S. Branded - Specialty & Established Pharmaceuticals
Goodwill [Roll Forward]
Goodwill, beginning balance	828,818	1,009,248
Effect of currency translation	0	0
Goodwill impairment charges	0	(180,430)
Allocation to current segments	0
Goodwill, ending balance	828,818	828,818	1,009,248
U.S. Branded - Sterile Injectables
Goodwill [Roll Forward]
Goodwill, beginning balance	0	0
Effect of currency translation	0	0
Goodwill impairment charges	0	0
Allocation to current segments	2,731,193
Goodwill, ending balance	2,731,193	0	0
U.S. Generic Pharmaceuticals
Goodwill [Roll Forward]
Goodwill, beginning balance	3,531,301	3,531,301
Effect of currency translation	0	0
Goodwill impairment charges	(649,000)	0
Allocation to current segments	(2,731,193)
Goodwill, ending balance	151,108	3,531,301	3,531,301
International Pharmaceuticals
Goodwill [Roll Forward]
Goodwill, beginning balance	89,963	188,846
Effect of currency translation	(5,446)	9,431
Goodwill impairment charges	(31,000)	(108,314)
Allocation to current segments	0
Goodwill, ending balance	$ 53,517	$ 89,963	$ 188,846

Goodwill And Other Intangibles - Accumulated Impairment (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Goodwill [Line Items]
Accumulated impairment losses	$ 4,303,767	$ 3,661,904
U.S. Branded - Specialty & Established Pharmaceuticals
Goodwill [Line Items]
Accumulated impairment losses	855,810	855,810
U.S. Branded - Sterile Injectables
Goodwill [Line Items]
Accumulated impairment losses	0	0
U.S. Generic Pharmaceuticals
Goodwill [Line Items]
Accumulated impairment losses	2,991,549	2,342,549
International Pharmaceuticals
Goodwill [Line Items]
Accumulated impairment losses	$ 456,408	$ 463,545

Goodwill And Other Intangibles - Schedule Of Other Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Indefinite-lived intangibles:
Beginning Balance		$ 347,200
Acquisitions		0
Impairments		(87,900)
Other		(165,400)
Effect of Currency Translation		0
Ending Balance		93,900	$ 347,200
Finite-lived intangibles:
Beginning Balance		6,651,575
Acquisitions		3,000
Impairments		(142,518)
Other		154,753
Effect of Currency Translation		(20,984)
Ending Balance		6,645,826	6,651,575
Total other intangibles
Beginning balance		6,998,775
Acquisitions		3,000
Impairments		(230,418)	(799,955)	$ (1,088,903)
Other		(10,647)
Effect of Currency Translation		(20,984)
Ending balance		6,739,726	6,998,775
Accumulated amortization:
Beginning Balance		(2,681,091)
Amortization		(622,339)	(773,800)	$ (876,500)
Impairments		0
Other		10,647
Effect of Currency Translation		10,363
Ending Balance		(3,282,420)	(2,681,091)
Net other intangibles		3,457,306	4,317,684
Licenses
Finite-lived intangibles:
Beginning Balance		457,402
Acquisitions		0
Impairments		0
Other		0
Effect of Currency Translation		0
Ending Balance		457,402	457,402
Accumulated amortization:
Beginning Balance		(370,221)
Amortization		(27,961)
Impairments		0
Other		0
Effect of Currency Translation		0
Ending Balance		(398,182)	(370,221)
Tradenames
Finite-lived intangibles:
Beginning Balance		6,409
Acquisitions		0
Impairments		0
Other		0
Effect of Currency Translation		0
Ending Balance		6,409	6,409
Accumulated amortization:
Beginning Balance		(6,409)
Amortization		0
Impairments		0
Other		0
Effect of Currency Translation		0
Ending Balance		(6,409)	(6,409)
Developed technology
Finite-lived intangibles:
Beginning Balance		6,187,764
Acquisitions		3,000
Impairments		(142,518)
Other		154,753
Effect of Currency Translation		(20,984)
Ending Balance		6,182,015	6,187,764
Total other intangibles
Impairments	$ (20,600)
Accumulated amortization:
Beginning Balance		(2,304,461)
Amortization		(594,378)
Impairments		0
Other		10,647
Effect of Currency Translation		10,363
Ending Balance		(2,877,829)	(2,304,461)
In-process research and development
Indefinite-lived intangibles:
Beginning Balance		347,200
Acquisitions		0
Impairments		(87,900)
Other		(165,400)
Effect of Currency Translation		0
Ending Balance		$ 93,900	$ 347,200
Weighted Average
Accumulated amortization:
Intangible life (years)		11 years
Weighted Average \| Licenses
Accumulated amortization:
Intangible life (years)		12 years
Weighted Average \| Developed technology
Accumulated amortization:
Intangible life (years)		11 years

Goodwill And Other Intangibles - Schedule Of Estimated Amortization Of Intangibles (Details) $ in Thousands	Dec. 31, 2018 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2019	$ 550,574
2020	479,358
2021	445,215
2022	418,844
2023	$ 384,223

Goodwill And Other Intangibles - Schedule of Intangible Asset Impairment Charges Including Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill impairment charges	$ 680,000	$ 288,745	$ 2,676,350
Other intangible asset impairment charges	$ 230,418	$ 799,955	$ 1,088,903

Goodwill And Other Intangibles - Impairments Narrative (Details)	3 Months Ended								12 Months Ended
	Dec. 31, 2018 USD ($)	Mar. 31, 2018 USD ($)	Sep. 30, 2017 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Sep. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Oct. 01, 2018	Oct. 01, 2017	Oct. 01, 2016
Goodwill [Line Items]
Other intangible asset impairment charges									$ 230,418,000	$ 799,955,000	$ 1,088,903,000
Goodwill impairment charges									680,000,000	288,745,000	2,676,350,000
Serelaxin In-Process Research and Development Intangible Assets
Goodwill [Line Items]
Other intangible asset impairment charges					$ 45,500,000
Paladin Labs Inc.
Goodwill [Line Items]
Goodwill impairment charges					$ 82,600,000
U.S. Generic Pharmaceuticals
Goodwill [Line Items]
Other intangible asset impairment charges								$ 100,300,000
Goodwill impairment charges									649,000,000	0
International Pharmaceuticals
Goodwill [Line Items]
Other intangible asset impairment charges							$ 16,200,000
Goodwill impairment charges									31,000,000	108,314,000
U.S. Branded - Specialty & Established Pharmaceuticals \| Sumavel DosePro
Goodwill [Line Items]
Other intangible asset impairment charges							$ 72,800,000
U.S. Branded - Specialty & Established Pharmaceuticals \| BELBUCA
Goodwill [Line Items]
Other intangible asset impairment charges						$ 37,600,000
In process research and development or developed technology
Goodwill [Line Items]
Other intangible asset impairment charges									$ 230,400,000	$ 586,900,000	862,000,000
Developed technology
Goodwill [Line Items]
Other intangible asset impairment charges				$ 20,600,000
Developed technology \| U.S. Generic Pharmaceuticals
Goodwill [Line Items]
Other intangible asset impairment charges				57,500,000
Somar \| Disposal Group, Held-for-sale, Not Discontinued Operations
Goodwill [Line Items]
Other intangible asset impairment charges				89,500,000
Goodwill impairment charges				$ 25,700,000
Measurement Input, Discount Rate \| Paladin Labs Inc.
Goodwill [Line Items]
Intangible assets and goodwill, measurement input					0.100
Minimum \| Significant Unobservable Inputs (Level 3) \| Measurement Input, Discount Rate
Goodwill [Line Items]
Intangible assets and goodwill, measurement input												0.095	0.095	0.085
Maximum \| Significant Unobservable Inputs (Level 3) \| Measurement Input, Discount Rate
Goodwill [Line Items]
Intangible assets and goodwill, measurement input												0.115	0.125	0.110
U.S. Generic Pharmaceuticals
Goodwill [Line Items]
Goodwill impairment charges	$ 258,000,000	$ 391,000,000									2,342,500,000
U.S. Generic Pharmaceuticals \| Measurement Input, Discount Rate
Goodwill [Line Items]
Intangible assets and goodwill, measurement input		0.095
Paladin Labs Inc.
Goodwill [Line Items]
Goodwill impairment charges	$ 31,000,000										272,600,000
Somar
Goodwill [Line Items]
Goodwill impairment charges											33,000,000
Lithia
Goodwill [Line Items]
Goodwill impairment charges											$ 26,300,000
Former U.S. Generic Pharmaceuticals
Goodwill [Line Items]
Goodwill impairment charges		$ 0
Former U.S. Generic Pharmaceuticals \| Measurement Input, Discount Rate
Goodwill [Line Items]
Intangible assets and goodwill, measurement input		0.095
U.S. Branded - Sterile Injectables
Goodwill [Line Items]
Goodwill impairment charges		$ 0
U.S. Branded - Sterile Injectables \| Measurement Input, Discount Rate
Goodwill [Line Items]
Intangible assets and goodwill, measurement input		0.095
U.S. Branded - Specialty & Established Pharmaceuticals \| BELBUCA
Goodwill [Line Items]
Goodwill impairment charges						$ 1,900,000
U.S. Branded - Specialty & Established Pharmaceuticals \| Developed technology
Goodwill [Line Items]
Other intangible asset impairment charges			$ 180,400,000
U.S. Branded - Specialty & Established Pharmaceuticals \| Measurement Input, Discount Rate
Goodwill [Line Items]
Intangible assets and goodwill, measurement input				0.095

License And Collaboration Agreements (BioSpecifics Technologies Corp) (Narrative) (Details)	12 Months Ended
	Dec. 31, 2018
License And Collaboration Agreements [Line Items]
License agreement, exclusivity period	12 years
Termination of agreement notice period	90 days
Minimum
License And Collaboration Agreements [Line Items]
Royalty rate on net sales	5.00%
Maximum
License And Collaboration Agreements [Line Items]
Royalty rate on net sales	15.00%

Contract Assets and Liabilities - Contract Assets and Contract Liabilities from Contracts with Customers (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Jan. 01, 2018
Contract with Customer, Asset and Liability [Abstract]
Contract assets, net	$ 12,065	$ 11,287
Contract assets, net - $ change	$ 778
Contract assets, net - % change	7.00%
Contract liabilities, net	$ 19,217	20,954
Contract liabilities, net - $ change	$ (1,737)
Contract liabilities, net - % change	(8.00%)
Contract asset amounts classified as current	$ 9,300	8,200
Contract liability amounts classified as current	1,700	$ 1,900
Revenue recognized	$ (1,700)

Accounts Payable And Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Accounts Payable and Accrued Liabilities, Current [Abstract]
Trade accounts payable	$ 96,024	$ 85,348
Returns and allowances	236,946	291,034
Rebates	144,860	168,333
Chargebacks	2,971	14,604
Accrued interest	130,182	130,257
Accrued payroll and related benefits	89,895	113,908
Accrued royalties and other distribution partner payables	122,028	63,114
Acquisition-related contingent consideration—short-term	36,514	70,543
Other	149,780	159,684
Total	$ 1,009,200	$ 1,096,825

Debt (Components Of Total Indebtedness) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Principal Amount	$ 8,348,775	$ 8,382,980
Carrying Amount	8,258,419	8,276,237
Less current portion, net	34,150	34,205
Principal amount of total long-term debt, less current portion, net	8,314,625	8,348,775
Carrying amount of total long-term debt, less current portion, net	8,224,269	8,242,032
Fair value of long term debt	$ 7,200,000	$ 7,500,000
7.25% Senior Notes due 2022
Debt Instrument [Line Items]
Effective interest rate (as percent)	7.91%	7.91%
Principal Amount	$ 400,000	$ 400,000
Carrying Amount	$ 392,947	$ 390,974
Interest rate (as percent)	7.25%
5.75% Senior Notes due 2022
Debt Instrument [Line Items]
Effective interest rate (as percent)	6.04%	6.04%
Principal Amount	$ 700,000	$ 700,000
Carrying Amount	$ 694,464	$ 692,855
Interest rate (as percent)	5.75%
5.375% Senior Notes due 2023
Debt Instrument [Line Items]
Effective interest rate (as percent)	5.62%	5.62%
Principal Amount	$ 750,000	$ 750,000
Carrying Amount	$ 743,438	$ 742,048
Interest rate (as percent)	5.375%
6.00% Senior Notes due 2023
Debt Instrument [Line Items]
Effective interest rate (as percent)	6.28%	6.28%
Principal Amount	$ 1,635,000	$ 1,635,000
Carrying Amount	$ 1,616,817	$ 1,613,446
Interest rate (as percent)	6.00%
5.875% Senior Secured Notes due 2024
Debt Instrument [Line Items]
Effective interest rate (as percent)	6.14%	6.14%
Principal Amount	$ 300,000	$ 300,000
Carrying Amount	$ 296,062	$ 295,513
Interest rate (as percent)	5.875%
6.00% Senior Notes due 2025
Debt Instrument [Line Items]
Effective interest rate (as percent)	6.27%	6.27%
Principal Amount	$ 1,200,000	$ 1,200,000
Carrying Amount	$ 1,183,415	$ 1,181,243
Interest rate (as percent)	6.00%
Term Loan B Facility Due 2024
Debt Instrument [Line Items]
Effective interest rate (as percent)	7.02%	6.09%
Principal Amount	$ 3,363,775	$ 3,397,925
Carrying Amount	3,331,276	$ 3,360,103
Other debt
Debt Instrument [Line Items]
Effective interest rate (as percent)		1.50%
Principal Amount	0	$ 55
Carrying Amount	$ 0	$ 55

Debt (Credit Facility) (Narrative) (Details)	12 Months Ended
Debt (Credit Facility) (Narrative) (Details)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)
Line of Credit Facility [Line Items]
Principal amount	$ 8,348,775,000	$ 8,382,980,000
Term Loan B Facility Due 2024
Line of Credit Facility [Line Items]
Percent of quarterly principal payment	0.25%
Revolving Credit Facility
Line of Credit Facility [Line Items]
Credit facility, remaining borrowing capacity	$ 997,300,000
2017 Credit Agreement \| Secured Debt
Line of Credit Facility [Line Items]
Principal amount	3,415,000,000.0
2017 Credit Agreement \| Revolving Credit Facility
Line of Credit Facility [Line Items]
Principal amount	$ 1,000,000,000.0
Debt instrument maximum leverage ratio	2.50
Debt instrument secured leverage ratio	3.50
Debt instrument unsecured leverage ratio	6.50
5.375% Senior Notes due 2023
Line of Credit Facility [Line Items]
Principal amount	$ 750,000,000	750,000,000
Interest rate (as percent)	5.375%
6.00% Senior Notes due 2023
Line of Credit Facility [Line Items]
Principal amount	$ 1,635,000,000	$ 1,635,000,000
Interest rate (as percent)	6.00%
London Interbank Offered Rate (LIBOR) \| 2017 Credit Agreement \| Secured Debt
Line of Credit Facility [Line Items]
Basis spread on variable rate (as percent)	4.25%
Basis spread floor (as percent)	0.75%
London Interbank Offered Rate (LIBOR) \| Minimum \| 2017 Credit Agreement \| Revolving Credit Facility
Line of Credit Facility [Line Items]
Basis spread on variable rate (as percent)	1.50%
London Interbank Offered Rate (LIBOR) \| Maximum \| 2017 Credit Agreement \| Revolving Credit Facility
Line of Credit Facility [Line Items]
Basis spread on variable rate (as percent)	3.00%
Base Rate \| 2017 Credit Agreement \| Secured Debt
Line of Credit Facility [Line Items]
Basis spread on variable rate (as percent)	3.75%
Basis spread floor (as percent)	1.75%
Base Rate \| Minimum \| 2017 Credit Agreement \| Revolving Credit Facility
Line of Credit Facility [Line Items]
Basis spread on variable rate (as percent)	0.50%
Base Rate \| Maximum \| 2017 Credit Agreement \| Revolving Credit Facility
Line of Credit Facility [Line Items]
Basis spread on variable rate (as percent)	2.00%

Debt (Senior Notes and Senior Secured Notes) (Details)	12 Months Ended
Debt (Senior Notes and Senior Secured Notes) (Details)	Dec. 31, 2018
After December 31, 2017
Debt Instrument, Redemption [Line Items]
Redemption price (as percent)	100.00%
After Non-Call Period
Debt Instrument, Redemption [Line Items]
Redemption price (as percent)	100.00%
After Non-Call Period \| Minimum
Debt Instrument, Redemption [Line Items]
Redemption price (as percent)	101.208%
After Non-Call Period \| Maximum
Debt Instrument, Redemption [Line Items]
Redemption price (as percent)	104.50%
As of December 31, 2018
Debt Instrument, Redemption [Line Items]
Percentage of principal that may be redeemed	35.00%
5.875% Senior Secured Notes due 2024
Debt Instrument, Redemption [Line Items]
Interest rate (as percent)	5.875%
5.875% Senior Secured Notes due 2024 \| As of December 31, 2018
Debt Instrument, Redemption [Line Items]
Redemption price (as percent)	105.875%
6.00% Senior Notes due 2025
Debt Instrument, Redemption [Line Items]
Interest rate (as percent)	6.00%

Debt (April 2017 Refinancing) (Details) - USD ($) $ in Millions		3 Months Ended
	Apr. 27, 2017	Jun. 30, 2017
Debt Instrument [Line Items]
Debt issuance costs	$ 56.7
Deferred debt issuance costs	10.1	$ 51.7
2017 Credit Agreement \| Term Loan Facility
Debt Instrument [Line Items]
Debt issuance costs	41.3
2017 Credit Agreement \| Revolving Credit Facility
Debt Instrument [Line Items]
Debt issuance costs	10.5
2017 Credit Agreement \| Senior Secured Notes
Debt Instrument [Line Items]
Debt issuance costs	$ 4.9

Debt (Maturities On Long-Term Debt For Each Of The Next Five Years) (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
2019	$ 34,150,000
2020	34,150,000
2021	34,150,000
2022	1,134,150,000
2023	2,419,150,000
Principal amount	8,348,775,000	$ 8,382,980,000
Senior Notes \| 2017 Credit Agreement
Debt Instrument [Line Items]
Principal amount	1,100,000,000.0
Senior Notes \| Senior Notes Maturing Due 2022
Debt Instrument [Line Items]
Principal amount	$ 750,000,000.0

Commitments And Contingencies (Narrative) (Details) $ in Thousands	1 Months Ended															3 Months Ended		12 Months Ended			64 Months Ended
	Feb. 28, 2019 USD ($)	Jan. 31, 2019 d defendant	Dec. 31, 2018 USD ($) defendant	Nov. 30, 2018	Oct. 31, 2018	Aug. 31, 2018 d	Jun. 30, 2018 theory	May 31, 2018	Apr. 30, 2018 case	Mar. 31, 2018 d defendant	Feb. 28, 2018 defendant	Jan. 31, 2018 employee d consultant	Oct. 31, 2017 patent	Aug. 31, 2017 defendant	Jul. 31, 2016	Dec. 31, 2017 USD ($)	Jun. 30, 2016	Dec. 31, 2018 USD ($) case	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Feb. 21, 2019 USD ($) case claim
Loss Contingencies [Line Items]
Reserve for loss contingencies			$ 905,100															$ 905,100
Increase in legal reserves																$ 200,000
Length of trial, number of days															3 days
Vaginal Mesh Cases
Loss Contingencies [Line Items]
Payments to plaintiffs and qualified settlement funds																		3,300,000
Settlement funds			299,733													$ 313,814		299,733	$ 313,814
Testosterone Cases \| Subsequent Event
Loss Contingencies [Line Items]
Pending claims, number \| claim																					1,105
Opioid-Related Matters
Loss Contingencies [Line Items]
Number of claims set for trial \| case									2
Opioid-Related Matters \| Subsequent Event
Loss Contingencies [Line Items]
Pending claims, number \| case																					1,711
Number of cases filed by states \| case																					12
Number of cases filed by hospitals, health systems, unions, welfare funds or other third-party \| case																					121
Number of cases alleging personal injury and/or wrongful death \| case																					56
Lidoderm cases
Loss Contingencies [Line Items]
Reserve for loss contingencies			$ 100,000															100,000
Payments to plaintiffs and qualified settlement funds																		60,000
Lidoderm cases \| Subsequent Event
Loss Contingencies [Line Items]
Payments to plaintiffs and qualified settlement funds	$ 10,000																				$ 70,000
AndroGel 1.62%
Loss Contingencies [Line Items]
Number of causation theories rejected \| theory							2
Number of causation theories \| theory							3
Bier v. Endo International plc, et al. \| Current and Former Directors and Officers
Loss Contingencies [Line Items]
Number of additional defendants \| defendant														4
Number of defendants \| defendant			4								20
AMS \| Vaginal Mesh Cases
Loss Contingencies [Line Items]
Product liability accrual			$ 748,600															$ 748,600
Loss contingency, claims settled, number \| case																		71,000
Par Pharmaceutical, Inc. \| VASOSTRICT Related Matters
Loss Contingencies [Line Items]
Number of additional defendants \| employee												4
Number of patents allegedly infringed upon \| patent													5
Length of trial, number of days \| consultant												1
Number of defendants filing motion to dismiss the breach of contract claim \| defendant										7
Number of defendants filing motion to dismiss for lack of personal injury jurisdiction \| defendant										4
Number of defendants filing motion to dismiss breach of contract claim \| defendant										1
Stay of litigation, number of days \| d												60
Extension of temporary stay, number of days \| d						180				180
Lawsuit filing period				45 days	45 days			45 days
Stay of approval period, hatch-waxman act				30 months	30 months			30 months
Par Pharmaceutical, Inc. \| VASOSTRICT Related Matters \| Subsequent Event
Loss Contingencies [Line Items]
Number of defendants \| defendant		4
Number of days for plantiff to file notice \| d		3
Jubilant HollisterStier Laboratories LLC
Loss Contingencies [Line Items]
JHS agreement, term																	3 years
JHS agreement, subsequent terms																	1 year
Long-term purchase commitment, purchased amount																		$ 7,500	$ 5,600	$ 6,300

Commitments And Contingencies - Schedule of Loss Contingencies (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Qualified Settlement Funds
Cash contributions to Qualified Settlement Funds		$ 336,648	$ 668,306	$ 831,131
Mesh Liability Accrual
Ending balance		905,100
Vaginal Mesh Cases
Qualified Settlement Funds
Beginning balance		313,814
Cash contributions to Qualified Settlement Funds		336,648
Cash distributions to settle disputes from Qualified Settlement Funds		(353,032)
Other		2,303
Ending balance		299,733	313,814
Mesh Liability Accrual
Other		2,303
Vaginal Mesh Cases \| Mesh Product Liability Accrual
Qualified Settlement Funds
Other	$ 5,700	5,688
Mesh Liability Accrual
Beginning balance		1,087,172
Additional charges		34,000
Cash distributions to settle disputes from Qualified Settlement Funds		(353,032)
Cash distributions to settle disputes		(25,222)
Other	5,700	5,688
Ending balance		$ 748,606	$ 1,087,172
Accrued interest	$ 4,400

Commitments And Contingencies - Summary Of Minimum Future Rental Payments Required Under Operating Leases and Capital Leases (Details) ft² in Thousands, $ in Thousands	Dec. 31, 2018 USD ($) ft²
Capital Leases
2019	$ 6,884
2020	6,819
2021	6,921
2022	7,072
2023	7,225
Thereafter	9,127
Total minimum lease payments	44,048
Less: Amount representing interest	4,084
Total present value of minimum payments	39,964
Less: Current portion of such obligations	5,845
Long-term capital lease obligations	$ 34,119
Area of real estate property \| ft²	140
Future minimum sublease rentals	$ 29,700
Operating Leases
2019	15,800
2020	14,519
2021	12,883
2022	12,454
2023	9,945
Thereafter	20,573
Total minimum lease payments	$ 86,174

Commitments And Contingencies - Leases (Narrative) (Details) $ in Millions		12 Months Ended
	Oct. 28, 2011 renewal_options	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Number of renewal options \| renewal_options	3
Additional period of renewal for lease agreement	60 months
Direct financing lease obligations		$ 33.8
Expenses incurred under operating leases		18.7	$ 18.7	$ 22.2
Accounts Payable
Direct financing lease obligations		4.9
Other Liabilities
Direct financing lease obligations		$ 28.9

Other Comprehensive (Loss) Income (Schedule Of Tax Effects Allocated To Each Component Of Other Comprehensive Income) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Accumulated Other Comprehensive Income (Loss) [Line Items]
Before- Tax Amount	$ (19,408)	$ 143,317	$ 16,673
Tax Benefit (Expense)	0	296	14,136
OTHER COMPREHENSIVE (LOSS) INCOME	(19,408)	143,613	30,809
Net unrealized gain (loss) on securities
Accumulated Other Comprehensive Income (Loss) [Line Items]
Before Reclassification, Before Tax Amount		(811)	(1,588)
Before Reclassification, Tax Benefit (Expense)		296	674
Before Reclassification, Net-of-Tax Amount	0	(515)	(914)
Reclassification, Before Tax Amount	0	0	(6)
Reclassification, Tax Benefit (Expense)	0	0	0
Reclassification, Net-of-Tax Amount	0	0	(6)
Before- Tax Amount		(811)	(1,594)
Tax Benefit (Expense)		296	674
OTHER COMPREHENSIVE (LOSS) INCOME	0	(515)	(920)
Net unrealized gain (loss) on foreign currency
Accumulated Other Comprehensive Income (Loss) [Line Items]
Before Reclassification, Before Tax Amount	(19,408)	31,202	18,267
Before Reclassification, Tax Benefit (Expense)	0	0	13,462
Before Reclassification, Net-of-Tax Amount	(19,408)	31,202	31,729
Reclassification, Before Tax Amount	0	112,926	0
Reclassification, Tax Benefit (Expense)	0	0	0
Reclassification, Net-of-Tax Amount	0	112,926	0
Before- Tax Amount	(19,408)	144,128	18,267
Tax Benefit (Expense)	0	0	13,462
OTHER COMPREHENSIVE (LOSS) INCOME	$ (19,408)	$ 144,128	$ 31,729

Shareholders' (Deficit) Equity (Narrative) (Details)	12 Months Ended	36 Months Ended
Shareholders' (Deficit) Equity (Narrative) (Details)	Dec. 31, 2018 USD ($) registered_shareholders $ / shares shares	Dec. 31, 2018 USD ($) $ / shares shares	Jan. 01, 2018 USD ($)	Dec. 31, 2017 USD ($) $ / shares shares	Jan. 01, 2017 USD ($)	Dec. 31, 2016 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Euro deferred shares, shares issued (in shares) \| shares	4,000,000	4,000,000		4,000,000
Euro deferred shares, par value (in dollars per share) \| $ / shares	$ 0.01	$ 0.01		$ 0.01
Number of registered shareholders (at least) \| registered_shareholders	7
Effect of adopting accounting principle in period of adoption				$ (3,076,000)		$ 372,825,000
Accumulated deficit	$ (9,124,932,000)	$ (9,124,932,000)		(8,096,539,000)
2015 Share Buyback Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share repurchase program, authorized amount	2,500,000,000.0	2,500,000,000.0
Share repurchases		$ 250,000,000
Share repurchases (in shares) \| shares		4,400,000
Accumulated Deficit \| Accounting Standards Update 2016-06
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Effect of adopting accounting principle in period of adoption					$ 372,800,000
Accumulated Deficit \| ASC 606
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Effect of adopting accounting principle in period of adoption				$ (3,076,000)
Effect of adoption of ASC 606 \| ASC 606
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Accumulated deficit	$ 4,836,000	$ 4,836,000	$ 3,100,000

Shared-based Compensation (Narrative) (Details)	3 Months Ended	9 Months Ended	12 Months Ended
Shared-based Compensation (Narrative) (Details)	Sep. 30, 2017 shares	Sep. 30, 2018 USD ($) employee shares	Dec. 31, 2018 USD ($) target $ / shares shares	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2016 USD ($) $ / shares shares
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Target amount of share-based compensation awards, stock options (in shares) \| shares	1,000,000.0
Tax benefit from exercise of stock options \| $			$ 0	$ 0	$ 0
Unrecognized compensation cost \| $			$ 68,300,000
Nonvested Restricted Stock
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Target amount of share-based compensation awards (in shares) \| shares	100,000.0
Performance Stock Units
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Performance target term			1 year
Target amount of share-based compensation awards (in shares) \| shares			500,000.0
Service period			3 years
Vesting period			3 years
Unrecognized compensation cost \| $			$ 4,700,000
PSU award percentage using free cash flow performance metric			50.00%
Number of performance targets \| target			3
PSU award percentage using TSR metric			50.00%
Performance cycle					3 years
Performance Stock Units \| Minimum
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Award adjustment rate			0.00%		0.00%
Performance Stock Units \| Maximum
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Award adjustment rate			200.00%		300.00%
Long-term Cash Incentive
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Service period		2 years 3 months 18 days	3 years
Unvested awards outstanding (in shares) \| shares		3,000,000
Number of employees \| employee		570
Corresponding liability \| $		$ 14,900,000
Stock Options
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Target amount of share-based compensation awards, stock options (in shares) \| shares			971,590	5,288,675	2,578,105
Expiration period			10 years
Dividend yield			0.00%	0.00%	0.00%
Exercise price range, lower range limit (in dollars per share) \| $ / shares			$ 7.55
Exercise price range, upper range limit (in dollars per share) \| $ / shares			$ 89.68
Options exercised intrinsic value \| $			$ 600,000		$ 1,300,000
Options grated, weighted average grant date fair value (in dollars per share) \| $ / shares			$ 3.97	$ 4.73	$ 11.46
Stock Options \| Minimum
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Vesting period			3 years
Stock Options \| Maximum
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Vesting period			4 years
Nonvested Stock Options
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Weighted average remaining requisite service period, non-vested stock options			1 year 8 months 12 days
Unrecognized compensation cost \| $			$ 9,400,000
Restricted Stock Units (RSUs)
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Unrecognized compensation cost \| $			$ 54,200,000
Weighted average remaining requisite service period, non-vested restricted stock units			1 year 10 months 24 days
Restricted and performance stock units, weighted average grant date fair value (in dollars per share) \| $ / shares			$ 6.88	$ 11.42	$ 43.52
Restricted Stock Units (RSUs) \| Minimum
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Vesting period			3 years
Restricted Stock Units (RSUs) \| Maximum
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Vesting period			4 years
2015 Stock Incentive Plan
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Number of shares available for grant (in shares) \| shares			5,500,000
Plans Other Than Twenty Fifteen Plan
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Number of shares available for grant (in shares) \| shares			0

Shared-based Compensation (Schedule Of Allocation Of Stock-Based Compensation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 54,071	$ 50,149	$ 59,769
Selling, general and administrative expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	44,454	38,292	54,176
Research and development expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	2,251	4,197	2,440
Cost of revenues
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	7,366	7,660	2,040
Discontinued Operations
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 0	$ 0	$ 1,113

Shared-based Compensation (Summary Of Activity Under Stock Incentive Plans) (Details) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Number of Shares
Granted (in shares)	1,000,000.0
Stock Options
Number of Shares
Outstanding, beginning balance (in shares)		8,248,130	4,325,209	2,768,567
Granted (in shares)		971,590	5,288,675	2,578,105
Exercised (in shares)		(94,392)		(62,589)
Forfeited (in shares)		(605,737)	(623,987)	(858,556)
Expired (in shares)		(446,873)	(741,767)	(100,318)
Outstanding, ending balance (in shares)		8,072,718	8,248,130	4,325,209
Vested and expected to vest (in shares)		7,833,930
Exercisable (in shares)		3,550,777
Weighted Average Exercise Price
Outstanding, weighted average exercise price, beginning balance (in dollars per share)		$ 22.79	$ 41.70	$ 51.56
Granted, weighted average exercise price (in dollars per share)		7.55	10.42	35.45
Exercised, weighted average exercise price (in dollars per share)		9.89		31.19
Forfeited, weighted average exercise price (in dollars per share)		19.01	28.32	52.27
Expired, weighted average exercise price (in dollars per share)		36.80	40.29	60.71
Outstanding, weighted average exercise price, ending balance (in dollars per share)		20.62	$ 22.79	$ 41.70
Vested and expected to vest, end of period, weighted average exercise price (in dollars per share)		20.86
Exercisable, end of period, weighted average exercise price (in dollars per share)		$ 28.07
Weighted Average Remaining Contractual Term and Aggregate Intrinsic Value
Outstanding, weighted average remaining contractual term		7 years 1 month 13 days
Vested and expected to vest, weighted average remaining contractual term		7 years 29 days
Exercisable, weighted average remaining contractual term		6 years
Outstanding, aggregate intrinsic value		$ 0
Vested and expected to vest, aggregate intrinsic value		0
Exercisable, aggregate intrinsic value		$ 0

Shared-based Compensation (Stock Option Assumption) (Details) - Stock Options	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	4 years	4 years	4 years
Risk-free interest rate	2.70%	1.70%	1.10%
Dividend yield	0.00%	0.00%	0.00%
Expected volatility	63.00%	58.00%	43.00%

Shared-based Compensation (Summary Of Restricted Stock Units and Performance Stock Units Activity) (Details) - Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Number of Shares
Outstanding, Beginning Balance (in shares)	4,724,673	1,685,060	1,806,853
Granted (in shares)	5,609,561	4,168,477	1,582,429
LTCI modification (in shares)	2,989,965
Forfeited (in shares)	(753,653)	(552,981)	(975,994)
Vested (in shares)	(1,551,074)	(575,883)	(728,228)
Outstanding, Ending Balance (in shares)	11,019,472	4,724,673	1,685,060
Vested and expected to vest, end of period (in shares)	10,250,560
Aggregate Intrinsic Value
Outstanding, end of period	$ 80,442,146
Vested and expected to vest	$ 74,829,088

Other Income, Net (Details) - USD ($) $ in Thousands	3 Months Ended							12 Months Ended
Other Income, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Net (gain) loss on sale of business and other assets	$ (15,300)	$ (2,900)	$ (24,600)	$ (2,400)	$ (8,700)	$ (2,800)	$ (2,300)	$ (45,155)	$ (13,809)	$ 3,192
Foreign currency (gain) loss, net								(3,762)	(2,801)	2,991
Net loss (gain) from our investments in the equity of other companies								3,444	898	(1,190)
Other miscellaneous, net								(6,480)	(1,311)	(5,331)
Other income, net								$ (51,953)	(17,023)	$ (338)
Litha Joint Venture Investment
Net (gain) loss on sale of business and other assets									$ (10,100)

- Definition

This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.

+ References + Details

Income Taxes (Narrative) (10K) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Operating Loss Carryforwards [Line Items]
Provisional tax benefit related to Tax Cuts And Jobs Act Of 2017	$ (5,664)	$ 36,216	$ 0
Worthless stock deduction			636,100
Valuation allowance	(9,877,617)	(8,062,975)
Increase (decrease) in valuation allowance	1,814,600	3,221,800
Undistributed earnings of foreign subsidiaries	1,231,800
Total unrecognized income tax benefits	479,429	435,100
Unrecognized tax benefits that would impact effective tax rate	304,300	289,900
Accrued interest and penalties	27,739	19,200
Interest and penalties	8,600	1,400	5,100
Current unrecognized tax benefit	451,690	415,951	$ 424,601	$ 316,247
Losses Within Jurisdictions, Primarily Luxembourg
Operating Loss Carryforwards [Line Items]
Increase (decrease) in valuation allowance		3,310,800
State Tax Benefits
Operating Loss Carryforwards [Line Items]
Increase (decrease) in valuation allowance		21,500
Remeasurement Of Certain Tax Assets
Operating Loss Carryforwards [Line Items]
Increase (decrease) in valuation allowance		$ (590,200)
Minimum
Operating Loss Carryforwards [Line Items]
Statues of limitation		3 years
Maximum
Operating Loss Carryforwards [Line Items]
Statues of limitation		5 years
Accounting Standards Update 2016-16 \| New Accounting Pronouncement, Early Adoption, Effect \| Accounting Standards Update 2016-16
Operating Loss Carryforwards [Line Items]
Deferred tax assets, net		$ 479,700
Accounts Payable and Accrued Liabilities
Operating Loss Carryforwards [Line Items]
Current unrecognized tax benefit	$ 6,500

Income Taxes (Components Of Income Before Income Tax By Geography) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
United States	$ (1,342,860)	$ (1,866,222)	$ (4,309,211)
International	404,028	383,218	385,355
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAX	$ (938,832)	$ (1,483,004)	$ (3,923,856)

Income Taxes (Schedule of Income Tax) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Current:
U.S. Federal	$ 6,236	$ (86,478)	$ 18,369
U.S. State	2,864	(6,462)	9,501
International	8,278	(1,224)	22,851
Total current income tax	17,378	(94,164)	50,721
Deferred:
U.S. Federal	10,084	(124,682)	(661,484)
U.S. State	(778)	(3,225)	(239)
International	(3,749)	(28,222)	(83,619)
Total deferred income tax	5,557	(156,129)	(745,342)
Excess tax benefits of stock compensation exercised	0	0	(5,463)
INCOME TAX	$ 22,935	$ (250,293)	$ (700,084)

Income Taxes (Schedule Of Reconciliation Of Income Tax At Federal Statutory Income Tax Rate To Total Income Tax Provision) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Notional U.S. federal income tax provision at the statutory rate	$ (197,155)	$ (519,051)	$ (1,373,350)
State income tax, net of federal benefit	494	(11,473)	5,182
U.S. tax reform impact	5,664	(36,216)	0
Uncertain tax positions	46,317	58,120	(18,111)
Residual tax on non-U.S. net earnings	(638,724)	(1,350,811)	(301,666)
Effects of outside basis differences	0	0	(636,134)
Non-deductible goodwill impairment	109,189	60,808	926,881
Change in valuation allowance	752,008	1,648,836	762,604
Intra-entity transfers of assets	(63,335)	(53,509)	(92,859)
International Pharmaceuticals segment divestitures	0	(56,092)	0
Other	8,477	9,095	27,369
INCOME TAX	$ 22,935	$ (250,293)	$ (700,084)

Income Taxes (Schedule Of Deferred Tax Assets And Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Accrued expenses and customer allowances	$ 185,910	$ 299,142
Deferred interest expense	240,736	46,230
Fixed assets and intangible assets	604,385	484,313
Loss on capital assets	62,033	49,585
Net operating loss carryforward	8,751,544	7,183,651
Other	65,266	56,828
Research and development and other tax credit carryforwards	9,551	6,354
Total gross deferred income tax assets	9,919,425	8,126,103
Deferred tax liabilities:
Other	(1,965)	(2,042)
Outside basis difference	(73,652)	(92,635)
Total gross deferred income tax liabilities	(75,617)	(94,677)
Valuation allowance	(9,877,617)	(8,062,975)
Net deferred income tax liability	$ (33,809)	$ (31,549)

Income Taxes (Tax Credit Carryforwards) (Details) $ in Thousands	Dec. 31, 2018 USD ($)
Foreign \| Ireland
Tax Credit Carryforward [Line Items]
Operating loss carryforwards	$ 13,254
Foreign \| Luxembourg
Tax Credit Carryforward [Line Items]
Operating loss carryforwards	8,378,742
Federal
Tax Credit Carryforward [Line Items]
Operating loss carryforwards	176,695
Federal \| Capital Loss Carryforward
Tax Credit Carryforward [Line Items]
Operating loss carryforwards	35,673
State
Tax Credit Carryforward [Line Items]
Operating loss carryforwards	178,732
State \| Capital Loss Carryforward
Tax Credit Carryforward [Line Items]
Operating loss carryforwards	$ 25,524

Income Taxes (Valuation Allowances) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Valuation Allowance [Line Items]
Valuation allowance	$ 9,877,617	$ 8,062,975
Foreign \| Ireland
Valuation Allowance [Line Items]
Valuation allowance	160,867
Foreign \| Luxembourg
Valuation Allowance [Line Items]
Valuation allowance	8,378,742
Domestic \| United States
Valuation Allowance [Line Items]
Valuation allowance	$ 1,334,463

Income Taxes (Schedule Of Reconciliation Of Change In Uncertain Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized tax benefits, beginning balance	$ 415,951	$ 424,601	$ 316,247
Gross additions for current year positions	36,088	44,293	142,778
Gross reductions for prior period positions	(3,570)	(64,887)	(35,888)
Gross additions for prior period positions	7,950	22,765	2,111
Decrease due to lapse of statute of limitations	(2,129)	(13,151)	(3,085)
Additions related to acquisitions			2,350
Currency translation adjustment		2,330	88
Currency translation adjustment	(2,600)
Unrecognized tax benefits, ending balance	451,690	415,951	$ 424,601
Accrued interest and penalties	27,739	19,200
Total UTB balance including accrued interest and penalties	$ 479,429	$ 435,100

Net Loss Per Share (Reconciliation Of The Numerator And Denominator Of Basic And Diluted Net Loss Per Share) (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Numerator:
Loss from continuing operations									$ (961,767)	$ (1,232,711)	$ (3,223,772)
Less: Net income from continuing operations attributable to noncontrolling interests									0	0	16
Loss from continuing operations attributable to Endo International plc	$ (265,479)	$ (146,071)	$ (52,479)	$ (497,738)	$ (271,581)	$ (99,687)	$ (696,020)	$ (165,423)	(961,767)	(1,232,711)	(3,223,788)
Loss from discontinued operations, net of tax attributable to Endo International plc	(26,429)	(27,134)	(8,388)	(7,751)	(96,836)	3,017	(700,498)	(8,405)	(69,702)	(802,722)	(123,278)
NET LOSS ATTRIBUTABLE TO ENDO INTERNATIONAL PLC	$ (291,908)	$ (173,205)	$ (60,867)	$ (505,489)	$ (368,417)	$ (96,670)	$ (1,396,518)	$ (173,828)	$ (1,031,469)	$ (2,035,433)	$ (3,347,066)
Denominator:
For basic per share data—weighted average shares (shares)	224,353	224,132	223,834	223,521	223,322	223,299	223,158	223,014	223,960	223,198	222,651
Dilutive effect of ordinary share equivalents (shares)									0	0	0
For diluted per share data—weighted average shares (shares)	224,353	224,132	223,834	223,521	223,322	223,299	223,158	223,014	223,960	223,198	222,651

Savings And Investment Plan And Deferred Compensation Plans (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Savings And Investment Plan And Deferred Compensation [Line Items]
Contributions towards defined contribution savings and investment plans	$ 6.4	$ 9.4	$ 11.5
Endo 401(k) Plan
Savings And Investment Plan And Deferred Compensation [Line Items]
Maximum annual contributions per employee (percent)	4.00%
Vesting period	2 years
Endo 401(k) Plan, Matching Tier One
Savings And Investment Plan And Deferred Compensation [Line Items]
Employer matching contribution (percent)	100.00%
Percentage of employees gross pay	3.00%
Endo 401(k) Plan, Matching Tier Two
Savings And Investment Plan And Deferred Compensation [Line Items]
Employer matching contribution (percent)	50.00%
Percentage of employees gross pay	2.00%

Quarterly Financial Data (Unaudited) (Schedule Of Quarterly Financial Data) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
TOTAL REVENUES	$ 786,389	$ 745,466	$ 714,696	$ 700,527	$ 768,640	$ 786,887	$ 875,731	$ 1,037,600	$ 2,947,078	$ 3,468,858	$ 4,010,274
Gross profit	353,175	332,501	332,791	296,929	262,995	272,365	336,330	368,638
Loss from continuing operations	(265,479)	(146,071)	(52,479)	(497,738)	(271,581)	(99,687)	(696,020)	(165,423)	(961,767)	(1,232,711)	(3,223,788)
Discontinued operations, net of tax	(26,429)	(27,134)	(8,388)	(7,751)	(96,836)	3,017	(700,498)	(8,405)	(69,702)	(802,722)	(123,278)
Net loss attributable to Endo International plc	$ (291,908)	$ (173,205)	$ (60,867)	$ (505,489)	$ (368,417)	$ (96,670)	$ (1,396,518)	$ (173,828)	$ (1,031,469)	$ (2,035,433)	$ (3,347,066)
Continuing operations, basic (in dollars per share)	$ (1.18)	$ (0.65)	$ (0.23)	$ (2.23)	$ (1.22)	$ (0.45)	$ (3.12)	$ (0.74)	$ (4.29)	$ (5.52)	$ (14.48)
Discontinued operations, basic (in dollars per share)	(0.12)	(0.12)	(0.04)	(0.03)	(0.43)	0.02	(3.14)	(0.04)	(0.32)	(3.60)	(0.55)
Basic (in dollars per share)	(1.30)	(0.77)	(0.27)	(2.26)	(1.65)	(0.43)	(6.26)	(0.78)	(4.61)	(9.12)	(15.03)
Continuing operations, diluted (in dollars per share)	(1.18)	(0.65)	(0.23)	(2.23)	(1.22)	(0.45)	(3.12)	(0.74)	(4.29)	(5.52)	(14.48)
Discontinued operations, diluted (in dollars per share)	(0.12)	(0.12)	(0.04)	(0.03)	(0.43)	0.02	(3.14)	(0.04)	(0.32)	(3.60)	(0.55)
Diluted (in dollars per share)	$ (1.30)	$ (0.77)	$ (0.27)	$ (2.26)	$ (1.65)	$ (0.43)	$ (6.26)	$ (0.78)	$ (4.61)	$ (9.12)	$ (15.03)
Weighted average shares—Basic (shares)	224,353	224,132	223,834	223,521	223,322	223,299	223,158	223,014	223,960	223,198	222,651
Weighted average shares—Diluted (shares)	224,353	224,132	223,834	223,521	223,322	223,299	223,158	223,014	223,960	223,198	222,651
Acquisition-related and integration items	$ 8,600	$ 1,300	$ 5,200	$ 6,800	$ 26,400	$ 16,600	$ 4,200	$ 10,900	$ 21,914	$ 58,086	$ 87,601
Change in fair value of contingent consideration	8,200	800	4,100	6,800	26,400	15,400	2,000	6,200	19,910	49,949	23,823
Asset impairment charges	303,500	142,200	22,800	448,400	130,400	94,900	725,000	204,000	916,939	1,154,376	3,781,165
Severance costs	4,200	4,000	29,200	49,000	84,500	80,700	24,600	22,700	31,700	53,000	60,200
Litigation-related and other contingencies, net	(1,600)	(1,800)	19,600	(2,500)	200,000	(12,400)	(2,600)	900
Net (gain) loss on sale of business and other assets	$ (15,300)	$ (2,900)	$ (24,600)	$ (2,400)	$ (8,700)	(2,800)		$ (2,300)	(45,155)	(13,809)	3,192
Loss on extinguishment of debt							$ (51,700)		$ 0	$ 51,734	$ 0
Assets Impaired Second Quarter Of 2017
Asset impairment charges						$ 14,200

Description of Business	12 Months Ended
Description of Business	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	NOTE 1. DESCRIPTION OF BUSINESS Endo International plc is an Ireland-domiciled, global specialty pharmaceutical company focused on generic and branded pharmaceuticals. We aim to be the premier partner to healthcare professionals and payment providers, delivering an innovative suite of generic and branded drugs to meet patients’ needs. Unless otherwise indicated or required by the context, references throughout to “Endo,” the “Company,” “we,” “our” or “us” refer to financial information and transactions of Endo International plc and its subsidiaries. The accompanying Consolidated Financial Statements of Endo International plc and its subsidiaries have been prepared in accordance with U.S. GAAP.

License And Collaboration Agreements (Narrative) (Details)	3 Months Ended
	Jun. 30, 2018 product_candidates
License And Collaboration Agreements [Abstract]
Number of sterile injectable product candidates	5

Contract Assets and Liabilities - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2018 USD ($)
Contract with Customer, Asset and Liability [Abstract]
Performance obligation, description of timing	We generally expect to fulfill these remaining performance obligations and recognize revenue within one week (7 days) of entering into the underlying contract.
Performance obligation satisfied in previous period	$ 2.8

Fair Value Measurements - Financial Assets And Liabilities Measured At Fair Value On Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Assets:
Fair value of financial assets measured on recurring basis	$ 137,953	$ 744,697
Liabilities:
Fair value of financial liabilities measured on recurring basis	116,703	190,442
Acquisition-related contingent consideration—short-term
Liabilities:
Fair value of financial liabilities measured on recurring basis	36,514	70,543
Acquisition-related contingent consideration—long-term
Liabilities:
Fair value of financial liabilities measured on recurring basis	80,189	119,899
Money market funds
Assets:
Fair value of financial assets measured on recurring basis	137,215	439,831
Time deposits
Assets:
Fair value of financial assets measured on recurring basis		303,410
Equity securities
Assets:
Fair value of financial assets measured on recurring basis	738	1,456
Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets:
Fair value of financial assets measured on recurring basis	137,953	441,287
Liabilities:
Fair value of financial liabilities measured on recurring basis	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Acquisition-related contingent consideration—short-term
Liabilities:
Fair value of financial liabilities measured on recurring basis	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Acquisition-related contingent consideration—long-term
Liabilities:
Fair value of financial liabilities measured on recurring basis	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Money market funds
Assets:
Fair value of financial assets measured on recurring basis	137,215	439,831
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Time deposits
Assets:
Fair value of financial assets measured on recurring basis		0
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Equity securities
Assets:
Fair value of financial assets measured on recurring basis	738	1,456
Significant Other Observable Inputs (Level 2)
Assets:
Fair value of financial assets measured on recurring basis	0	303,410
Liabilities:
Fair value of financial liabilities measured on recurring basis	0	0
Significant Other Observable Inputs (Level 2) \| Acquisition-related contingent consideration—short-term
Liabilities:
Fair value of financial liabilities measured on recurring basis	0	0
Significant Other Observable Inputs (Level 2) \| Acquisition-related contingent consideration—long-term
Liabilities:
Fair value of financial liabilities measured on recurring basis	0	0
Significant Other Observable Inputs (Level 2) \| Money market funds
Assets:
Fair value of financial assets measured on recurring basis	0	0
Significant Other Observable Inputs (Level 2) \| Time deposits
Assets:
Fair value of financial assets measured on recurring basis		303,410
Significant Other Observable Inputs (Level 2) \| Equity securities
Assets:
Fair value of financial assets measured on recurring basis	0	0
Significant Unobservable Inputs (Level 3)
Assets:
Fair value of financial assets measured on recurring basis	0	0
Liabilities:
Fair value of financial liabilities measured on recurring basis	116,703	190,442
Significant Unobservable Inputs (Level 3) \| Acquisition-related contingent consideration—short-term
Liabilities:
Fair value of financial liabilities measured on recurring basis	36,514	70,543
Significant Unobservable Inputs (Level 3) \| Acquisition-related contingent consideration—long-term
Liabilities:
Fair value of financial liabilities measured on recurring basis	80,189	119,899
Significant Unobservable Inputs (Level 3) \| Money market funds
Assets:
Fair value of financial assets measured on recurring basis	0	0
Significant Unobservable Inputs (Level 3) \| Time deposits
Assets:
Fair value of financial assets measured on recurring basis		0
Significant Unobservable Inputs (Level 3) \| Equity securities
Assets:
Fair value of financial assets measured on recurring basis	$ 0	$ 0